Page last updated: 2024-08-23

etoposide and Neoplasms

etoposide has been researched along with Neoplasms in 603 studies

Research

Studies (603)

Timeframe	Studies, this research(%)	All Research%
pre-1990	83 (13.76)	18.7374
1990's	228 (37.81)	18.2507
2000's	112 (18.57)	29.6817
2010's	138 (22.89)	24.3611
2020's	42 (6.97)	2.80

Authors

Authors	Studies
Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J	1
Guziec, FS; Guziec, LJ; Hasinoff, BB; Liang, H; Marshall, K; Wu, X; Yalowich, JC	1
Bolognese, A; Correale, G; Esposito, A; Lavecchia, A; Manfra, M; Novellino, E	1
Chang, CY; Chang, JY; Chiang, YK; Coumar, MS; Hsieh, HP; Kuo, CC; Lai, MJ; Liou, JP; Reddy, GR; Tan, UK; Wu, SY; Yeh, JY	1
Jahng, Y; Jung, MJ; Karki, R; Kwon, Y; Lee, ES; Na, Y; Nam, JM; Thapa, P; Thapa, U	1
Cho, HJ; Jung, MJ; Kim, J; Kwon, Y; Lee, ES; Na, Y; Woo, S	1
Ballestrero, A; Bello, C; Cea, M; Cirmena, G; Dal Bello, G; Duchosal, MA; Dupuis, M; Fruscione, F; Garuti, A; Grossi, F; Moran, E; Nahimana, A; Nencioni, A; Patrone, F; Pronzato, P; Rocco, I; Sordat, B; Vogel, P	1
Kamiie, K; Kidachi, Y; Noshita, T; Ryoyama, K; Umetsu, H; Yamaguchi, H; Yu, T	1
Fang, JH; Ge, CW; Wang, CN; Wu, ZH; Zhao, Y; Zhu, L	1
Juvekar, A; Kamal, A; Kumar, BA; Suresh, P; Zingde, S	1
Cho, WJ; Choi, JH; Ha, EM; Jahng, Y; Jeon, KH; Karki, R; Kwon, Y; Lee, E; Lee, ES; Na, Y; Thapa, P; Thapa, U; Yun, M	1
Janaki Ramaiah, M; Kamal, A; Kumar, BA; Lavanya, A; Mallareddy, A; Pal-Bhadra, M; Pushpavalli, SN; Raju, P; Sarma, P; Suresh, P; Vinay Gopal, J	1
Cikotiene, I; Díaz-Rodríguez, E; Domínguez-Kelly, R; Freire, R; León, LG; Padrón, JM; Pandiella, A; Ríos-Luci, C	1
Chen, SW; Ding, YL; Huang, WT; Hui, L; Liu, J; Liu, JF	1
Cho, WJ; Choi, H; Jeon, KH; Kadayat, TM; Karki, R; Kwon, Y; Lee, E; Lee, ES; Na, Y; Park, PH; Thapa, P; Yoo, HY	1
Bose, DS; Idrees, M; Jakka, NM; Rao, JV; Todewale, IK	1
Li, N; Li, X; Liu, ZY; Wu, CF; Xu, XY; Zhao, YQ	1
Imthiajali, S; Kamal, A; Lavanya, A; Mallareddy, A; Pal-Bhadra, M; Pushpavalli, SN; Ramaiah, MJ; Suresh, P	1
Addepally, U; Chinta Rao, TS; Chiranjeevi, T; Patro, B; Saha, S; Venkata Ramana Reddy, Ch	1
Banerjee, UC; Baviskar, AT; Das, D; Guchhait, SK; Kandekar, S; Kashyap, M; Kundu, CN; Mohapatra, P; Preet, R; Satapathy, SR; Siddharth, S	1
Chang, CY; Chang, JY; Chang, YT; Kuo, CC; Lai, MJ; Lee, HY; Liou, JP; Liu, YM; Mehndiratta, S; Nien, CY; Pan, SL; Su, MC; Wu, JS; Wu, SY	1
Aleksić, M; Bertoša, B; David-Cordonnier, MH; Depauw, S; Karminski-Zamola, G; Kralj, M; Martin-Kleiner, I; Nhili, R; Tomić, S	1
Kou, L; Lee, KH; Liu, YQ; Morris-Natschke, SL; Nan, X; Wang, LT; Wang, MJ; Yang, L; Zhao, XB	1
Jee, JG; Jun, KY; Kadayat, TM; Karki, R; Kwon, Y; Lee, ES; Lee, JH; Park, C; Thapa, P	1
Encío, I; Palop, JA; Plano, D; Romano, B; Sanmartín, C	1
Chandra, G; Chang, TS; Choi, S; Jang, JY; Jeong, LS; Kim, G; Lee, SK; Lee, Y; Moon, YW; Mulamoottil, VA; Nayak, A; Noh, M; Oh, K; Sahu, PK; Song, J	1
Choi, SU; Kim, CS; Kim, SY; Kwon, OK; Lee, KR; Subedi, L; Yeo, EJ	1
Ayad, T; Fahy, J; Maillos, P; Perez, M; Poughon, V; Ratovelomanana-Vidal, V	1
Jones, AT; Kandil, S; Kariuki, BM; McGuigan, C; Westwell, AD; Wymant, JM	1
Dezhenkova, LG; Kalinina, AA; Kaluzhny, DN; Kubbutat, M; Luzikov, YN; Pommier, Y; Preobrazhenskaya, MN; Romanenko, VI; Schols, D; Shchekotikhin, AE; Shtil, AA; Tatarskiy, VV; Treshalin, MI; Treshalina, HM; Tsvetkov, VB; Volodina, YL	1
Bahulayan, AK; Kabeer, FA; Madhusoodhanan, AR; Nair, MS; Prakasan, N; Prathapan, R; Rajalekshmi, DS; Varughese, S	1
Dai, SJ; Han, QT; Xiao, K; Zhang, L	1
Jung, SJ; Lee, YH; Lee, YS; Park, KT; Yun, BH	1
Crespín, GD; Daranas, AH; Febles, M; Fernández, JJ; Montalvão, S; Norte, M; Padrón, JM; Tammela, P	1
Battu, S; Bethu, MS; Iska, VBR; Janapala, VR; Katangoor, V; Pottabathini, N; Poudapally, S; Sen, S; Sharma, S; Velatooru, LR	1
Bist, G; Kwon, Y; Lee, ES; Park, S; Shrestha, A; Song, C; Thapa Magar, TB	1
Ding, Q; Han, X; Li, S; Liu, Z; Qi, H; Qiao, X; Song, Y; Zhong, Y; Zhou, G	1
Bist, G; Kadayat, TM; Kwon, Y; Lee, ES; Lee, HJ; Park, S; Shrestha, A; Thapa Magar, TB	1
Asiri, AM; Manukumar, HM; Marwani, HM; Qin, HL; Rakesh, KP; Shantharam, CS; Zhang, X	1
Cai, B; Cui, CB; Li, CW; Wang, N; Xu, LL; Zhu, HJ	1
Tang, YJ; Zhang, QY; Zhao, W	1
Gao, F; Wang, T; Xiao, J; Zhang, X	1
Ann, J; Byun, WS; Kim, C; Kim, JH; Kim, S; Kim, SE; Lee, J; Lee, S; Tran, PT; Yoon, I; Yoon, S	1
Kamal, A; Kankala, S; Nerella, S; Paidakula, S; Vadde, R	1
Xu, Z; Zhang, L	1
Liu, Y; Xu, Z; Zhao, SJ	1
Bansal, R; Malhotra, A	1
Chen, S; Dong, G; Huang, Y; Liu, D; Ma, Z; Sheng, C; Wan, K; Zhu, F	1
Chen, G; Huang, G; Zhou, S	1
Dou, X; Huang, H; Jiang, L; Jiao, N; Jin, H; Jin, Z; Li, Z; Liu, Y; Liu, Z; Sun, X; Zhang, L; Zhu, G; Zou, Y	1
Guo, D; Kong, X; Liu, S; Yu, C; Zhu, Y	1
Boutros, SW; Holden, S; Krenik, D; Raber, J; Unni, VK	1
Chen, J; Feng, J; Guo, J; Hu, L; Li, K; Liu, Y; Lu, Y; Ma, C; Pang, X; Wu, Z; Yuan, K	1
Chang, HH; Chang, JY; Chen, HH; Chen, YT; Chuang, YJ; Kuo, CC; Tang, YC; Yao, JY	1
Bilston, L; Croden, J; Grossman, J; Sun, HL; Taparia, M	1
Bourzikat, O; Daniellou, R; El Abbouchi, A; El Brahmi, N; El Fahime, E; El Kazzouli, S; Ghammaz, H; Guillaumet, G; Paris, A; Suzenet, F	1
Feng, X; Han, R; Liu, Q; Qin, Y; Ren, Z; Sun, Y; Wang, J; Wang, X	1
Albert, MH; Bader, P; Basu, O; Beier, R; Burkhardt, B; Classen, CF; Claviez, A; Corbacioglu, S; Deubzer, HE; Eichinger, A; Glogova, E; Greil, J; Gruhn, B; Güngör, T; Kafa, K; Kühl, JS; Lang, P; Lange, BS; Meisel, R; Müller, I; Peters, C; Poetschger, U; Sauer, MG; Schlegel, PG; Schulz, A; Stachel, D; Strahm, B; Wawer, A	1
Chang, R; Chen, X; Guo, AY; Han, L; He, Y; Jing, Y; Li, S; Liu, C; Liu, H; Liu, Y; Luo, M; Ruan, H; Xue, Y; Ye, L; Ye, Y; Zhang, G; Zhang, Z	1
Dodier, K; Laverdière, I; Roy, MJ	1
Aulenbacher, K; Bartzsch, S; Dimroth, A; Matejcek, C; Natour, G; Winter, J	1
Fukushima, H; Hosaka, S; Inaba, M; Masumoto, K; Mizumoto, M; Muroi, A; Okunushi, T; Sakurai, H; Suzuki, R; Tagawa, M; Takada, H; Watanabe, A; Yamaki, Y	1
Ahmed, AAS; Binsuwaidan, R; El Sayed, IET; Elmongy, EI; Hassan, EA; Nofal, AE; Sakr, M; Tousson, E	1
Benedetti, DJ; Kao, PC; Ma, C; Marcus, KJ; Mullen, EA; Wong, CI	1
Hu, Y; Li, Q; Liang, T; Ma, S; Shen, C; Wei, X; Yang, H	1
Bandak, AF; Berger, JM; Blower, TR; Guha, R; Gupta, R; Lau, AY; Nitiss, JL; Nitiss, KC	1
Soejima, T	1
Arshad, R; Behzadmehr, R; Fathi-Karkan, S; Ghotekar, S; Pandey, S; Rahdar, A; Ramezani, A	1
Baker, JHE; Banáth, JP; Kyle, AH; Liu, NA; Minchinton, AI; Wang, T	1
Gandhi, K; Garg, M; Gota, V; Gurjar, M; Jadhav, SM	1
Cai, G; Chen, J; Guo, J; Kong, L; Ren, Y; Song, D; Wan, C; Yu, W; Zhang, W; Zhu, J	1
Cash, T; Goldsmith, KC; Katzenstein, HM; Kean, L; MacDonald, TJ; Qayed, M; Suessmuth, Y; Tanos, R; Tighiouart, M; Watkins, B; Wetmore, C	1
Adachi, S; Hiramatsu, H; Horikoshi, Y; Kato, I; Kawaguchi, K; Ogura, T; Saida, S; Takachi, T; Takita, J; Umeda, K; Watanabe, K	1
Fujiwara, K; Goto, K; Harada, T; Hayashi, T; Kaneda, H; Kenmotsu, H; Kimura, M; Kogure, Y; Koike, T; Matsui, R; Nishio, M; Nogami, N; Seto, T; Shimizu, S; Shimokawa, M; Suzuki, K; Takiguchi, T	1
Annereau, M; Bally, M; Corvis, Y; Fleury, T; Lai-Kuen, R; Lam, A; Martin, B; Mignet, N; Neri, G; Seguin, J	1
Fazal, F; Gupta, N; Mittal, A; Ray, A	1
Gao, S; Leng, SX; Meng, X; Miao, Y; Tao, Y; Wang, B; Yue, P; Zhang, H	1
Kirov, I; Lam, F; Nguyen, T; Stockton, W	1
Ali, S; Allsopp, RC; Buluwela, L; Charmsaz, S; Coombes, RC; Cunnea, P; Farzan, R; Gemma, C; Győrffy, B; Periyasamy, M; Shaw, JA; Singh, AK; Young, LS	1
Bush, R; Buxton, A; Constine, LS; Friedman, DL; Giulino-Roth, L; Kelly, KM; Pei, Q; Schwartz, CL; Wolden, SL; Wu, Y	1
Aschauer, L; Behan, C; Janus, J; Kelly, M; Le Quesne, J; Mackay, H; Muller, PAJ; Norman, JC; Officer, L; Phatak, V; Pinon, L; von Grabowiecki, Y; Zanivan, S	1
Bellet, MM; Castelli, M; Costantini, C; Della-Fazia, MA; Gargaro, M; Pieroni, S; Piobbico, D; Romani, L; Sassone-Corsi, P; Servillo, G; Stincardini, C	1
Duty, AM; Goldman, JL; Kelley, KL; Miles, N; Suppes, SL; Tillman, EM	1
Du, Z; Pian, Y; Ren, S; Xu, C	1
Kluska, M; Woźniak, K	1
Bosch, M; Danyluk, P; Dusyk, T; Elemary, M; Hahn, L; Lim, H; Sabry, W; Stakiw, J	1
Beijersbergen, RL; Bernards, R; De Conti, G; Groot, K; Jansen, R; Jin, H; Jochems, F; Leite de Oliveira, R; Pogacar, Z; Schepers, A; Thijssen, B; Wang, C; Wang, L; Wessels, LFA	1
Agarwala, S; Bakhshi, S; Batra, A; Dhawan, D; Gupta, YK; Pramanik, R; Thulkar, S; Vishnubhatla, S	1
Abou Karam, P; Biran, A; Krizhanovsky, V; Ovadya, Y; Porat, Z; Roitman, L; Vadai, E; Zada, L	1
Li, JC; Liang, L; Sun, L; Tian, Y; Zhang, HM; Zhu, JX; Zhu, N	1
Keilholz, U; Klinghammer, K; Knoedler, M; Kümmerlen, V; Lassus, M; Machacek, M; Mehlitz, P; Rohde, L; Schmittel, A; Steventon, G; Treasure, P; Utku, N	1
Bansal, R; Kumar, P	1
Bruni, E; De Nicola, M; Ghibelli, L; Traversa, E	1
Apel-Sarid, L; Ayyathan, DM; Blank, M; Borroni, AP; Emanuelli, A; Koganti, P; Levy-Cohen, G; Shah, PA	1
Frank, JP; Martin, AL; Waggoner, ML	1
Lei, KF; Liu, TK; Tsang, NM	1
Aston, WJ; Hope, DE; Lake, RA; Lesterhuis, WJ; Nowak, AK; Robinson, BW	1
Engel, C; Loeffler, M; Loibl, S; Schirm, S; Scholz, M	1
Hu, B; Ji, Y; Liu, Z; Luo, A; Tang, Z; Xu, R; Yang, C; Yang, Y; Zang, W; Zhang, Z; Zheng, X	1
Boddy, AV; Chatelut, E; Osborne, C; Paci, A; Veal, GJ; White-Koning, M	1
Adamkiewicz-Drożynska, E; Bączek, T; Bień, E; Kowalski, P; Krawczyk, MA; Maliszewska, O; Miękus, N; Olędzka, I; Plenis, A	1
Aksenov, ND; Druzhilovskiy, DS; Guzhova, IV; Komarova, EY; Lazarev, VF; Margulis, BA; Mikhaylova, ER; Mitkevich, VA; Nikotina, AD; Poroikov, VV; Suezov, R; Sverchinsky, DV	1
Atrafi, F; Byers, LA; Calles, A; Camidge, DR; Chae, YK; Gabrail, NY; Garralda, E; Groen, HJM; He, L; Hoening, E; Hu, B; Komarnitsky, P; Lolkema, MP; Nuthalapati, S; Sangha, RS; Tian, T; Viteri, S	1
Andersen, MØ; Arnspang, EC; Code, C; Notabi, MK; Popova, P	1
Castellano, G; Torrens, F	1
Cai, K; Chen, Q; Hou, Y; Hu, Y; Li, K; Li, M; Li, Y; Luo, Z; Song, G; Xue, C; Zhou, J	1
Casti, P; Comes, MC; Corsi, F; Di Giuseppe, D; Di Natale, C; Ghibelli, L; Martinelli, E; Mencattini, A	1
Atar, N; Özkan, A; Yola, ML	1
Dhagat, S; Eswari, JS; Yadav, M	1
Bai, J; He, N; Hu, P; Li, X; Liu, F; Liu, M; Lu, X; Shao, Y; Tang, Q; Tian, Y; Wang, J; Xue, B; Zhu, G	1
Bianco, S; Bouwman, BAM; Chiariello, AM; Cittaro, D; Crosetto, N; De Conti, G; Dellino, GI; Faretta, M; Furia, L; Giacò, L; Guido, D; Luzi, L; Melloni, G; Nicodemi, M; Palluzzi, F; Pelicci, PG; Piccioni, R	1
Bhattacharjee, S; Chatterjee, S; Espey, MG; Jiang, J; Kumar, A; Mason, RP; Motten, AG; Sinha, BK	1
Brady, D; de Koning, CB; Kolesnikova, NI; Qwebani-Ogunleye, T; Wellington, KW	1
Batey, MA; Curtin, NJ; Kyle, S; Lau, A; Martin, NM; Newell, DR; Richardson, C; Slade, A; Zhao, Y	1
Kokache, A; Mahmoud, S; Sambasivan, K; Savage, P; Seckl, M	1
Lee, SH; Lee, SJ; Park, BJ; Yoon, MH	1
Alberti, DB; Eickhoff, J; Keppen, M; Kolesar, JM; Liu, G; Marnocha, RM; Mohammed, TA; Schelman, WR; Takebe, N; Traynor, AM; Wilding, G	1
Friis, R; Maskey, D; Perren, A; Schmid, I; Simon, HU; Yousefi, S; Zlobec, I	1
Bokemeyer, C; Budach, W; de Zwart, P; Eckert, F; Hartmann, JT; Horger, M; Kluba, T; Königsrainer, A; von Weyhern, CH	1
Kumar, D; Kumari, A; Yadav, R; Yadav, SK	1
Allen, JC; Bendel, AE; Campigotto, F; Chi, SN; Chordas, CA; Comito, MA; Goldman, S; Hubbs, SM; Isakoff, MS; Khatib, ZA; Kieran, MW; Kondrat, L; Manley, PE; Neuberg, DS; Pan, WJ; Pietrantonio, JB; Robison, NJ; Rubin, JB; Turner, CD; Werger, AM; Zimmerman, MA	1
Mulchandani, M; Sankaranarayanan, A; Tirupati, S	1
Boren, J; Brindle, KM; Mahajan, S; Patel, II; Reichelt, S; Schreiner, A; Steuwe, C; Ul-Hasan, M	1
WOOD, CA	2
CHARTERIS, AA	1
Blower, PJ; Diocou, S; Fruhwirth, GO; Mullen, GE; Ng, T	1
Desmaris, R; Grill, J; Kessari, R; Klasen, A; Mercier, L; Paci, A; Valade, C	1
Bean, AJ; Brown, BS; Celia, C; Mobli, K; Patanam, T; Tasciotti, E; Zage, PE	1
Furman, WL; Ivy, P; Lam, CG; McGregor, LM; Santana, VM; Spunt, SL; Wang, C; Wu, J	1
Chamani, E; Rabbani-Chadegani, A; Zahraei, Z	1
Li, M; Mi, J; Shi, Z; Zhang, D	1
Acikelli, AH; Aldinger, C; Araúzo-Bravo, MJ; Bardenheuer, W; Dammann, P; Dembinski, U; Díaz-Carballo, D; Gustmann, S; Jastrow, H; Klein, J; Malak, S; Schultheis, B; Strumberg, D	1
Dalla Costa, T; Mossmann, DL; Pigatto, MC	1
Hasinoff, BB; Patel, D; Wu, X; Yadav, AA; Yalowich, JC	1
Adiguzel, R; Andreana, PR; Arslan, Z; Ates, M; Bemis, T; Bercovitch, LG; Bögli, S; Boucherez, J; Boudouf, S; Briat, JF; Brown, BM; Busemann, A; Buters, J; Byers, JS; Cairo, MS; Carrier, F; Chalmers, JJ; Chang, E; Chen, J; Chen, Y; Christenson, MK; Cielecka-Piontek, J; Cole, PA; Cooper, BS; Davis, PH; De Silva, RA; Decato, S; DeFries, RS; Demir, V; Denic, A; Deserno, M; Dickey, AM; Diss, E; Eberlein, B; Eyerich, S; Faluvegi, G; Farlow, MR; Fletcher, JW; Francetic, T; Furlan, L; Garbacki, P; Gartung, A; Garvin, JH; Gates, L; Gaymard, F; Ghetti, B; Gibson, MP; Griffin, RG; Hamed, M; Hammad, LA; Hammond, GB; Han, J; Hann, R; Hao, N; Harrison, LA; Heidecke, CD; Hutchins, GD; Inlow, M; Irmer, H; Jani, P; Jara-Cavieres, A; Jawadi, H; Jiang, Q; Jiang, Y; Kameda, T; Keeler, EG; Kim, H; Kim, R; Kim, S; Kinney, PL; Krause, A; Kumar, V; Kwok, Y; Lam, T; Lanni, F; Le May, M; Lee, A; Lee, JF; Lee, MJ; Leontyev, IV; Li, Q; Li, X; Liu, J; Liu, NK; Lominadze, D; Lösche, M; Lu, QB; Lu, Y; Lu, Z; Mach, H; Madsen, E; Marletta, M; Marlier, ME; McDonald, BC; McKay, IS; Mckenzie, CL; Mecozzi, S; Menges, P; Meyers, D; Michaelis, VK; Montooth, KL; Moore, LR; Morgan, JK; Morris, E; Movahed, M; Nalabothula, N; Narayanan, S; Nguyen, D; Nho, K; Oken, B; Ong, TC; Osborne, LS; Paczkowska, M; Park, EK; Pennino, D; Peters, S; Potluri, LP; Qin, C; Radhakrishnan, K; Randerson, JT; Rantanen, J; Reyt, G; Ring, J; Risacher, SL; Rodriguez, M; Saykin, AJ; Schmidt-Weber, CB; Sengelaub, DR; Shatters, RG; Shen, L; Shen, V; Shindell, DT; Stuchebrukhov, AA; Swaminathan, S; Takahashi, K; Talaczyńska, A; Tallman, EF; Tan, C; Terry, SF; Trabbic, KR; Trease, AJ; Tretter, C; Uitto, J; Váradi, A; von Bernstorff, W; Voulgarakis, A; Wagenhofer, M; Wahbeh, H; Wang, EN; Wang, X; Wells, RJ; West, JD; Williams, PS; Wolff, JE; Wootla, B; Xu, B; Xu, XM; Yoder, KK; Zalewski, P; Zan, GH; Zborowski, M; Zhang, HH; Zhang, W; Zhao, J; Zoecklein, L	1
Fukao, T; Fukuda-Yuzawa, Y; Kiga, K; Sasakawa, C; Tanabe, M; Tsuji, S	1
Leifert, WR; Siddiqui, SM	1
de Jong, J; Neefjes, J; Pang, B; Qiao, X; Wessels, LF	1
Abriola, L; Fernandez, RJ; Glazer, PM; Hoyer, D; Hungerford, W; Liu, Y; Merkel, J; Peterson-Roth, E; Pike, LR; Qian, JM; Stachelek, GC	1
Jiang, Z; Liu, R; Shen, Z; Wang, P; Yao, Y; Zhu, J	1
Clement, F; Fattaccioli, A; Genin, M; Michiels, C; Raes, M	1
Al-Nedawi, K; Garnier, D; Guha, A; Lee, TH; Lee, WJ; Meehan, B; Montermini, L; Rak, J	1
Balasubramaniam, S; Bates, SE; Bryla, C; Ehrlich, S; Figg, WD; Goey, AK; Lee, MJ; Peer, CJ; Piekarz, R; Sissung, TM; Steinberg, SM; Tomita, Y; Trepel, JB	1
Huang, RC; Kimura, K	1
Adam, V; Eckschlager, T; Jimenez, AM; Kizek, R; Kopel, P; Kremplova, M; Kudr, J; Masarik, M; Nejdl, L; Ruttkay-Nedecky, B; Skalickova, S; Stiborova, M	1
Dalla Costa, T; de Araujo, BV; Magni, P; Pigatto, MC; Schmidt, S; Torres, BG	1
Inanami, O; Suzuki, M; Yamamori, T; Yasui, H	1
Agarwal, P; Jackson, SP	1
Bohgaki, M; Bohgaki, T; Bristow, R; Cheung, P; El Ghamrasni, S; Eldin, MS; Guturi, KKN; Hakem, A; Hakem, R; Jeon, J; Kumareswaran, R; Ng, D; Patel, P; Raught, B; Srikumar, T; Stewart, GS	1
Beyer, M; Dietrich, S; Göder, A; Heinzel, T; Kiweler, N; Krämer, OH; Linnebacher, M; Mahboobi, S; Mahendrarajah, N; Nikolova, T; Rauch, A; Reich, TR; Schäfer, C; Schneider, G; Sellmer, A; Sonnemann, J; Stojanovic, N; Tomicic, MT; Wieczorek, M	1
Abbadie, C; Dehennaut, V; Dubuissez, M; Harmon, BT; Leprince, D; Loison, I; Nassour, J; Paget, S; Rood, BR; Spruyt, N	1
Atwal, M; Austin, CA; Cowell, IG; Lishman, EL	1
Fu, W; Hou, T; Li, R; Li, X; Lu, X; Ma, K; Tang, M; Wang, L; Wang, Y; Zhang, C; Zhang, L; Zhao, Y; Zhou, J; Zhu, WG	1
Cassaday, RD; Chamberlain, MC; Floeter, AE; Gopal, AK; Hendrie, PC; Patel, A; Tran, M	1
Chow, L; Eckhardt, SG; Gore, L; Lieu, C; Morrow, M; O'Bryant, CL; Pierson, AS; Tran, ZV; Wright, JJ	1
Arva, NC; Bargonetti, J; Brekman, A; Okoro, DR; Qiu, WG; Talbott, KE	1
André, N; Camoin, L; Coze, C; Gentet, JC; Padovani, L; Pasquier, E; Rome, A	1
Biegel, JA; Cho, YJ; Evans, JA; Greulich, H; McKenna, ES; Moreau, LA; Pomeroy, SL; Roberts, CW; Sansam, CG; Thom, CS	1
Autio, K; Balkman, CE; Beaulieu, BB; Flory, AB; Kiselow, MA; Lewis, LD; Rassnick, KM	1
Greco, FA; Hainsworth, JD; Wolff, SN	1
Annereau, JP; Bailly, C; Barret, JM; Brel, V; Delcros, JG; Guilbaud, N; Guminski, Y; Imbert, T; Kruczynski, A; Lansiaux, A; Vispé, S	1
Corn, PG; Logothetis, CJ; Pataer, A; Roth, JA; Swisher, SG	1
Fouladi, M; Furman, WL; Ivy, P; Laningham, FH; McGregor, LM; Santana, VM; Spunt, SL; Stewart, CF; Ward, DA; Watkins, A	1
Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M	1
Ferguson, DM; Flatten, KS; Gálvez-Peralta, M; Hackbarth, JS; Hiasa, H; Kaufmann, SH; Xing, C	1
Ghaderi, A; Javidnia, K; Mehdipour, AR; Soltani, M; Varamini, P	1
Ambrose, EC; Kornbluth, J	1
Friberg, LE; Hansson, EK; Karlsson, MO; Lindman, H; Sandström, M; Wallin, JE	1
Kepp, O; Kroemer, G; Martins, I; Métivier, D; Michaud, M; Perfettini, JL; Schlemmer, F; Senovilla, L; Séror, C; Tesniere, A; Zitvogel, L	1
Bohndiek, SE; Brindle, KM; Gallagher, FA; Gisselsson, A; Hansson, G; Hu, DE; Jensen, PR; Karlsson, M; Kettunen, MI; Lerche, MH; Nelson, SK; Peitersen, T; Witney, TH; Zandt, RI	1
Brahimi-Horn, MC; Chiche, J; Gounon, P; Mazure, NM; Pouysségur, J; Rouleau, M	1
Agarwal, R; Ali, N; Biris, AR; Biris, AS; Dervishi, E; Fejleh, A; Galanzha, EI; Iancu, C; Iancu, DT; Karmakar, A; Li, Z; Mahmood, M; Mocan, L; Mocan, T; Xu, Y; Zharov, VP	1
Bazan, F; Dixit, VM; Dornan, D; Eastham-Anderson, J; Ferrando, R; French, DM; Huang, DC; Huang, X; Lill, JR; Liu, J; Maecker, H; O'Rourke, K; Schwickart, M; Yue, P	1
Du, W; He, Q; Hu, C; Hu, Y; Lou, J; Qian, S; Wang, L; Xu, D; Yang, B	1
Füllgrabe, J; Hajji, N; Hermanson, O; Joseph, B; Vlachos, P; Wallenborg, K	1
Auvrignon, A; Chastagner, P; Corradini, N; Doz, F; Gentet, JC; Giraud, C; Leblond, P; Rey, E; Rubie, H; Treluyer, JM; Urien, S; Vassal, G	1
Ando, K; Fukawa, T; Furusawa, Y; Hirayama, R; Musha, A; Nakano, T; Takahashi, T; Yoshida, Y	1
Choudhary, B; Kavitha, CV; Muniyappa, K; Raghavan, SC	1
Bazan, F; Chaigneau, L; Demarchi, M; Dobi, E; Ivanaj, A; Kalbacher, E; Maurina, T; Montange, D; Nguyen, T; Pivot, X; Royer, B; Thiery-Vuillemin, A; Villanueva, C	1
Kang, DH; Kang, SW; Kwon, J; Lee, DJ; Lee, JY; Lee, KW	1
Cross, JR; Downward, J; Iaccarino, I; Loffreda, A; Stoppelli, MP; Vento, MT; Zazzu, V	1
Blagosklonny, MV; Leontieva, OV	1
Glimelius, B; Lahn, M	1
Anisimov, AP; Cragg, MS; Erenpreisa, J; Huna, A; Ianzini, F; Kosmacek, EA; Salmina, K	1
Fanti, PA; Misciali, C; Miteva, M; Romanelli, P; Tosti, A; Vincenzi, C	1
Cox, NJ; Dolan, ME; Gamazon, ER; Huang, RS	1
Boos, J; Hempel, G; Kersting, G; Lippert, J; Willmann, S; Würthwein, G	1
Dawson, JL; Field, TL; Fields, KK; Goldstein, SC; Kim, J; Lush, RM; Maddox, BL; Neuger, AM; Partyka, JS; Perkins, JB; Simonelli, CE; Sullivan, DM	1
Belkina, MV; Kaigorodova, EV; Maroshkina, AN; Novitskii, VV; Ryazantseva, NV	1
Jaiswal, AK; Niture, SK	1
Karantzelis, N; Kotsantis, P; Lygerou, Z; Nishitani, H; Petropoulou, C; Roukos, V; Stathopoulou, A; Taraviras, S	1
Ai, R; Jin, H; Li, X; Lu, J; Sha, S; Yang, J	1
André, N; Bajciova, V; Deak, L; Demlova, R; Doubek, M; Dubska, L; Husek, K; Kepak, T; Kutnikova, L; Kyr, M; Martincekova, A; Mazanek, P; Mudry, P; Pavelka, Z; Skotakova, J; Sterba, J; Valik, D; Zapletalova, D; Zitterbart, K	1
Braess, J; Holdenrieder, S; Kolligs, FT; Manukyan, D; Stieber, P	1
Boudou-Rouquette, P; Cessot, A; Coriat, R; Durand, JP; Gaillard, R; Giroux, J; Goldwasser, F; Mir, O; Ropert, S	1
Li, Y; Peng, L; Rao, Q; Tang, K; Tian, Z; Wang, J; Wang, L; Wang, M; Xing, H	1
Baheti, G; Davda, JP; Gordon, BB; Gwilt, PR; Manouilov, KK; McGuire, TR; Wall, D	1
Andrews, E; Benjamin, T; Drapkin, R; Duraisamy, S; Gu, H; Li, C; Li, D; Sung, CK; Yim, H	1
Ahn, MY; Choi, G; Kim, HS; Kim, JH; Kim, WK; Lee, HJ; Lee, YJ; Moon, HR; Yang, Z; Yoon, S	1
Arnould, T; Fransolet, M; Genin, M; Leclere, L; Maincent, A; Michiels, C; Notte, A; Riquier, H; Sermeus, A	1
Ahn, JS; Asami, Y; Erikson, RL; Jang, JH; Kim, BY; Kim, SO; Kim, YS; Kwon, YT; Lee, KS; N R, T; Sakchaisri, K; Soung, NK; Thimmegowda, NR	1
Basu Baul, TS; de Vos, D; Dutta, D; Höpfl, H; Singh, P	1
Lode, HN; Satchi-Fainaro, R; Shabat, D; Wrasidlo, W	1
Brunetto, AL; Costa, TD; Di Leone, L; Gregianin, LJ; Santos, PP; Schwartsmann, G	1
Bessho, A; Fujii, N; Harada, M; Hiramatsu, Y; Ikeda, K; Imai, T; Ishimaru, F; Koide, N; Kojima, K; Kozuka, T; Maeda, Y; Matsuo, K; Niiya, K; Noguchi, T; Shinagawa, K; Sunami, K; Takenaka, K; Tanimoto, M; Teshima, T; Yamamoto, K	1
Buglova, SE; Ismail-zade, RS; Potapnev, MP; Rud'ko, VS; Sachivko, NV; Semenov, AS; Shman, TV; Zhavrid, EA	1
Davidson, A; Dick, G; Pinkerton, R; Pritchard-Jones, K	1
Bayle, C; Bernheim, A; Cayuela, JM; Chompret, A; de Vathaire, F; Hill, C; Lacour, B; Le Deley, MC; Leblanc, T; Raquin, MA; Shamsaldin, A; Sommelet, D; Vassal, G	1
Aisner, J; Beers, S; Gounder, M; Licitra, EJ; Lin, Y; Musanti, R; Nelson, K; Poplin, E; Rajendra, R; Rubin, EH; Saleem, A; Schaaf, LJ; Smith, S; Thomas, C; Toppmeyer, D; Vyas, V	1
Aisner, J; Beers, S; Locsin, S; Musanti, R; Rubin, EH; Smith, S	1
GIAUX, G; SWYNGEDAUW, J; TOISON, G	1
BAEUMER, J; KEPP, RK	1
RAMIOUL, H	1
SMITH, IH	1
SUTHERLAND, WH	1
BESKA, F; BRUCKNER, L; CERNY, J	1
Kéri, G; Szende, B	1
Bahrs, H; Gruber, Y; Kempgens, B; Kisro, J; Wagner, T	1
Akaike, T; Fang, J; Greish, K; Maeda, H; Sawa, T	1
Brunetto, AL; Leone, LD; Loss, JF; Santos, PP	1
Francia, G; Green, SK; Isidoro, C; Kerbel, RS	1
Cawthorne, CJ; Demonacos, C; Dive, C; Erler, JT; Koritzinsky, M; Miller, C; Stratford, IJ; Williams, KJ; Wilson, C; Wouters, BG	1
Blair, IA; Boston, R; Felix, CA; Moate, P; Pang, S; Scavuzzo, J; Zheng, N	1
Basso, B; Boiocchi, M; Corona, G; Toffoli, G	1
Catapano, CV; Freeman, KD; Green, MR; Mushtaq, C; Oakhill, G; Pacheco, D; Rocha Lima, CM; Sherman, CA	1
Alaoui-Jamali, MA; Chow, TY; Griller, D; Yeh, C; Yuen, L	1
Gavrilov, BA; Grudinkin, PS; Kropotov, AV; Pleskach, NM; Tomilin, NV; Zhivotovsky, B	1
Ahmed, S; Jeyapalan, J; Leake, A; Saretzki, G; Tilby, M; von Zglinicki, T	1
Hande, KR	4
Belka, C; Goecke, B; Güner, D; Jendrossek, V; Weinmann, M	1
Ikarashi, Y; Imai, C; Kakihara, T; Tanaka, A; Uchiyama, M; Watanabe, A	1
Aubin, F; Burgot, G; Gandemer, V; Le Gall, E; Marigny, K	1
Berg, SL; Bessmertny, O; Cairo, MS; Davenport, V; Goldman, SC; Kreissman, SG; Laver, J; Reaman, GH; Secola, R; Shen, V; van de Ven, C	1
Barnes, C; Blanchette, V; Canning, P; Greenberg, M; Price, V	1
Iliadis, A	1
Atienza, JM; Denissenko, MF; Ekblom, J; Kammerer, S; Rehbock, J; Rosette, C; Roth, RB; Smylie, KJ	1
Hartmann, O; Le Deley, MC; Leblanc, T; Shamsaldin, A; Taïbi, A; Vassal, G	1
Debatin, KM; Fulda, S	1
Angiolillo, AL; Ayello, J; Bonilla, MA; Cairo, MS; Davenport, V; Krailo, M; Militano, O; Miller, LL; Reaman, G; van de Ven, C	1
Ayene, IS; Ford, LP; Koch, CJ	1
Epstein, AL; Hu, P; Khawli, LA	1
Ariyoshi, Y; Fukuoka, M; Furuse, K; Hatae, M; Hirabayashi, K; Noda, K; Ogawa, M; Takaku, F; Yakushiji, M	1
Lin, C; Liu, ZR; Yang, L	1
Appleman, LJ; Campos, SM; Clark, JW; Eder, JP; Fuller, AF; Goodman, A; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV	1
Baldwin, EL; Osheroff, N	1
Hande, KR; Martincic, D	1
Kekre, N; McNulty, J; Naderi, J; Pandey, S	1
Alberts, SR; Erlichman, C; Furth, A; Lathia, CD; Molina, JR; Reid, JM; Safgren, SL; Sloan, JA	1
Asanuma, H; Hata, F; Hirata, K; Hirohashi, Y; Kamiguchi, K; Kurotaki, T; Nabeta, C; Nakanishi, K; Ohmura, T; Sato, N; Sato, T; Torigoe, T; Tsuruma, T; Yamaguchi, K; Yamamoto, M	1
Brown, LM; Cowen, RL; Debray, C; Erler, JT; Eustace, A; Parker, CA; Sheppard, FC; Stratford, IJ; Williams, KJ	1
Cohn, RJ; McCowage, G; White, L; Ziegler, DS	1
Ashworth, A; Caplin, M; Friedmann, BJ; Hartley, JA; Hochhauser, D; Lord, CJ; Savic, B; Shah, T	1
Chamberlain, MC; Groshen, S; Tsao-Wei, DD	1
Busonera, B; Carta, A; Collu, G; La Colla, P; Loddo, R; Loriga, M; Paglietti, G; Piras, S	1
Aressy, B; Brezak, MC; Bugler, B; Ducommun, B; Prevost, G; Quaranta, M	1
Brunetto, AL; Castro, CG; Cruz, LB; Rech, A; Ribeiro, AS; Rosa, LG	1
Bajciova, V; Kadlecova, V; Kepak, T; Mazanek, P; Mudry, P; Pavelka, Z; Sterba, J; Valik, D; Zitterbart, K	1
Antonia, S; Cantor, A; Fishman, M; Garrett, C; Gump, J; Lush, RM; Munster, PN; Rocha-Lima, C; Simon, GR; Sullivan, DM; Tetteh, L; Williams, C	1
Argnani, M; Cariello, A; Dazzi, C; De Giorgi, U; Frassineti, L; Kopf, B; Leoni, M; Marangolo, M; Molinari, A; Monti, G; Rosti, G; Scarpi, E; Tienghi, A; Turci, D; Vertogen, B	1
Lowinger, JS; Pearson, S-; Ringland, C; Stark, H; Tan, EL; Ward, R	1
Kantidze, OL; Razin, SV	1
Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M	1
Arao, T; Igarashi, T; Izumi, H; Kohno, K; Nishio, K; Otsuji, Y; Sasaguri, Y; Sugio, K; Tanabe, M; Uchiumi, T; Uramoto, H; Wang, KY; Yasumoto, K	1
Havredaki, M; Scorilas, A; Thomadaki, H; Tsiapalis, CM	1
Alimirah, F; Chen, J; Choubey, D; Davis, FJ; Panchanathan, R	1
Ding, J; Duan, W; Hu, C; Lin, L; Meng, L; Qin, Y; Zhang, X; Zuo, Z	1
Cosse, JP; Michiels, C; Ninane, N; Raes, M; Sermeus, A; Vannuvel, K	1
Azad, MB; Chen, Y; Cizeau, J; Gibson, SB; Henson, ES; Israels, SJ; McMillan-Ward, E	1
Carroll, M; Frankel, P; Ruel, C; Smith-Powell, L; Synold, TW; Twardowski, PW; VanBalgooy, J	1
Benesch, M; Lackner, H; Moser, A; Schwinger, W; Sovinz, P; Urban, C	1
Bayliss, SJ; Hayashi, RJ; Lloyd, BM; Rosman, IS	1
Marik, PE; Vahid, B	1
Aoyagi, S; Fukuda, I; Higashio, M; Ito, K; Jomgeow, T; Kitamura, Y; Li, Z; Miyai, S; Nakamura, J; Nishida, S; Oji, Y; Oka, Y; Shirakata, T; Sugiyama, H; Takashima, S; Tatsumi, N; Tsuboi, A; Tsuda, A; Tsuji, N	1
Collier, K; How, K; Savage, P; Schink, C; Seckl, M; Young, AM	1
Cheerva, AC; Gross, TG; Kadota, RP; Levine, JE; Ozkaynak, MF; Richards, MK; Rozans, MK; Sahdev, I; Shaw, PJ	1
Chu, F; Davis, FB; Davis, PJ; Mousa, SA; Rebbaa, A	1
Beaujouin, M; Liaudet-Coopman, E	1
de Vries, EG; De Vries-Hospers, HG; Holthuis, JJ; Mulder, NH; Postmus, PE; Sibinga, CT; Sleijfer, DT; van Imhoff, GW; Vriesendorp, R	1
Arnold, AM; Whitehouse, JM	1
Pawlicki, M; Zuchowska-Vogelgesang, B	1
Dill, PL; Macaluso, CK; Marsden, JA; Weisenthal, LM	1
Coombs, A; Hanson, J; Moore, JL	1
Jungi, WF	1
Płuzańska, A; Robak, T	1
Blackledge, G; Smith, SR	1
Fer, MF; Greco, FA; Hainsworth, JD; Hande, KR; McKay, CM; Wolff, SN	1
Klastersky, J; Sculier, JP	2
Ogawa, M	2
Hillcoat, BL	1
Belanger, R; Dennery, JM; Gerin-Lajoie, J; Hopkins, HS; Hugenholtz, H; Montpetit, V; Nundy, D; Prior, J; Richard, MT; Stewart, DJ	1
de Vries, EG; Meinesz, AF; Mulder, NH; Postmus, PE; Sleijfer, DT; Vriesendorp, R	1
Etcubanas, E; Evans, W; Hayes, FA; Hutson, P; Sinkule, JA	1
Greco, FA; Hande, KR; Noone, RM; Wedlund, PJ; Wilkinson, GR; Wolff, SN	1
Schmoll, H	1
Kaye, SB	1
Fuerst, ML	1
Eagan, RT	1
Bergevin, PR; Bloomfield, CD; Cuttner, J; Ellison, RR; Falkson, G; Holland, JF; Kennedy, BJ; Kung, F; Leone, LA; Nissen, NI; Pajak, TF; Silver, RT; Weiss, RB	1
Dicke, KA; Lanzotti, V; Litam, J; McCredie, KB; Samuels, ML; Spitzer, G; Valdivieso, M; Verma, DS; Zander, A	1
Achterrath, W; Niederle, N; Schmoll, HJ	1
Issell, BF	1
Cavalli, F	2
Curry, ME; Issell, BF; Tihon, C	1
Crom, WR; Dow, L; Evans, WE; Look, AT; Rivera, G; Sinkule, JA	1
Aisner, J; Van Echo, DA; Whitacre, M; Wiernik, PH	1
Dicato, M	1
Creagan, ET; Eagan, RT; Kvols, LK	1
Antman, K; Canellos, G; Karp, G	1
Akard, L; Chang, Q; English, D; Hanks, S; Harvey, K; Jansen, J; Thompson, J	1
Bugat, R; Canal, P; Chatelut, E; Chevreau, C; De Fenin, V; Houin, G; Lavit, M; Lochon, I	1
Pang, YK; Tsang, YC; Wong, SW; Yeung, AW	1
Berenson, RJ; Brugger, W; Heimfeld, S; Henschler, R; Kanz, L; Mertelsmann, R	1
Ballester, OF; Elfenbein, GJ; Fields, KK; Foody, MC; Hiemenz, JW; Janssen, WE; Kronish, LE; Perkins, JB; Zorsky, PE	1
Chen, B; Chen, S; Galy, A; Jagannath, S; Murray, L; Negrin, R; Tricot, G; Tushinski, R; Uchida, N; Vesole, D	1
Gabizon, AA; Gorodetsky, R; Mou, X; Vexler, AM	1
Clark, RE; Creagh, MD; Shlebak, AA	1
Basile, M; Communal, Y; Condat, P; Curé, H; Fleury, J; Legros, M; Lenat, A; Sanderson, D; Subtil, E; Tavernier, F	1
Chen, B; Chen, S; Combs, J; Conti, A; DiGiusto, D; Galy, A; Murray, L; Negrin, R; Tricot, G; Tsukamoto, A	1
Bender, J; Burgess, J; Law, P; Lee, W; Schilling, M; Smith, A; Smith, S; Unverzagt, K; Van Epps, DE	1
Dercksen, MW; Dirkson, MK; Gerritsen, WR; Pinedo, HM; Rodenhuis, S; Schaasberg, WP; Slaper-Cortenbach, IC; van der Schoot, CE; von dem Borne, AE	1
Green, MR; Lilenbaum, RC; MacManus, DA	1
Dunn, J; Earl, HM; Kerr, DJ; Liu, B; Poole, CJ	1
Endo, M; Tanosaki, R	1
Allen, C; Birch, R; Hazelton, B; Palmer, P; Schwartzberg, L; Weaver, CH; West, W	1
Dolter, KE; Frisch, SM	1
Bukowski, R; Fields, SZ; Gandara, D; Goss, G; Igwemezie, LN; Kaul, S; Kosty, M; Levithan, N; O'Dwyer, P; Stewart, DJ	1
Cairo, MS	1
Greco, FA; Hainsworth, JD	2
Desai, SJ; Dickerman, JD; Goorin, AM; Harris, MB; Inoue, S; Krischer, JP; Kung, FH; Murphy, SB; Pratt, CB; Toledano, S	1
Richel, DJ; Rodenhuis, S; Schornagel, JH; ten Bokkel Huinink, WW; van der Wall, E; Vlasveld, LT	1
Luo, X; Mathew, P; Relling, MV; Ribeiro, RC; Sonnichsen, DS	1
Alonso, E; Berlanga, JJ; Ferrà, C; Gallardo, D; Grañena, A; Ponce, C; Riu, C; Salar, A	1
Ishida, Y; Kishi, H; Yanagisawa, R; Yoshida, M	1
Urushizaki, I	1
Arioka, H; Eguchi, K; Karato, A; Kunikane, H; Nishio, M; Ohe, Y; Oshita, F; Sasaki, Y; Shinkai, T; Tamura, T	1
Bertz, H; Birken, R; Brugger, W; Frisch, J; Hecht, T; Kanz, L; Mertelsmann, R; Pressler, K; Schulz, G	1
Adler, KM; Brophy, NA; Fisher, GA; Halsey, J; Lum, BL; Sikic, BI; Yahanda, AM	1
Cowie, FJ; Dick, G; Flanagan, RJ; Judson, I; McCarthy, PT; Phillips, M; Pinkerton, CR	1
Smith, DC; Trump, DL	1
Berger, C; Bewermeier, P; Krüger, WH; Mross, KB; Pichlmeier, U; Schleimer, B; Stockschläder, M; Zander, AR	1
Felix, CA; Hosler, MR; Lange, BJ; Masterson, M; Wilson, AE; Winick, NJ	1
Bout, M; Brémond, JL; Dayan, A; Delain, M; Domenech, J; Gihana, E; Linassier, C; Petit, A; Petitdidier, C; Truglio, D	1
Barbhaiya, RH; Garrow, C; Greco, A; Hainsworth, JD; Igwenezue, KB; Kaul, S; Miller, AA; Schacter, LP; Srinivas, NR; Thompson, DS	1
Douglass, EC; Green, DM; Grier, HE; van Hoff, J	1
de Boer-Dennert, M; Planting, AS; Stoter, G; van der Burg, ME; Verweij, J	1
Abe, T; Kawano, Y; Makimoto, A; Nakagawa, R; Okamoto, Y; Saito, S; Sato, J; Shimizu, T; Suzue, T; Takaue, Y	1
Cavalli, F; Cerny, T; De Fusco, M; De Jong, J; Gentili, D; McDaniel, C; Pagani, O; Prins, C; Sessa, C; Zucchetti, M	1
Mehta, J; Philpott, N; Powles, R; Treleaven, J	1
de Boer-Dennert, M; Ma, J; Planting, AS; Schellens, JH; Stoter, G; van der Burg, ME; van Ingen, HE; Verweij, J	1
Adler, KM; Brophy, NA; Fisher, GA; Halsey, J; Kaubisch, S; Lum, BL; Sikic, BI; Yahanda, AM	1
Coccia, P; Gordon, B; Hodges, E; Ruby, E; Spadinger, A; Stanley, R	1
Madden, T; Murry, DJ; Rodman, JH; Santana, VM	1
Antman, KH; Ayash, LJ; Elias, AD; Frei, E; Mazanet, R; McCauley, M; Schnipper, L; Schwartz, G; Tepler, I; Wheeler, C	1
Adler, SS; Feingold, JM; Ghalie, R; Kaizer, H; Korenblit, AD; Manson, S; Pruett, J; Reynolds, J; Valentino, LA	1
Ciobanu, N; Gray, R; Lazarus, HM; Weiner, RS; Winter, J	1
Avery, L; Bowman, L; Crist, W; Mahmoud, H; Mathew, P; Meyer, W; Pratt, C; Relling, M; Ribeiro, RC; Sonnichsen, D	1
Bewermeier, P; Hossfeld, DK; Krüger, W; Mross, K; Stockschläder, M; Zander, A	1
Formenti, SC; Mazumder, A; Muggia, FM; Uziely, B; Watkins, K	1
Ariyoshi, Y; Fukuoka, M; Furuse, K; Hayashihara, K; Komatsu, H; Nagao, K; Nakajima, H; Noda, K; Tanaka, K; Terashima, Y	1
Cassidy, J	1
Eguchi, K; Kanzawa, F; Karato, A; Kubota, N; Nishio, K; Ohe, Y; Saijo, N; Sasaki, Y; Shinkai, T; Tamura, T	1
Aisner, J; Belani, CP; Doyle, LA	1
Muggia, FM	1
Albert, E; Igwemezie, LN; Morgenthien, E; Randolph, J; Santabárbara, P; Schacter, LP; Seyedsadr, M	1
Kobayashi, K; Ratain, MJ	1
Stewart, CF	1
Joel, SP; Slevin, ML	1
Crist, WM; Pratt, CB; Pui, CH; Rivera, GK; Santana, VM	1
Allen, SL; Behr, J; Budman, DR; Hock, K; Igwemezie, LN; Kaul, S; Kolitz, J; Lichtman, S; Schulman, P; Vinciguerra, V	1
de Souza, P; Friedlander, M; Kirsten, F; Ryan, M; Wilde, C	1
Broxterman, HJ; Eekman, CA; Kuiper, CM; Lankelma, J; Pinedo, HM; Schuurhuis, GJ; Versantvoort, CH	1
Colnan, L; Kannourakis, G; Kellie, S; Lockwood, L; McCowage, G; Nayanar, V; Seshadri, R; Shaw, P; Tiedemann, K; White, L	1
Elfenbein, GJ; Fields, KK; Hiemenz, JW; Kronish, LE; Zorsky, PE	1
Bowman, LC; Furman, W; Jones, DP; Marina, NM; Meyer, WH; Murry, DJ; Pratt, CB; Rodman, JH; Shema, SJ	1
Evans, WE; McLeod, HL	2
Greco, FA; Hainsworth, JD; Hande, KR; Holzmer, M; Thompson, DS	1
Greco, FA	3
Bourhis, JH; Castagna, L; Chazard, M; Droz, JP; Ibrahim, A; Maraninchi, D; Pico, JL	1
Andersson, M; Daugaard, G; Ersbøll, J; Hansen, SW; Hou-Jensen, K; Larsen, SO; Nielsen, D; Pedersen-Bjergaard, J; Philip, P; Sigsgaard, TC	1
Brugger, W; Kanz, L; Mertelsmann, R	1
Bowen, KJ; Burris, HA; Clark, GM; Eckardt, JR; Fields, SM; Kuhn, JG; Rinaldi, DA; Shaffer, DW; Smith, LS; Weiss, GR	1
Ferguson, J; Holdsworth, MT; Martinez, L; Neidhart, JA; Roon, R; Stidley, CA	1
Greco, FA; Hainsworth, JD; Hande, KR; Holzmer, MC; Thompson, DS	1
Kohno, K; Kuwano, M; Matsuo, K; Sato, S; Tanimura, H; Uchiumi, T; Yamada, Y	1
Beaujean, F; Bourhis, JH; Chazard, M; Hayat, M; Ibrahim, A; Lhomme, C; Maraninchi, D; Ostronoff, M; Viens, P; Zambon, E	1
Alcaraz, J; Andrews, P; Braly, P; Goel, R; Gorelick, S; Hoff, S; Kim, S; Kirmani, S; McClay, EF; Plaxe, S	1
Cole, M; Lowis, SP; Newell, DR; Pearson, AD	1
Mick, R; Ratain, MJ	1
Fritsch, HW; Hahn, M; Havemann, K; Holz, JB; Jungclas, H; Köhl, P; Pflüger, KH; Schmidt, L	1
Bowman, LC; Douglass, E; Furman, W; Hudson, M; Marina, NM; Meyer, W; Rodman, J; Santana, VM; Shema, SJ; Wilimas, J	1
Grosh, WW; Lowry, P; Quesenberry, PJ; Stewart, FM; Temeles, D; Thraves, T	1
Confer, DL; Epstein, RB; Saez, RA; Selby, GB; Slease, RB; Strnad, C	1
Fritsch, HW; Holz, JB; Jungclas, H; Köppler, H; Pflüger, KH; Schmidt, L	1
Block, T; Depenbrock, H; Fellbaum, C; Hanauske, AR; Peter, R; Rastetter, J; Wenger, M	1
Lokich, J	1
Anderson, PM; Skubitz, KM	1
Bleehen, NM; Boote, DJ; Brampton, MH; Dennis, IF; Hensel, S; Laburte, C; Osborne, RJ; Smyth, JF; Twentyman, PR	1
Balmanno, K; Chapman, F; Charlton, CJ; Gumbrell, L; Igwemezie, LN; Lind, MJ; Millward, MJ; Mummaneni, V; Newell, DR; Proctor, M	1
Baer, J; Budman, DR; Fields, SZ; Hock, K; Ingram, R; Kreis, W; Schacter, LP; Vinciguerra, V	1
Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L	1
Munck, JN	1
Abigerges, D; Armand, JP; Bonnay, M; Chabot, GG; de Forni, M; Igwemezie, L; Kaul, S; Ropers, J; Schacter, L; Terret, C; Winograd, B	1
Nakaya, K	2
Arbuck, SG; DeMaria, D; Ford, PA; Miller, LL; Minniti, C; O'Dwyer, PJ	1
Abe, T; Hisano, T; Kohno, K; Koike, K; Kubo, T; Kuwano, M; Wada, M	1
Avery, L; Fang, L; Furman, WL; Luo, X; Marina, N; Pratt, CB	1
Bucsky, P; d'Oleire, F; Eleftheriadis, S; Feyerabend, T; Freund, C; Gillis, W; Katschinski, DM; Mentzel, M; Robins, HI; Touhidi, RR; van Heek, R; Wagner, T; Weiss, C; Wiedemann, GJ	1
Ager, S; Baglin, TP; Barker, P; Bass, G; Bloxham, DM; Boraks, PA; Hood, IM; Jestice, HK; Johnson, D; Mahendra, P; Marcus, RE; Scott, MA	1
Aguilar-Ponce, L; Dueñas-Gonzalez, A; Frias-Mendivil, M; Gallardo-Rincon, D; Lara-Medina, F; Miranda-Lopez, E; Reynoso-Gomez, E; Sobrevilla-Calvo, P; Zinser-Sierra, J	1
Izrael, V; Lotz, JP	1
Lock, RB; Stribinskiene, L	1
Chen, S; Lee, BC; Miller, AA; Molthrop, DC; Robert, F; Wheeler, RH	1
DeMoor, C; Eckardt, JR; Rinaldi, DA; Rodriguez, GI; Shaffer, DW; Stephens, C; Von Hoff, DD; Weiss, GR	1
Joel, S	1
Alberts, DS; Barbhaiya, RH; Brooks, DJ; Igwemzie, LM; Kaul, S; McKinney, LM; Randolph, J; Schacter, L; Srinivas, NR; Thomas, T	1
Clynes, M; Dolan, E; Heenan, M; Kavanagh, K; Maher, M; Moriarty, M; O'Neill, P; Redmond, A	1
Gaarsdal, E; Jensen, L; Johnsen, HE; Knudsen, LM; Nielsen, KJ; Nikolaisen, K	1
Behr, J; Budman, DR; Cherny, RC; Fields, SZ; Ingram, R; Kreis, W; Schacter, LP; Schulman, P; Snow, C; Wright, J; Young, RR	1
McMillan, R; Meisenberg, BR; Miller, WE	1
Curry, J; da Cruz, A; de Boer, J; Glickman, BW; Karnaoukhova, L; Khaidakov, M; Kusser, WC; Moffat, J	1
Lowis, SP; Newell, DR	1
Barbhaiya, RH; Calvert, AH; Igwemezie, LN; Kaul, S; Mummaneni, V; Newell, DR; Porter, D; Thomas, H; Winograd, B	1
Creaven, PJ; Gunton, KE; Meropol, NJ; Noel, D; Pendyala, L; Schacter, LP; Soni, N	1
Linsenmeyer, ME; Millward, MJ; Rischin, D; Urch, ME; Webster, LK; Woodcock, DM	1
De Filippis, S; Frati, L; Gulino, A; Quaglino, D; Rea, S; Recchia, F; Torchio, P	1
Belasco, JB; Geyer, JR; Goldwein, JW; Herman-Liu, A; Molloy, PT; Needle, MN; Phillips, PC; Sutton, L	1
Bleyer, A; Fairclough, D; Furman, WL; Garrison, L; Luo, X; Marina, N; Meyer, WH; Pratt, CB	1
Furukawa, M; Harada, T; Kuwano, M; Tanaka, T	1
Carpenter, P; Lockwood, L; McCowage, GB; Shaw, PJ; Tiedemann, K; Toogood, I; White, L	1
Bessho, A; Harada, M; Higuchi, M; Miyamoto, T; Miyoshi, T; Ohno, Y; Omoto, E; Shinagawa, K; Sunami, K; Teshima, T; Ueoka, H	1
Bergman, AM; Guechev, A; Peters, GJ; Postmus, PE; van Moorsel, CJ; Veerman, G; Vermorken, JB	1
Carpenter, PA; Lockwood, L; McCowage, GB; Nayanar, V; Shaw, PJ; Tiedemann, K; Toogood, I; White, L	1
Buhles, W; Hersh, E; Issell, B; Neidhart, J; Rinehart, J; Triozzi, P	1
Agaliotis, DP; Ballester, OF; Elfenbein, GJ; Fields, KK; Goldstein, SC; Hiemenz, JW; Mattox, T; Perkins, JB; Rosen, RM; Zorsky, PE	1
Beijnen, JH; Dubbelman, AC; Groot, Y; Herben, VM; Mandjes, IA; ten Bokkel Huinink, WW; van Gortel-van Zomeren, DM	1
Becker, AT; Gruppo, RA; Harris, RE; Hashmi, R; Morris, CL; Morris, JD; Sambrano, JE	1
Fojo, T; Iglesias, A; Matsumoto, Y; Nagao, S; Takano, H	1
Bajera, I; Chciałowski, A; Jahnz-Rózyk, K; Targowski, T	1
Bachaud, JM; Bugat, R; Canal, P; Chatelut, E; Chevreau, C; Houin, G; Lochon, I; Nguyen, L; Pujol, A; Tranchand, B	1
Arnold, B; Furman, WL; Garrison, L; Hanna, R; Luo, X; Marina, N; Meyer, WH; Pratt, CB; Rodman, JH; Tonda, ME	1
Davidson, A; Dicks-Mireaux, C; Gowing, R; Lewis, I; Lowis, S; Newell, D; Pinkerton, CR	1
Greco, FA; Hainsworth, JD; Utley, SM	1
Antman, KH; Ayash, LJ; Coleman, N; Elias, AD; Frei, E; Ibrahim, J; McCauley, M; Mills, L; Schnipper, L; Schwartz, G; Teicher, BA; Warren, D; Wheeler, C	1
Burris, HA; Eckardt, JR; Eckhardt, SG; Ganapathi, R; Hammond, LA; Hodges, S; Kuhn, JG; Rodriguez, GA; Rothenberg, ML; Rowinsky, EK; Von Hoff, DD; Weiss, GR	1
Austin, CA; Marsh, KL	1
Rowinsky, EK; Siu, LL	1
Bisogno, G; Boddy, A; Cowie, F; Dick, G; Pinkerton, CR; Thomas, HD	1
Cole, M; Lowis, SP; Newell, DR; Pearson, AD; Price, L	1
Fojo, T; Kunishio, K; Matsumoto, Y; Morisaki, K; Nagao, S; Takano, H	1
Blumenstengel, K; Fricke, HJ; Höffken, K; Kath, R; Kunert, C; Sayer, HG; Vogel, W	1
Anderson, N; Bern, M; Coco, F; Dow, E; Lokich, J; Moore, C; Sonneborn, H; Strong, D	1
Bajorin, D; Cheung, NK; Heller, G; Kramer, K; Kushner, BH; Meyers, PA; Polyak, T; Wollner, N	1
Bergeron, S; Blazar, BR; Cairo, MS; Garrison, L; Krailo, MD; Reaman, GH; Secola, R; van de Ven, C; Weinthal, JA	1
Abboudi, Z; Abrahamson, G; Apperley, JF; Chilcott, S; Craddock, C; Davis, J; Kanfer, EJ; MacDonald, C; Macdonald, D; McGuigan, D; Newlands, ES; Olavarria, E; Philpott, N; Rustin, GJ; Samson, D; Seckl, MJ; Sekhar, M; Stern, S	1
Fukuda, H; Kunitoh, H; Saijo, N; Sekine, I	1
Barbhaiya, RH; Fields, SZ; Himpler, BS; Igwemezie, LN; Kaul, S; Litam, PP; McAleer, C; Schacter, LP; Schilder, RJ; Wright, J	1
Campion, M; Hersh, E; Levitt, D; Margolin, KA; Resta, D; Rinehart, J; Triozzi, P	1
Oltersdorf, T; Reed, JC; Sausville, E; Scudiero, DA; Tamm, I; Vigna, N; Wang, Y	1
Armand, JP; Couteau, C	1
Amsellem, C; Ardiet, CJ; Canal, P; Chatelut, E; Freyer, G; Iliadis, A; Ligneau, B; Lochon, I; Tranchand, B; Trillet-Lenoir, V	1
Bramwell, V; Rusthoven, J; Stephenson, B	1
Amarante-Mendes, GP; Cotter, TG; Finucane, DM; Green, DR; Martin, SJ; Salvesen, GS	1
Furue, H	1
Bishop, WR; Izbicka, E; Lawrence, RA; Petit, T; Von Hoff, DD; Weitman, S	1
Beijnen, JH; de Wit, R; Lieverst, J; Nannan Panday, VR; Rosing, H; Schellens, JH; Schornagel, JH; Schot, M; ten Bokkel Huinink, WW	1
Chao, Y; Chen, LL; Chen, LT; Chen, MH; Huang, TS; Lee, CC; Shu, CH; Whang-Peng, J; Yuan, CC	1
Caramatti, C; Cesana, C; Garau, D; Mangoni, L; Regazzi, E; Rizzoli, V	1
Vastag, B	1
Joseph, CD; Kuttan, G; Kuttan, R; Praveenkumar, V	1
Hainsworth, JD	1
Bamias, A; Katsimbri, P; Pavlidis, N	1
Bash, RO; Herrera, L; Kamen, BA; Leavey, PJ; Mantadakis, E; Winick, NJ	1
Chen, CL; Uckun, FM	1
Pappo, AS; Spunt, SL	1
Durand, RE; Olive, PL	1
Chow, W; Coluzzi, P; Doroshow, JH; Hamasaki, V; Leong, LA; Margolin, KA; Morgan, RJ; Raschko, JW; Shibata, SI; Somlo, G; Synold, TW; ter Veer, A; Tetef, ML; Yen, Y	1
Bauer, M; Blatt, J; Blazar, BR; Cairo, MS; Frierdich, S; Krailo, MD; Liu-Mares, W; Miser, JS; Reaman, GH; Sato, JK; Shen, V	1
Ames, MM; Bergeron, S; Blazar, BR; Bracho, F; Cairo, MS; Davenport, V; Krailo, MD; Liu-Mares, W; Panoskaltsis-Mortari, A; Reaman, GH; Reid, JM; Secola, R; Shen, V; van de Ven, C	1
Cannizzaro, L; Chin, L; DePinho, RA; Greenberg, RA; Ju, YJ; Lee, KH; Rudolph, KL; Weiler, SR	1
Boos, J; Würthwein, G	1
Herman, ZS; Machalski, M; Scieszka, M; Zielinski, M	1
Engels, IH; Janssen, O; Kabelitz, D; Lauber, K; Schulze-Osthoff, K; Stepczynska, A; Wesselborg, S	1
Ratain, MJ; Sawyer, M	1
Baruchel, S; Fouladi, M; Gammon, J; Grant, R; Greenberg, ML; Klein, J; Koren, G; Stempak, D	1
Dixon, JE; Donner, DB; Durden, DL; Mayo, LD; Tonks, NK	1
Adamson, ED; Baron, V; Birle, D; de Belle, I; Mercola, D; Mustelin, T; Virolle, T	1
Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T	1
Gawron, A; Jakubowicz-Gil, J; Kandefer-Szerszeń, M; Paduch, R	1
Christodoulou, C; Efstathiou, E; Klouvas, G; Papazachariou, E; Plyta, M; Skarlos, DV; Zervakis, D	1
Boos, J; Klingebiel, T; Kranz, K; Krümpelmann, S; Lanvers, C; Metz, M; Schwenker, K; Würthwein, G	1
Herrera, P; Jodra, MH; Laraña, JG; López, J; Navarro, JL; Odriozola, J; Pérez de Oteyza, J; Ramos, ML; Ramos, P; Roldán, E; Villalón, L; Zamora, C	1
Lichtman, SM; Skirvin, JA	1
Carter, SK; Slavik, M	1
Adamson, RH; Mead, JA; Sieber, SM	1
Carter, SK; Muggia, FM; Rozencweig, M; Slavik, M	1
Beckmann, C; Flury, R; Frei, P; Holdener, E; Jungi, WF; Senn, HJ	1
Barlogie, B; Corry, PM; Dosik, G; Freireich, EJ; Hankenson, R; Johnston, DA; Khalil, K; Lawson, R; Lippman, L; Reilly, E; Rigor, B; Tenczynski, TF; Yip, E	1
Hansen, HH; Lau, ME; Nissen, NI; Pedersen, H	1
Crooke, ST; Issell, BF	1
Arnold, AM	1
Crooke, ST; Gutierrez, ML	1
Brunner, KW; Cavalli, F; Ryssel, HJ; Sonntag, RW	1
Allen, LM; Creaven, PJ	1
Arnold, BA; Cain, AM; Crist, WM; Fairclough, D; Furman, WL; Meyer, WH; Pratt, CB	1
Loehrer, PJ	1
Carmichael, J; Harris, AL; Houlbrook, S; Kirk, J; Lien, EA; Philip, P; Stuart, NS; Tonkin, K	1
Bross, K; Brugger, W; Dern, P; Frisch, J; Kanz, L; Mertelsmann, R; Weber, B	1
Weiss, RB	1
Alder, KM; Brophy, NA; Fisher, GA; Gosland, MP; Halsey, J; Hardy, RI; Lum, BL; Sikic, BI; Yahanda, AM	1
Adler, KM; Brophy, NA; Ehsan, MN; Gosland, MP; Halsey, J; Jew, L; Kaubisch, S; Lum, BL; Sikic, BI; Yahanda, AM	1
Bryant, G; Carter, C; Cottler-Fox, M; Cowan, KH; Goldspiel, B; Jain, V; Longo, DL; Steinberg, SM; Wilson, WH; Wittes, RE	1
Fay, JW; Harden, EA; Herzig, GP; Herzig, RH; Heye, MM; Meagher, RC; Montes, VM; Stevens, DA	1
Kok, TC; Splinter, TA; van der Gaast, A	1
Kok, TC; Splinter, TA; van der Gaast, A; Vlastuin, M	1
Crist, WM; Crom, WR; Evans, WE; Groom, S; McLeod, HL; Relling, MV; Rivera, GK; Rodman, JH; Silverstein, K	1
Anderson, N; Bern, M; Gonsalves, L; Lokich, J; Moore, C; Zipoli, T	1
Brugger, W; Frisch, J; Kanz, L; Mertelsmann, R; Pressler, K; Schulz, G	1
Cantwell, BM; Carmichael, J; Harris, AL; Lien, EA; Millward, MJ	1
Bokemeyer, C; Harstrick, A; Hohnloser, J; Illiger, HJ; Metzner, B; Osternamm, A; Preiss, J; Ruther, U; Schmoll, HJ; Wilke, H	1
Andersson, BS; Dicke, K; Dunphy, FR; Hester, J; Huan, SD; LeMaistre, CF; Spencer, V; Spitzer, G; Wallerstein, RO; Yau, JC	1
Madden, T; Rodman, JH; Santana, VM; Sunderland, M	1
de Vries, EG; Meijer, C; Mulder, NH; Mulder, PO; Nanninga, AG; Uges, DR; van der Graaf, WT; Vellenga, E	1
Kohno, K; Kuwano, M; Ono, M; Takano, H; Uchida, Y	1
Bremer, K; Uhlenbusch, R	1
Buscema, J; Currie, JL; McLellan, R; Woodruff, JD	1
Carmichael, J; Dolega-Ossowski, E; Harris, AL; Idle, JR; Joel, S; Monkman, SC; Philip, PA; Tonkin, K	1
Hausamen, TU; Loeffler, TM; Weber, FW	1
Einhorn, LH	1
Deisseroth, AB; Dicke, K; Dunphy, FR; Holmes, FA; Hortobagyi, GN; Huan, SD; LeMaistre, CF; Spencer, V; Wallerstein, RO; Yau, JC	1
Havemann, K; Köppler, H; Pflüger, KH	1
Arbuck, SG; Evans, WE; Fleming, RA; Stewart, CF	3
D'Incalci, M; Garattini, S	1
Emminger, W; Emminger-Schmidmeier, W; Gadner, H; Hawliczek, R; Höcker, P; Peters, C	1
Albertini, M; Saphner, T; Tormey, DC	1
Von Hoff, DD	1
Aisner, J; Lee, EJ	1
Herzig, RH	1
Carney, DN	1
Greco, FA; Hainsworth, JD; Johnson, DH	2
Slevin, ML	1
Berthelot, P; Boboc, B; Carnot, F; Housset, C; Tourani, JM; Tran, A	1
Kiue, A; Kohno, K; Kuwano, M; Takano, H; Watanabe, Y	1
Berezin, F; Mick, R; Ratain, MJ; Schilsky, RL; Vogelzang, NJ	1
Brenner, DE	1
Miller, AA; Stewart, CF; Tolley, EA	1
Creger, RJ; Fox, RM; Lazarus, HM	1
Brogden, RN; Henwood, JM	1
Dhingra, HM; Engineer, MS; Holmes, FA; Holoye, PY; Jeffries, DG; Newman, RA; Raber, M	1
Castello, MA; Clerico, A; Dominici, C; Jenkner, A	1
Anderson, T; Kohler, W; Mangalik, A; Neidhart, JA; Plauche, A; Quenzer, RW; Rinehart, JJ; Stidley, C	1
Akiyama, Y; Ito, M; Kamiya, H; Kawa, K; Mikawa, H; Miyazaki, S; Sakurai, M; Tujino, G; Ueda, K	1
Cattan, A; Desoize, B; Marechal, F	1
Laurell, G; Skedinger, M	1
Chauvenet, AR; Cruz, JM; Jackson, DV; Muss, HB; White, DR	1
Markman, M	1
Bagshawe, KD; Begent, RH; Crawford, SM; Ledermann, JA; Newlands, ES; Rustin, GJ; Turkie, W	1
Bregni, M; Gianni, AM; Siena, S; Tarella, C	1
Ishitani, KP; Kaiser, DL; Niskanen, E; Pirsch, GW; Stewart, FM	1
Alimonti, A; Caroli, S; Castello, MA; Dominici, C; La Torre, F; Petrucci, F	1
Caponera, ME; Cruz, JM; Jackson, DV; Muss, HB; Richards, F; Spurr, CL; White, DR; Zekan, PJ	1
McVie, G; Muggia, FM	1
Arbuck, SG; Evans, WE; Pieper, JA; Stewart, CF	1
Frazier, SR; Greco, FA; Hainsworth, JD; Johnson, DH	1
Kimura, K; Niitani, H; Yamada, K	1
Peters, W; Souhami, R	1
Cummings, J; Cunningham, D; Forrest, GJ; McTaggart, L; Soukop, M; Stuart, JF	1
Helson, L	1
Beekhuis, H; de Jong, R; de Vries, EG; Mulder, NH; Piers, DA	1
Dallorso, S; De Bernardi, B; Dini, G; Moroni, C; Perin, G; Rogers, D; Stura, M	1
Ratain, MJ; Schilsky, RL; Senekjian, EK; Simon, T; Vogelzang, NJ; Wojack, BR	1
Berger, NA; Lazarus, HM	1
Berry, DH; Brodeur, G; Dubowy, R; Hayes, FA; Krischer, J; Kung, F; Leventhal, B; Mahoney, D; Toledano, S	1
Betcher, D; Burnham, N	1
Appelbaum, FR; Buckner, CD	1
Lampkin, BC; Wong, KY	1
Havemann, K; Jungclas, H; Merkel, M; Pflüger, KH; Schmidt, L	1
Cummings, J; Cunningham, D; Forrest, GJ; Gilchrist, NL; Soukop, M	1
Arbuck, SG; Cooper, C; Crom, WR; Douglass, HO; Evans, WE; Goodwin, P; Silk, Y	1
Maroun, JA; Nundy, D; Prior, J; Stewart, DJ; Tetreault, L	1
de Gast, GC; Dekker, AW; Rozenberg-Arska, M; Schornagel, JH; van Kempen, ML; Vendrik, CP; Verdonck, LF	1
Hashimoto, S; Kano, A; Kawamoto, K; Konno, K; Sakata, Y; Sato, S; Takahashi, H; Wakui, A; Yokoyama, M; Yoshida, Y	1

Reviews

87 review(s) available for etoposide and Neoplasms

Article	Year
Podophyllotoxin derivatives as an excellent anticancer aspirant for future chemotherapy: A key current imminent needs. Bioorganic & medicinal chemistry, 2018, 01-15, Volume: 26, Issue:2 Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neoplasms; Podophyllotoxin; Structure-Activity Relationship	2018
Quinolone hybrids and their anti-cancer activities: An overview. European journal of medicinal chemistry, 2019, Mar-01, Volume: 165 Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship	2019
Coumarin-containing hybrids and their anticancer activities. European journal of medicinal chemistry, 2019, Nov-01, Volume: 181 Topics: Animals; Antineoplastic Agents; Coumarins; Drug Design; Drug Discovery; Humans; Neoplasms; Structure-Activity Relationship	2019
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. European journal of medicinal chemistry, 2019, Dec-01, Volume: 183 Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles	2019
Therapeutic progression of quinazolines as targeted chemotherapeutic agents. European journal of medicinal chemistry, 2021, Feb-05, Volume: 211 Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines	2021
Synthesis and anti-tumor activity of marine alkaloids. Bioorganic & medicinal chemistry letters, 2021, 06-01, Volume: 41 Topics: Alkaloids; Antineoplastic Agents; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Neoplasms	2021
Clinical factors of PICC-RVT in cancer patients: a meta-analysis. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023, Jun-14, Volume: 31, Issue:7 Topics: Catheters; China; Databases, Factual; Etoposide; Humans; Neoplasms	2023
Radiation therapy of cancer in the adolescent and young adult (AYA) generation. Japanese journal of radiology, 2023, Volume: 41, Issue:12 Topics: Adolescent; Child; Etoposide; Fertility; Humans; Neoplasms; Young Adult	2023
Recent advancements in the targeted delivery of etoposide nanomedicine for cancer therapy: A comprehensive review. European journal of medicinal chemistry, 2023, Nov-05, Volume: 259 Topics: Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Etoposide; Humans; Liposomes; Nanomedicine; Nanoparticles; Neoplasms	2023
Haemophagocytic lymphohistiocytosis in human immunodeficiency virus: a systematic review of literature. Drug discoveries & therapeutics, 2020, Nov-04, Volume: 14, Issue:5 Topics: Adult; Anti-Retroviral Agents; Etoposide; Female; HIV; HIV Infections; Humans; Lymphohistiocytosis, Hemophagocytic; Male; Middle Aged; Neoplasms; Opportunistic Infections; Retrospective Studies; Steroids; Topoisomerase II Inhibitors	2020
Natural Polyphenols as Modulators of Etoposide Anti-Cancer Activity. International journal of molecular sciences, 2021, Jun-20, Volume: 22, Issue:12 Topics: Animals; Antineoplastic Agents, Phytogenic; Biomarkers; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Etoposide; Humans; Neoplasms; Polyphenols; Structure-Activity Relationship; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays	2021
Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:8 Topics: Adult; Antineoplastic Agents; Child; Clinical Trials as Topic; Epirubicin; Etoposide; Humans; Melphalan; Molecular Targeted Therapy; Neoplasms; Topotecan	2011
TT-232: a somatostatin structural derivative as a potent antitumor drug candidate. Anti-cancer drugs, 2003, Volume: 14, Issue:8 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Dacarbazine; Etoposide; Humans; Neoplasms; Peptides, Cyclic; Somatostatin	2003
Pharmacokinetic optimisation of treatment with oral etoposide. Clinical pharmacokinetics, 2004, Volume: 43, Issue:7 Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Etoposide; Half-Life; Humans; Intestinal Absorption; Neoplasms; Structure-Activity Relationship; Tissue Distribution	2004
Topoisomerase II inhibitors. Cancer chemotherapy and biological response modifiers, 2003, Volume: 21 Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; DNA Damage; Enzyme Inhibitors; Etoposide; Humans; Neoplasms; Topoisomerase II Inhibitors	2003
Etoposide, topoisomerase II and cancer. Current medicinal chemistry. Anti-cancer agents, 2005, Volume: 5, Issue:4 Topics: Animals; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Humans; Neoplasms; Structure-Activity Relationship; Topoisomerase II Inhibitors	2005
Topoisomerase II inhibitors. Cancer chemotherapy and biological response modifiers, 2005, Volume: 22 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Enzyme Inhibitors; Etoposide; Humans; Neoplasms; Topoisomerase II Inhibitors	2005
Pulmonary complications of novel antineoplastic agents for solid tumors. Chest, 2008, Volume: 133, Issue:2 Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Everolimus; Gemcitabine; Humans; Lung; Lung Diseases; Mitoxantrone; Neoplasms; Pneumonia; Pyrimidines; Risk Factors; Sirolimus; Teniposide; Trastuzumab	2008
[New antineoplastic agents, their value and use]. Przeglad lekarski, 1982, Volume: 39, Issue:8 Topics: Aminacrine; Antineoplastic Agents; Aspartic Acid; Cisplatin; Etoposide; Humans; Ifosfamide; Interferons; Medroxyprogesterone; Medroxyprogesterone Acetate; Methyltestosterone; Neoplasms; Phosphonoacetic Acid; Razoxane; Tamoxifen; Teniposide; Vinca Alkaloids	1982
Therapeutic progress--review VIII. Do the newer cytotoxic drugs represent a significant advance in the treatment of cancer? Journal of clinical and hospital pharmacy, 1983, Volume: 8, Issue:2 Topics: Animals; Antineoplastic Agents; Cisplatin; Etoposide; Humans; Neoplasms	1983
Review of etoposide single-agent activity. Cancer treatment reviews, 1982, Volume: 9 Suppl Topics: Animals; Drug Administration Schedule; Etoposide; Female; Humans; Male; Neoplasms; Podophyllotoxin	1982
Intensive chemotherapy for solid tumours--current clinical applications. Cancer chemotherapy and pharmacology, 1982, Volume: 9, Issue:3 Topics: Antineoplastic Agents; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Forecasting; Humans; Melphalan; Neoplasms	1982
The podophyllotoxin derivatives VP16-213 and VM26. Cancer chemotherapy and pharmacology, 1982, Volume: 7, Issue:2-3 Topics: Animals; Chemical Phenomena; Chemistry; Drug Therapy, Combination; Etoposide; Humans; Neoplasms; Podophyllotoxin; Teniposide	1982
VP16-213 (etoposide). A critical review of its activity. Cancer chemotherapy and pharmacology, 1982, Volume: 7, Issue:2-3 Topics: Drug Evaluation; Etoposide; Humans; Neoplasms; Podophyllotoxin; Research Design	1982
[Myeloablative chemotherapy with autologous bone marrow and/or peripheral blood stem cell transplantation in children with high-risk solid tumor]. Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Carboplatin; Child; Combined Modality Therapy; Cryopreservation; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Kidney Neoplasms; Neoplasms; Neuroblastoma; Rhabdomyosarcoma; Wilms Tumor	1995
The use of ifosfamide, carboplatin, and etoposide in children with solid tumors. Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 7 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Neoplasms; Neuroblastoma; Neutropenia; Sarcoma; Thrombocytopenia; Wilms Tumor	1995
Etoposide: twenty years later. Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:4 Topics: Drug Administration Schedule; Drug Synergism; Etoposide; Humans; Neoplasms	1995
Clinical reversal of multidrug resistance. Cancer treatment and research, 1994, Volume: 73 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Clinical Trials as Topic; Cyclosporine; Drug Resistance, Multiple; Etoposide; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel; Pharmaceutical Preparations; Verapamil	1994
Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations. Cancer, 1993, Dec-01, Volume: 72, Issue:11 Suppl Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Clinical Trials as Topic; Cyclosporine; Drug Resistance; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Membrane Glycoproteins; Neoplasm Proteins; Neoplasms	1993
Chemotherapy administration: doses, infusions and choice of schedule. Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5 Suppl 4 Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Neoplasms	1994
Prolonged administration of low-daily-dose etoposide: a superior dosing schedule? Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Neoplasms; Pilot Projects; Time Factors	1994
7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials. Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl Topics: Amino Acid Sequence; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; CHO Cells; Clinical Trials, Phase I as Topic; Cricetinae; DNA Topoisomerases, Type I; Drug Resistance; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Molecular Sequence Data; Neoplasms; Ovarian Neoplasms; Point Mutation; Topoisomerase I Inhibitors; Tumor Cells, Cultured	1994
Etoposide: current status and future perspectives in the management of malignant neoplasms. Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl Topics: Acquired Immunodeficiency Syndrome; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Etoposide; Germinoma; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Neoplasms; Sarcoma, Kaposi; Stomach Neoplasms	1994
Teniposide: overview of its therapeutic potential in adult cancers. Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl Topics: Acquired Immunodeficiency Syndrome; Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Etoposide; Female; Genital Neoplasms, Female; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Sarcoma, Kaposi; Teniposide	1994
Pharmacodynamics and long-term toxicity of etoposide. Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl Topics: Child; Etoposide; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Neoplasms; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Testicular Neoplasms	1994
Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl Topics: Etoposide; Humans; Intestinal Absorption; Kidney; Liver; Neoplasms; Renal Dialysis	1994
Schedule-dependent topoisomerase II-inhibiting drugs. Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl Topics: Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Cycle; Clinical Trials, Phase I as Topic; DNA Repair; Drug Administration Schedule; Etoposide; Humans; Metabolic Clearance Rate; Neoplasms; Teniposide; Topoisomerase II Inhibitors	1994
Epipodophyllotoxins in the treatment of childhood cancer. Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Neoplasms; Neoplasms, Second Primary; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Teniposide	1994
Hypersensitivity reactions to etoposide. A report of three cases and review of the literature. American journal of clinical oncology, 1994, Volume: 17, Issue:5 Topics: Adult; Drug Hypersensitivity; Etoposide; Female; Humans; Neoplasms	1994
Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins. Cancer surveys, 1993, Volume: 17 Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Etoposide; Humans; Leukemia; Neoplasms; Neoplasms, Second Primary; Teniposide; Topoisomerase II Inhibitors	1993
Chronic etoposide administration: overview of clinical experience. Cancer treatment reviews, 1993, Volume: 19 Suppl C Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Drug Administration Schedule; Etoposide; Female; Germinoma; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasms; Ovarian Neoplasms	1993
Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification. European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A Suppl 5 Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion, Autologous; Cisplatin; Drug Administration Schedule; Etoposide; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cells; Humans; Ifosfamide; Neoplasms	1993
[Etoposide: specificity of prolonged oral administration]. Bulletin du cancer, 1996, Volume: 83, Issue:5 Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Neoplasms; Quality of Life; Remission Induction; Treatment Outcome	1996
[On the novel differentiation-apoptosis inducers in tumor cells]. Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme, 1996, Volume: 41, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Bufanolides; Camptothecin; Cell Differentiation; Etoposide; Humans; Neoplasms; Sodium-Potassium-Exchanging ATPase; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors	1996
[Clinical studies on combination of ifosfamide, carboplatin and etoposide (ICE) with whole body hyperthermia]. Medizinische Klinik (Munich, Germany : 1983), 1996, May-15, Volume: 91, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Humans; Hyperthermia, Induced; Ifosfamide; Neoplasms; Treatment Outcome	1996
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients. Bone marrow transplantation, 1996, Volume: 17, Issue:4 Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Movement; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Kidney Diseases; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning	1996
The importance of drug scheduling in cancer chemotherapy: etoposide as an example. Stem cells (Dayton, Ohio), 1996, Volume: 14, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Humans; Neoplasms	1996
The clinical pharmacology of etoposide: an update. Cancer treatment reviews, 1996, Volume: 22, Issue:3 Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Humans; Neoplasms; Neoplasms, Second Primary	1996
[Mechanism of the induction of apoptosis in cancer cells]. Seikagaku. The Journal of Japanese Biochemical Society, 1996, Volume: 68, Issue:12 Topics: Animals; Antineoplastic Agents; Apoptosis; Bufanolides; Diterpenes; Drug Design; Etoposide; Humans; Neoplasms; Protein Prenylation; Signal Transduction; Topoisomerase I Inhibitors; Ultraviolet Rays	1996
Mutational specificity and cancer chemoprevention. Journal of cellular biochemistry. Supplement, 1996, Volume: 25 Topics: Animals; Animals, Genetically Modified; Biomarkers, Tumor; Chemoprevention; DNA Mutational Analysis; Etoposide; Genetic Testing; Humans; Hypoxanthine Phosphoribosyltransferase; Mutagenicity Tests; Neoplasms; T-Lymphocytes; Tumor Suppressor Protein p53	1996
Etoposide for the treatment of paediatric tumours: what is the best way to give it? European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:13 Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Etoposide; Humans; Infant; Infusions, Intravenous; Neoplasms	1996
[DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance]. Nihon rinsho. Japanese journal of clinical medicine, 1997, Volume: 55, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Irinotecan; Mutation; Neoplasms; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured	1997
Combination chemotherapy studies with gemcitabine. Seminars in oncology, 1997, Volume: 24, Issue:2 Suppl 7 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Deoxycytidine; Drug Synergism; Etoposide; Gemcitabine; Humans; Mitomycin; Neoplasms; Ribonucleotide Reductases; Tumor Cells, Cultured	1997
[Tumor necrosis factor-alpha--phase I and phase II clinical trials]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 1997, Volume: 2, Issue:12 Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Drug Synergism; Etoposide; Humans; Immunotherapy; Interferon-gamma; Interleukin-2; Neoplasms; Tumor Necrosis Factor-alpha	1997
Eukaryotic DNA topoisomerase II beta. BioEssays : news and reviews in molecular, cellular and developmental biology, 1998, Volume: 20, Issue:3 Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Cell Cycle; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Superhelical; Etoposide; Humans; Mice; Molecular Sequence Data; Neoplasms; Sequence Alignment; Sequence Homology, Amino Acid	1998
Cancer chemotherapy in the elderly. Japanese journal of clinical oncology, 1998, Volume: 28, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Busulfan; Daunorubicin; Doxorubicin; Etoposide; Female; Fluorouracil; Heart; Hematologic Neoplasms; Humans; Lung; Male; Middle Aged; Neoplasms; Pyrazoles	1998
Etoposide: four decades of development of a topoisomerase II inhibitor. European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:10 Topics: Administration, Oral; Anthracyclines; Antineoplastic Agents, Phytogenic; Etoposide; Humans; Mitoxantrone; Neoplasms; Technology, Pharmaceutical; Teniposide; Topoisomerase II Inhibitors	1998
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas]. Bulletin du cancer, 1998, Volume: Spec No Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome	1998
[Combination chemotherapy--present status and problems]. Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:5 Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Mitomycin; Neoplasms	1999
Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issues. Drugs, 1999, Volume: 58 Suppl 3 Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Etoposide; Humans; Neoplasms; Neoplasms, Experimental	1999
DNA topoisomerase II inhibitors. IARC monographs on the evaluation of carcinogenic risks to humans, 2000, Volume: 76 Topics: Amsacrine; Antineoplastic Agents; Carcinogens; Disease Models, Animal; Etoposide; Evidence-Based Medicine; Humans; Intestinal Absorption; Mitoxantrone; Neoplasms; Nucleic Acid Synthesis Inhibitors; Research Design; Risk Factors; Teniposide; Tissue Distribution; Topoisomerase II Inhibitors	2000
Body surface area as a determinant of pharmacokinetics and drug dosing. Investigational new drugs, 2001, Volume: 19, Issue:2 Topics: Adult; Animals; Anthropometry; Antineoplastic Agents; Area Under Curve; Body Surface Area; Carboplatin; Cardiac Output; Child; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Kidney; Liver; Medical Oncology; Neoplasms; Paclitaxel; Taxoids	2001
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs & aging, 2002, Volume: 19, Issue:1 Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Complementary Therapies; Cytochrome P-450 Enzyme System; Dacarbazine; Etoposide; Humans; Idarubicin; Neoplasms; Tamoxifen; Temozolomide; Thalidomide; Topotecan	2002
Investigational drugs under study by the United States National Cancer Institute. Cancer treatment reviews, 1976, Volume: 3, Issue:1 Topics: Acrylates; Alkylating Agents; Ancitabine; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Chemical Phenomena; Chemistry; Chromomycins; Cisplatin; DNA, Neoplasm; Drug Evaluation, Preclinical; Etoposide; Humans; Ifosfamide; Leukemia L1210; Mice; Mitosis; National Institutes of Health (U.S.); Neoplasms; Neoplasms, Experimental; Razoxane; Tegafur; Teniposide; United States	1976
Pharmacology of antitumor agents from higher plants. Cancer treatment reports, 1976, Volume: 60, Issue:8 Topics: Animals; Antineoplastic Agents, Phytogenic; Aporphines; Camptothecin; Carcinoma, Squamous Cell; Chemical Phenomena; Chemistry; Etoposide; Humans; Leukemia L1210; Leukemia, Experimental; Leukemia, Lymphoid; Maytansine; Melanoma; Naphthoquinones; Nasopharyngeal Neoplasms; Neoplasms; Neoplasms, Experimental; Phenanthrenes; Structure-Activity Relationship; Teniposide; Vinblastine; Vincristine	1976
[New substances in oncologic therapy]. Schweizerische medizinische Wochenschrift, 1978, Aug-12, Volume: 108, Issue:32 Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Cisplatin; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Evaluation, Preclinical; Etoposide; Humans; Neoplasms; Nitrosourea Compounds; Razoxane; Tamoxifen; Vinca Alkaloids; Zinostatin	1978
Etoposide (VP-16-213). Cancer treatment reviews, 1979, Volume: 6, Issue:2 Topics: Adult; Animals; Bone Marrow; Cell Cycle; Child; Digestive System; Drug Therapy, Combination; Etoposide; Female; Humans; Leukemia; Lung Neoplasms; Lymphoma; Male; Mice; Neoplasms; Neoplasms, Experimental; Podophyllotoxin; Rats	1979
Podophyllotoxin derivative VP 16-213. Cancer chemotherapy and pharmacology, 1979, Volume: 3, Issue:2 Topics: Animals; Bronchial Neoplasms; Carcinoma; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; In Vitro Techniques; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Lymphoma; Mice; Neoplasms; Podophyllotoxin; Rabbits; Rats; Sarcoma	1979
Pediatric cancer chemotherapy: an updated review. I. Cis-Diammine--dichloroplatinum II (cisplatin), VM-26 (teniposide), VP-16 (etoposide), mitomycin C. Cancer treatment reviews, 1979, Volume: 6, Issue:3 Topics: Child; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Humans; Leukemia; Mitomycins; Neoplasms; Podophyllotoxin; Teniposide	1979
Chronic oral etoposide: trials at Indiana University and with the Hoosier Oncology Group. Seminars in oncology, 1992, Volume: 19, Issue:6 Suppl 14 Topics: Administration, Oral; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Neoplasms; Neoplasms, Germ Cell and Embryonal; Testicular Neoplasms	1992
Hypersensitivity reactions. Seminars in oncology, 1992, Volume: 19, Issue:5 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomycin; Chlorambucil; Cisplatin; Cyclophosphamide; Cytarabine; Dacarbazine; Drug Hypersensitivity; Etoposide; Fluorouracil; Humans; Ifosfamide; Melphalan; Methotrexate; Mitomycins; Neoplasms; Paclitaxel; Pentostatin; Procarbazine; Teniposide	1992
Etoposide: seeking the best dose and schedule. Seminars in oncology, 1992, Volume: 19, Issue:6 Suppl 14 Topics: Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Humans; Neoplasms	1992
Disposition of antineoplastic agents in the very young child. The British journal of cancer. Supplement, 1992, Volume: 18 Topics: Age Factors; Antineoplastic Agents; Blood Proteins; Child; Child, Preschool; Doxorubicin; Etoposide; Humans; Infant; Infant, Newborn; Liver; Mercaptopurine; Methotrexate; Neoplasms; Nervous System; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Teniposide	1992
Podophyllotoxin derivatives. Cancer chemotherapy and biological response modifiers, 1991, Volume: 12 Topics: Animals; Drug Interactions; Drug Resistance; Etoposide; Humans; Neoplasms; Teniposide	1991
Etoposide. Current and future status. Cancer, 1991, Jan-01, Volume: 67, Issue:1 Suppl Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Neoplasms	1991
High-dose etoposide and marrow transplantation. Cancer, 1991, Jan-01, Volume: 67, Issue:1 Suppl Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Etoposide; Humans; Neoplasms	1991
The pharmacology of intravenous and oral etoposide. Cancer, 1991, Jan-01, Volume: 67, Issue:1 Suppl Topics: Administration, Oral; Etoposide; Humans; Injections, Intravenous; Neoplasms	1991
Chronic oral etoposide. Cancer, 1991, Jan-01, Volume: 67, Issue:1 Suppl Topics: Drug Administration Schedule; Etoposide; Humans; Neoplasms; Time Factors	1991
Future directions for etoposide therapy. Cancer, 1991, Jan-01, Volume: 67, Issue:1 Suppl Topics: Drug Administration Schedule; Etoposide; Forecasting; Humans; Neoplasms	1991
The clinical pharmacology of etoposide. Cancer, 1991, Jan-01, Volume: 67, Issue:1 Suppl Topics: Etoposide; Humans; Neoplasms	1991
Antitumor antibiotics, epipodophyllotoxins, and vinca alkaloids: clinical developments. Current opinion in oncology, 1990, Volume: 2, Issue:6 Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Etoposide; Humans; Neoplasms; Vinca Alkaloids	1990
Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs, 1990, Volume: 39, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Neoplasms	1990
[Use of recombinant hematopoietic growth factors after chemotherapy and high-dose chemo-radiotherapy]. Haematologica, 1989, Volume: 74, Issue:5 Suppl Topics: Anemia, Aplastic; Antineoplastic Agents; Colony-Stimulating Factors; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Melphalan; Neoplasms; Radiotherapy	1989
High dose chemotherapy in solid tumours in adults. Clinics in haematology, 1986, Volume: 15, Issue:1 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Breast Neoplasms; Carcinoma, Small Cell; Carmustine; Cell Separation; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Etoposide; Glioma; Humans; Lung Neoplasms; Male; Melanoma; Melphalan; Neoplasms; Testicular Neoplasms; Whole-Body Irradiation	1986
Chemotherapy of malignant disease: an update. Comprehensive therapy, 1988, Volume: 14, Issue:5 Topics: Amsacrine; Antineoplastic Agents; Cisplatin; Coformycin; Etoposide; Female; Humans; Ifosfamide; Male; Mitoxantrone; Neoplasms; Pentostatin; Pregnancy	1988
Overview of the clinical relevance of autologous bone marrow transplantation. Clinics in haematology, 1986, Volume: 15, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Neoplasm Recurrence, Local; Neoplasms; Thioguanine; Transplantation, Autologous	1986
Indications for and benefits of intensive therapies in treatment of childhood cancers. Cancer, 1986, Jul-15, Volume: 58, Issue:2 Suppl Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Methotrexate; Neoplasms; Osteosarcoma; Risk; Sarcoma, Ewing	1986

Trials

149 trial(s) available for etoposide and Neoplasms

Article	Year
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. Pediatric blood & cancer, 2020, Volume: 67, Issue:4 Topics: Administration, Metronomic; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Child; Child, Preschool; Cyclophosphamide; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Sirolimus; Young Adult	2020
Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group. Blood, 2021, 03-18, Volume: 137, Issue:11 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Incidence; Male; Neoplasms; Prednisone; Vincristine	2021
Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial. JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9 Topics: Administration, Metronomic; Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Celecoxib; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Follow-Up Studies; Humans; Male; Neoplasms; Response Elements; Retreatment; Sarcoma, Ewing; Survival Rate; Thalidomide; Time Factors	2017
First-in-man dose escalation and pharmacokinetic study of CAP7.1, a novel prodrug of etoposide, in adults with refractory solid tumours. European journal of cancer (Oxford, England : 1990), 2017, Volume: 80 Topics: Adult; Aged; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prodrugs	2017
A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 01-15, Volume: 25, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Small Cell Lung Carcinoma; Treatment Outcome	2019
A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Investigational new drugs, 2014, Volume: 32, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Gossypol; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms	2014
A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas. Investigational new drugs, 2013, Volume: 31, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Etoposide; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasms; Young Adult	2013
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatric blood & cancer, 2014, Volume: 61, Issue:4 Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Fenofibrate; Follow-Up Studies; Humans; Infant; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Neovascularization, Pathologic; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Survival Rate; Thalidomide; Young Adult	2014
Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors. Journal of pediatric hematology/oncology, 2015, Volume: 37, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Maximum Tolerated Dose; Neoplasms; Organoplatinum Compounds; Oxaliplatin	2015
Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. Journal of clinical pharmacology, 2016, Volume: 56, Issue:4 Topics: Adult; Aged; Area Under Curve; Cisplatin; Etoposide; Female; Genotype; Glucuronosyltransferase; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Middle Aged; Neoplasms; Polymorphism, Single Nucleotide; Sulfonamides	2016
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. Investigational new drugs, 2009, Volume: 27, Issue:1 Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Thrombocytopenia	2009
Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors. Cancer, 2009, Feb-01, Volume: 115, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Recurrence	2009
Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:3 Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Body Weight; Carboplatin; Child; Child, Preschool; Cytochrome P-450 CYP3A; Dexamethasone; Drug Interactions; Etoposide; Humans; Infant; Models, Biological; Neoplasms; Nonlinear Dynamics; Ondansetron; Polymorphism, Single Nucleotide	2011
Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors. Anti-cancer drugs, 2010, Volume: 21, Issue:10 Topics: Administration, Oral; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Etoposide; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasms; Neutropenia; Salvage Therapy; Thrombocytopenia	2010
Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Dec-15, Volume: 17, Issue:24 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Combined Modality Therapy; DNA Topoisomerases, Type I; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Metabolic Clearance Rate; Middle Aged; Mucositis; Multivariate Analysis; Neoplasms; Proportional Hazards Models; Topotecan; Transplantation, Autologous; Treatment Outcome	2011
Clinical pharmacology of etoposide in children undergoing autologous stem cell transplantation for various solid tumours. Xenobiotica; the fate of foreign compounds in biological systems, 2013, Volume: 43, Issue:3 Topics: Adolescent; Age Distribution; Body Weight; Child; Child, Preschool; Confidence Intervals; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Models, Biological; Neoplasms; Transplantation, Autologous; Young Adult	2013
Clinical and pharmacokinetic study of fractionated doses of oral etoposide in pediatric patients with advanced malignancies. Medical science monitor : international medical journal of experimental and clinical research, 2002, Volume: 8, Issue:9 Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Phytogenic; Area Under Curve; Child; Child, Preschool; Etoposide; Female; Humans; Male; Neoplasms; Time Factors; Treatment Outcome	2002
Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:5 Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cisplatin; Cohort Studies; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors	2003
Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Treatment Outcome	2003
Two schedules of application for mesna and their influence on the thiol-metabolism. International journal of clinical pharmacology and therapeutics, 2003, Volume: 41, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Etoposide; Humans; Ifosfamide; Infusions, Intravenous; Injections, Intravenous; Mesna; Neoplasms; Protective Agents; Sulfhydryl Compounds	2003
Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil. Pediatric blood & cancer, 2004, Volume: 42, Issue:2 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carboplatin; Child; Child, Preschool; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence, Local; Neoplasms; Remission Induction; Survival Rate; Treatment Outcome	2004
Plasma etoposide catechol increases in pediatric patients undergoing multiple-day chemotherapy with etoposide. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, May-01, Volume: 10, Issue:9 Topics: Adolescent; Antineoplastic Agents, Phytogenic; Area Under Curve; Catechols; Child; Etoposide; Female; Hodgkin Disease; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Neoplasms; Sarcoma, Ewing; Time Factors	2004
Glomerular dysfunction, independent of tubular dysfunction, induced by antineoplastic chemotherapy in children. Pediatrics international : official journal of the Japan Pediatric Society, 2004, Volume: 46, Issue:5 Topics: Acute Disease; Adolescent; Albuminuria; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Creatinine; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Glomerular Filtration Rate; Humans; Kidney Tubules; Leukemia; Lymphoma; Methotrexate; Neoplasms; Neuroblastoma; Osteosarcoma; Proteinuria; Rhabdomyosarcoma; Vincristine	2004
Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. British journal of haematology, 2005, Volume: 128, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Infant; Interleukin-11; Lymphoma; Male; Neoplasms; Platelet Count; Recombinant Proteins; Thrombocytopenia	2005
A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Gro Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Apr-01, Volume: 11, Issue:7 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Ifosfamide; Male; Megakaryocytes; Neoplasms; Recombinant Proteins; Thrombopoietin	2005
[An early phase II clinical study of YM 294 (rhlL-11) in patients with solid tumors and malignant lymphoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Administration Schedule; Edema; Etoposide; Female; Fever; Humans; Interleukin-11; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Platelet Count; Recombinant Proteins; Thrombocytopenia	2005
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. British journal of cancer, 2005, Jul-11, Volume: 93, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Humans; Middle Aged; Neoplasms; Topotecan	2005
A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin. Anti-cancer drugs, 2005, Volume: 16, Issue:9 Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biphenyl Compounds; Carboplatin; Cohort Studies; Colonic Neoplasms; Enzyme Inhibitors; Etoposide; Female; Humans; Male; Matrix Metalloproteinase Inhibitors; Melanoma; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Neutropenia; Organic Chemicals; Phenylbutyrates; Thrombocytopenia; Thymoma; Treatment Outcome; Vomiting	2005
Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer, 2006, May-01, Volume: 106, Issue:9 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Male; Meningitis; Middle Aged; Neoplasms	2006
Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy. Pediatric blood & cancer, 2007, Volume: 48, Issue:4 Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Child; Child, Preschool; Cohort Studies; Etoposide; Female; Humans; Ifosfamide; Irinotecan; Low-Level Light Therapy; Male; Methotrexate; Mouth Mucosa; Neoplasms; Nutritional Status; Oral Hygiene; Severity of Illness Index; Stomatitis; Treatment Outcome	2007
Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie, 2006, Volume: 29, Issue:7 Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Child, Preschool; Dacarbazine; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasms; Pilot Projects; Pyrazoles; Sulfonamides; Temozolomide; Treatment Outcome; Tretinoin	2006
Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Molecular cancer therapeutics, 2006, Volume: 5, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome	2006
A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization. Bone marrow transplantation, 2006, Volume: 38, Issue:6 Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lenograstim; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Time Factors; Transplantation, Autologous; Vinblastine	2006
Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib. Cancer investigation, 2008, Volume: 26, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Celecoxib; Cyclophosphamide; Endothelial Cells; Etoposide; Female; Flow Cytometry; Humans; Male; Middle Aged; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Pyrazoles; Sensitivity and Specificity; Stem Cells; Sulfonamides	2008
A pilot study of addition of amifostine to melphalan, carboplatin, etoposide, and cyclophosphamide with autologous hematopoietic stem cell transplantation in pediatric solid tumors-A pediatric blood and marrow transplant consortium study. Journal of pediatric hematology/oncology, 2008, Volume: 30, Issue:3 Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Carboplatin; Central Nervous System Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Etoposide; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hypocalcemia; Kidney Neoplasms; Melphalan; Neoplasms; Neuroblastoma; Pilot Projects; Recurrence; Risk Factors; Sarcoma; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Wilms Tumor	2008
[New antineoplastic drugs of the podophyllotoxin derivative group]. Polski tygodnik lekarski (Warsaw, Poland : 1960), 1983, Jan-03, Volume: 38, Issue:1 Topics: Adult; Child; Clinical Trials as Topic; Etoposide; Female; Humans; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Podophyllotoxin; Teniposide; Urinary Bladder Neoplasms	1983
Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B. Cancer, 1980, Jan-15, Volume: 45, Issue:2 Topics: Adult; Bone Marrow; Child; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Male; Neoplasms; Podophyllotoxin; Remission, Spontaneous	1980
[Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)]. Klinische Wochenschrift, 1981, Nov-02, Volume: 59, Issue:21 Topics: Animals; Chemical Phenomena; Chemistry; Clinical Trials as Topic; DNA, Neoplasm; Drug Therapy, Combination; Etoposide; Humans; Neoplasms; Neoplasms, Experimental; Podophyllotoxin; RNA, Neoplasm	1981
Maturation of mobilized peripheral blood progenitor cells: preclinical and phase I clinical studies. Journal of hematotherapy, 1995, Volume: 4, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Differentiation; Cell Division; Colony-Forming Units Assay; Cryopreservation; Culture Techniques; Cyclophosphamide; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Growth Substances; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Interleukin-3; Leukapheresis; Neoplasms; Neutropenia; Thiotepa	1995
Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood, 1994, Sep-01, Volume: 84, Issue:5 Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bleomycin; Blood Transfusion, Autologous; Breast Neoplasms; Carboplatin; Carcinoma, Small Cell; Combined Modality Therapy; Epirubicin; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasms; Predictive Value of Tests; Vincristine	1994
High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion. Seminars in oncology, 1994, Volume: 21, Issue:5 Suppl 12 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Length of Stay; Male; Middle Aged; Neoplasms; Transplantation, Autologous; Treatment Outcome	1994
Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies. International journal of cancer, 1995, Mar-03, Volume: 60, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Kidney Diseases; Leucovorin; Liver; Liver Neoplasms; Methotrexate; Neoplasms; Nervous System Diseases; Ovarian Neoplasms; Remission Induction; Spectrophotometry, Atomic; Tumor Cells, Cultured; Vinblastine	1995
Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective. Leukemia & lymphoma, 1994, Volume: 16, Issue:1-2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms; Neutrophils; Pilot Projects	1994
A phase I trial of paclitaxel and etoposide for metastatic or recurrent malignancies. Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 6 Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia	1995
An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood, 1995, Nov-15, Volume: 86, Issue:10 Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Carboplatin; Cell Survival; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Life Tables; Male; Middle Aged; Neoplasms; Proportional Hazards Models; Retrospective Studies; Thiotepa; Time Factors; Treatment Outcome	1995
Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:11 Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Biological Availability; Chromatography, High Pressure Liquid; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Therapeutic Equivalency	1995
Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study. Journal of pediatric hematology/oncology, 1995, Volume: 17, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Neoplasms; Recurrence	1995
Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer. Cancer investigation, 1995, Volume: 13, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Pilot Projects; Reoperation; Salvage Therapy; Thiotepa	1995
Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors. Clinical pharmacology and therapeutics, 1995, Volume: 58, Issue:1 Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Male; Neoplasms; Predictive Value of Tests; Regression Analysis; Serum Albumin; Solutions	1995
Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:10 Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Middle Aged; Neoplasms; Treatment Outcome	1993
Clinical reversal of multidrug resistance. Cancer treatment and research, 1994, Volume: 73 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Clinical Trials as Topic; Cyclosporine; Drug Resistance, Multiple; Etoposide; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel; Pharmaceutical Preparations; Verapamil	1994
Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers. British journal of cancer, 1995, Volume: 71, Issue:4 Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Multiple; Etoposide; Female; Hodgkin Disease; Humans; Infant; Infusions, Intravenous; Kidney Neoplasms; Male; Neoplasms; Neuroblastoma; Osteosarcoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Rhabdomyosarcoma; Sarcoma, Ewing; Verapamil; Wilms Tumor	1995
A phase I trial of high-dose oral tamoxifen and CHOPE. Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:1 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Prednisone; Tamoxifen; Vincristine	1995
A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days. Clinical pharmacology and therapeutics, 1995, Volume: 57, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Chromatography, High Pressure Liquid; Cohort Studies; Dose-Response Relationship, Drug; Etoposide; Female; Half-Life; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Organophosphorus Compounds	1995
Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity. Cancer, 1995, Jun-15, Volume: 75, Issue:12 Topics: Adolescent; Adult; Bone Marrow; Child; Child, Preschool; Cisplatin; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Humans; Ifosfamide; Infant; Kidney; Male; Neoplasms; Treatment Outcome	1995
Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:2 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Remission Induction; Salvage Therapy; Treatment Outcome	1995
Phase I clinical and pharmacokinetic study of oral etoposide phosphate. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:1 Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Biological Availability; Drug Administration Schedule; Etoposide; Humans; Injections, Intravenous; Lymphoma; Middle Aged; Models, Biological; Neoplasms; Neutropenia; Organophosphorus Compounds; Prodrugs	1995
Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia. Leukemia & lymphoma, 1994, Volume: 15, Issue:1-2 Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Marrow Diseases; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Etoposide; Female; Gastrointestinal Diseases; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Middle Aged; Neoplasms; Prospective Studies; Radiotherapy; Remission Induction; Salvage Therapy; Treatment Outcome	1994
Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:11 Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Child; Child, Preschool; Drug Interactions; Etoposide; Half-Life; Humans; Infant; Metabolic Clearance Rate; Neoplasms; Transplantation, Autologous	1994
High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions. Seminars in oncology, 1994, Volume: 21, Issue:5 Suppl 12 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Forecasting; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Neoplasms; Transplantation, Autologous; Treatment Outcome	1994
Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study. Bone marrow transplantation, 1994, Volume: 14, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infusions, Intravenous; Melphalan; Middle Aged; Neoplasms; Retrospective Studies; Transplantation, Autologous	1994
Phase I study of oral etoposide in children with refractory solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:7 Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Male; Neoplasms; Treatment Outcome	1994
Calvert's formula and high-dose carboplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:8 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Creatinine; DNA; DNA Adducts; Etoposide; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Neoplasms; Thiotepa	1994
[Phase I clinical study of 21-consecutive-day oral administration of etoposide]. Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:10 Topics: Administration, Oral; Adult; Aged; Drug Tolerance; Etoposide; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms	1994
Clinical and pharmacokinetic overview of parenteral etoposide phosphate. Cancer chemotherapy and pharmacology, 1994, Volume: 34 Suppl Topics: Animals; Blood Pressure; Drug Administration Schedule; Etoposide; Humans; Infusions, Intravenous; Leukocyte Count; Neoplasms; Organophosphorus Compounds	1994
Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:9 Topics: Adult; Aged; Alopecia; Chromatography, High Pressure Liquid; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Organophosphorus Compounds; Prodrugs; Regression Analysis; Solubility; Vomiting	1994
Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Male; Neoplasms; Pilot Projects; Treatment Outcome; Vincristine	1994
Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Hematopoiesis; Humans; Ifosfamide; Male; Middle Aged; Neoplasms; Treatment Outcome	1994
Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. Journal of the National Cancer Institute, 1994, Apr-06, Volume: 86, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Child; Child, Preschool; Etoposide; Female; Humans; Ifosfamide; Infant; Male; Neoplasms; Treatment Outcome	1994
Prolonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II study. Cancer, 1994, Jun-01, Volume: 73, Issue:11 Topics: Adult; Bone Marrow; Carcinoma, Small Cell; Drug Administration Schedule; Drug Tolerance; Erythrocyte Transfusion; Etoposide; Female; Humans; Infusions, Parenteral; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms; Platelet Transfusion	1994
Escalating high-dose carboplatin and autologous bone marrow transplantation in solid tumors. Oncology, 1993, Volume: 50 Suppl 2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Germinoma; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Prospective Studies; Rhabdomyosarcoma; Transplantation, Autologous; Treatment Outcome	1993
A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies. Cancer research, 1993, Dec-15, Volume: 53, Issue:24 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Prospective Studies; Thrombocytopenia	1993
Granulocyte-macrophage colony-stimulating factor given before dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP). Biotechnology therapeutics, 1993, Volume: 4, Issue:3-4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Escherichia coli; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Recombinant Proteins; Yeasts	1993
Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:7 Topics: Adult; Bone Marrow Diseases; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukocyte Count; Male; Middle Aged; Neoplasms; Treatment Outcome	1993
A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide. British journal of cancer, 1993, Volume: 68, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Humans; Injections, Intraperitoneal; Kidney; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms	1993
Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Infant; Least-Squares Analysis; Male; Neoplasms; Neutropenia; Thrombocytopenia; Treatment Outcome	1993
Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation. Blood, 1993, May-01, Volume: 81, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Carmustine; Cells, Cultured; Colony-Forming Units Assay; Colony-Stimulating Factors; Cyclophosphamide; Etoposide; Fluorouracil; Growth Substances; Hematopoietic Stem Cells; Hodgkin Disease; Humans; Interleukins; Leukocyte Count; Neoplasms; Platelet Count; Transplantation, Autologous	1993
High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation for the treatment of advanced malignancies: a phase I study. Bone marrow transplantation, 1995, Volume: 16, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Kidney; Male; Middle Aged; Neoplasms; Transplantation, Autologous	1995
Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. The Journal of laboratory and clinical medicine, 1996, Volume: 127, Issue:2 Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cyclophosphamide; Dacarbazine; Double-Blind Method; Doxorubicin; Etoposide; Female; Fluorouracil; Glutamine; Humans; Ifosfamide; Male; Neoplasms; Pilot Projects; Placebos; Sarcoma, Kaposi; Stomatitis; Vincristine	1996
Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Cyclosporins; Drug Resistance, Multiple; Etoposide; Female; Half-Life; Humans; Male; Middle Aged; Neoplasms	1996
Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481). European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:13-14 Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Ovarian Neoplasms; Prodrugs	1995
Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors. Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:4 Topics: Antineoplastic Agents; Etoposide; Female; Half-Life; Humans; Infusions, Intravenous; Linear Models; Male; Metabolic Clearance Rate; Neoplasms; Organophosphorus Compounds	1996
Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:7 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Biological Availability; Chromatography, High Pressure Liquid; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Prodrugs	1996
Phase I trial of etoposide, doxorubicin and cisplatin (EAP) in combination with GM-CSF. European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Recombinant Proteins; Thrombocytopenia	1996
Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience. Medical and pediatric oncology, 1996, Volume: 27, Issue:3 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Female; Humans; Ifosfamide; Male; Mesna; Neoplasms	1996
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients. Bone marrow transplantation, 1996, Volume: 17, Issue:4 Topics: Adolescent; Adult; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Cell Movement; Colony-Forming Units Assay; Cyclophosphamide; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Kidney Diseases; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning	1996
Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. Bone marrow transplantation, 1996, Volume: 17, Issue:5 Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Double-Blind Method; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Middle Aged; Misoprostol; Mouth Mucosa; Neoplasms; Stomatitis	1996
Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Bone marrow transplantation, 1995, Volume: 16, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Neoplasms; Transplantation, Autologous	1995
Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer. Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:5 Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Creatinine; Etoposide; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Mouth Mucosa; Neoplasms; Statistics, Nonparametric; Stomatitis	1996
A randomized phase I study of oral etoposide with or without granulocyte-macrophage colony-stimulating factor for the treatment of patients with advanced cancer. Anti-cancer drugs, 1996, Volume: 7, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms; Neutropenia	1996
Phase I and pharmacokinetic study of etoposide phosphate. Anti-cancer drugs, 1995, Volume: 6, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Diarrhea; Dose-Response Relationship, Drug; Etoposide; Humans; Middle Aged; Neoplasms; Organophosphorus Compounds; Regression Analysis; Thrombocytopenia	1995
Phase I study of high-dose etoposide phosphate in man. Bone marrow transplantation, 1996, Volume: 18, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Combined Modality Therapy; Etoposide; Female; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Organophosphorus Compounds	1996
Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters. Journal of pharmacokinetics and biopharmaceutics, 1996, Volume: 24, Issue:4 Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Cross-Over Studies; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Prodrugs; Therapeutic Equivalency	1996
Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:2 Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Biological Availability; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Treatment Outcome	1997
Randomized trial of filgrastim vs. sequential filgrastim and molgramostim after dose-intensified carboplatin, cyclophosphamide, and etoposide: a phase I pilot study. American journal of clinical oncology, 1997, Volume: 20, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Middle Aged; Neoplasms; Pilot Projects; Platelet Count; Recombinant Proteins; Survival Rate	1997
Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Medical and pediatric oncology, 1997, Volume: 29, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Humans; Infant; Neoplasm Recurrence, Local; Neoplasms; Treatment Outcome	1997
Phase I trial of subcutaneous interleukin-1 alpha in children with malignant solid tumors. Medical and pediatric oncology, 1997, Volume: 28, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Marrow; Bone Marrow Diseases; Carboplatin; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Granulocytes; Humans; Ifosfamide; Infant; Injections, Subcutaneous; Interleukin-1; Male; Neoplasms; Recombinant Proteins	1997
Granulocyte-macrophage colony-stimulating factor in association with high-dose chemotherapy (VETOPEC) for childhood solid tumors: a report from the Australia and New Zealand Children's Cancer Study Group. Medical and pediatric oncology, 1997, Volume: 29, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infant; Neoplasm Recurrence, Local; Neoplasms; Neutropenia; Vincristine	1997
A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group. Cancer, 1997, Aug-01, Volume: 80, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infant; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Survival Analysis; Vincristine	1997
Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940. Cancer investigation, 1997, Volume: 15, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Interleukin-1; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Recombinant Proteins; Thrombocytopenia	1997
Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. British journal of cancer, 1997, Volume: 76, Issue:11 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Topotecan	1997
Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy. Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Half-Life; Humans; Ifosfamide; Infant; Interleukin-3; Male; Metabolic Clearance Rate; Neoplasms; Neutropenia; Recombinant Fusion Proteins	1998
Phase II study of 21 day schedule oral etoposide in children. New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG). European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:11 Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Etoposide; Humans; Neoplasms; Time Factors; Treatment Outcome	1997
Phase I study of high dose etoposide phosphatase with filgrastim (G-CSF) in the treatment of advanced refractory malignancies. Investigational new drugs, 1997, Volume: 15, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Drug Resistance, Neoplasm; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukocyte Count; Male; Middle Aged; Neoplasms; Organophosphorus Compounds; Platelet Count; Recombinant Proteins	1997
Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Hypoxia; Disease-Free Survival; Dose-Response Relationship, Drug; Etanidazole; Etoposide; Expectorants; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Infusions, Intravenous; Male; Mesna; Middle Aged; Neoplasms; Recurrence; Survival Rate	1998
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan	1998
High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours. British journal of cancer, 1998, Volume: 77, Issue:12 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Etoposide; Female; Humans; Male; Neoplasms	1998
A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children. British journal of cancer, 1998, Volume: 77, Issue:12 Topics: Adolescent; Antineoplastic Agents, Phytogenic; Area Under Curve; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Humans; Male; Neoplasms	1998
Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells. Journal of cancer research and clinical oncology, 1998, Volume: 124, Issue:6 Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carmustine; Cell Separation; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Epirubicin; Etoposide; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Ifosfamide; Macrophages; Male; Melphalan; Neoplasms; Prednisolone; Vincristine	1998
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:9 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Leukemia; Male; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Prospective Studies; Risk Factors; Vincristine	1998
A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer G Cancer, 1998, Oct-01, Volume: 83, Issue:7 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Carboplatin; Child; Child, Preschool; Cytokines; Drug Tolerance; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Ifosfamide; Infant; Interleukin-3; Length of Stay; Neoplasm Recurrence, Local; Neoplasms; Recombinant Fusion Proteins	1998
High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels. British journal of cancer, 1998, Volume: 78, Issue:7 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Etoposide; Female; Germinoma; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Leukemia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms	1998
Phase I study of etoposide phosphate (etopophos) as a 30-minute infusion on days 1, 3, and 5. Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Half-Life; Hemoglobins; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Organophosphorus Compounds; Thrombocytopenia	1995
Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study. Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Etoposide; Female; Humans; Interleukin-3; Male; Middle Aged; Neoplasms; Neutrophils; Platelet Count; Platelet Transfusion; Recombinant Proteins; Thrombocytopenia	1995
A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer chemotherapy and pharmacology, 1999, Volume: 43, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Etoposide; Female; Half-Life; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Reproducibility of Results; Selection Bias	1999
Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group. Cancer prevention & control : CPC = Prevention & controle en cancerologie : PCC, 1998, Volume: 2, Issue:4 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Canada; Cisplatin; Confidence Intervals; Disease-Free Survival; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Meta-Analysis as Topic; Neoplasms; Neutropenia; Odds Ratio; Quality of Life; Treatment Outcome; Vincristine	1998
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:4 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasms; Paclitaxel	1999
Myeloprotective effect of a non-toxic indigenous preparation Rasayana in cancer patients receiving chemotherapy and radiation therapy. A pilot study. Journal of experimental & clinical cancer research : CR, 1999, Volume: 18, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bone Marrow; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Fluorouracil; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; India; Leukocyte Count; Leukopenia; Lipid Peroxidation; Male; Mitoxantrone; Neoplasms; Pharmaceutical Preparations; Pilot Projects; Plant Extracts; Radiation Injuries; Radiotherapy	1999
Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:6 Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cryotherapy; Docetaxel; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Scalp; Taxoids	2000
Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: a phase II window study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:13 Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Male; Neoplasms; Sarcoma	2000
A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A. Cancer chemotherapy and pharmacology, 2000, Volume: 46, Issue:5 Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclosporine; Dipyridamole; Etoposide; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasms; Prochlorperazine; Treatment Outcome; Vasodilator Agents	2000
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report. Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Dose-Response Relationship, Drug; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Infant; Leukocyte Count; Male; Neoplasms; Neutropenia; Neutrophils; Prospective Studies; Racial Groups; Recombinant Proteins; Recurrence; Survival Rate; Time Factors; United States	2001
A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a h Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Ifosfamide; Infant; Infusions, Intravenous; Interleukin-6; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Recombinant Proteins	2001
Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. Cancer, 2001, Aug-15, Volume: 92, Issue:4 Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Male; Mercaptoethylamines; Neoplasms; Treatment Failure	2001
Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. Oncology, 2002, Volume: 62, Issue:2 Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Humans; Hypothermia, Induced; Ifosfamide; Male; Middle Aged; Neoplasms; Paclitaxel; Scalp; Severity of Illness Index; Treatment Outcome	2002
Phase I trial of a new form of an oral administration of VP-16-213. Cancer treatment reports, 1979, Volume: 63, Issue:3 Topics: Administration, Oral; Adult; Aged; Capsules; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Podophyllotoxin	1979
Podophyllotoxin derivative VP 16-213. Cancer chemotherapy and pharmacology, 1979, Volume: 3, Issue:2 Topics: Animals; Bronchial Neoplasms; Carcinoma; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; In Vitro Techniques; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Lymphoma; Mice; Neoplasms; Podophyllotoxin; Rabbits; Rats; Sarcoma	1979
Pediatric cancer chemotherapy: an updated review. I. Cis-Diammine--dichloroplatinum II (cisplatin), VM-26 (teniposide), VP-16 (etoposide), mitomycin C. Cancer treatment reviews, 1979, Volume: 6, Issue:3 Topics: Child; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Humans; Leukemia; Mitomycins; Neoplasms; Podophyllotoxin; Teniposide	1979
High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. British journal of cancer, 1992, Volume: 66, Issue:5 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dose-Response Relationship, Drug; Drug Resistance; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Humans; Male; Membrane Glycoproteins; Middle Aged; Neoplasms; Tamoxifen; Tumor Cells, Cultured; Verapamil	1992
Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Drug Resistance; Etoposide; Female; Gene Expression; Humans; Male; Middle Aged; Neoplasms	1992
Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:10 Topics: Adult; Aged; Cyclosporine; Drug Interactions; Drug Resistance; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms	1992
Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma; Male; Middle Aged; Neoplasms; Survival Analysis; Transplantation, Autologous	1992
Etoposide plus carboplatin admixture. Phase I study of five- or seven-day continuous infusion. American journal of clinical oncology, 1992, Volume: 15, Issue:4 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusion Pumps, Implantable; Male; Middle Aged; Neoplasms	1992
Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Evaluation; Etoposide; Feasibility Studies; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Humans; Ifosfamide; Interleukin-3; Male; Middle Aged; Neoplasms; Neutrophils; Recombinant Proteins	1992
Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:4-5 Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cricetinae; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Synergism; Etoposide; Female; Humans; Male; Neoplasms; Tamoxifen	1992
[Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy]. Deutsche medizinische Wochenschrift (1946), 1991, Nov-29, Volume: 116, Issue:48 Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Granisetron; Humans; Ifosfamide; Indazoles; Male; Middle Aged; Neoplasms; Pyrrolidines; Serotonin Antagonists; Single-Blind Method	1991
A phase I study on the reversal of multidrug resistance (MDR) in vivo: nifedipine plus etoposide. British journal of cancer, 1992, Volume: 65, Issue:2 Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Drug Evaluation; Drug Interactions; Drug Resistance; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Nifedipine	1992
Daily oral etoposide in the treatment of cancer. Seminars in oncology, 1991, Volume: 18, Issue:1 Suppl 2 Topics: Administration, Oral; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Neoplasms; Neoplasms, Germ Cell and Embryonal	1991
Impact of autologous bone marrow infusion on hematopoietic recovery after high-dose cyclophosphamide, etoposide, and cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Hematopoiesis; Humans; Middle Aged; Neoplasms; Transplantation, Homologous	1991
Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study. Cancer, 1991, Dec-01, Volume: 68, Issue:11 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Stomatitis	1991
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:8 Topics: Aged; Blood Transfusion; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infusions, Intravenous; Leukocyte Count; Male; Middle Aged; Models, Biological; Neoplasms; Serum Albumin	1991
Intrapleural etoposide for malignant effusion. Cancer chemotherapy and pharmacology, 1990, Volume: 26, Issue:2 Topics: Adult; Aged; Body Fluids; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Pleura; Pleural Effusion; Radiography, Thoracic	1990
Treatment of pediatric malignant tumors with VP-16. West Japan Pediatric Oncology Group. Acta paediatrica Japonica : Overseas edition, 1990, Volume: 32, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Etoposide; Histiocytosis; Humans; Infant; Leukemia, Myeloid, Acute; Lymphoma; Neoplasms; Neuroblastoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma	1990
Intracavitary chemotherapy. Current problems in cancer, 1986, Volume: 10, Issue:8 Topics: Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Catheters, Indwelling; Cisplatin; Clinical Trials as Topic; Cytarabine; Doxorubicin; Etoposide; Fluorouracil; Humans; Immunotherapy; Infusions, Parenteral; Melphalan; Methotrexate; Mitomycins; Mitoxantrone; Neoplasms; Organoplatinum Compounds	1986
[Phase I clinical study of NK 171 (etoposide)]. Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:4 Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Liver Neoplasms; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Podophyllotoxin	1985
How much progress has been achieved in cancer therapy? Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1988, Volume: 42, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Drug Therapy; Etoposide; Humans; Medical Oncology; Neoplasms; Neuroblastoma	1988
Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial. Journal of the National Cancer Institute, 1988, Nov-02, Volume: 80, Issue:17 Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Drug Synergism; Etoposide; Female; Humans; Hydroxyurea; Leukemia L1210; Male; Mice; Middle Aged; Neoplasms; Tumor Cells, Cultured	1988
Overview of the clinical relevance of autologous bone marrow transplantation. Clinics in haematology, 1986, Volume: 15, Issue:1 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Evaluation; Drug Resistance; Etoposide; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Melphalan; Neoplasm Recurrence, Local; Neoplasms; Thioguanine; Transplantation, Autologous	1986
Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. Cancer treatment reports, 1985, Volume: 69, Issue:3 Topics: Administration, Oral; Biological Availability; Capsules; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Granulocytes; Half-Life; Humans; Infusions, Parenteral; Kinetics; Leukocyte Count; Nausea; Neoplasms; Platelet Count; Podophyllotoxin; Random Allocation	1985

Other Studies

372 other study(ies) available for etoposide and Neoplasms

Article	Year
Chemical genetics reveals a complex functional ground state of neural stem cells. Nature chemical biology, 2007, Volume: 3, Issue:5 Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells	2007
The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds. Bioorganic & medicinal chemistry, 2008, Apr-01, Volume: 16, Issue:7 Topics: Anthracyclines; Antigens, Neoplasm; Antineoplastic Agents; Cell Line; Cell Survival; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Neoplasms; Nucleic Acid Denaturation; Plasmids; Protein Binding; Quantitative Structure-Activity Relationship; Temperature; Topoisomerase II Inhibitors	2008
Antitumor agents 6. Synthesis, structure-activity relationships, and biological evaluation of spiro[imidazolidine-4,3'-thieno[2,3-g]quinoline]-tetraones and spiro[thieno[2,3-g]quinoline-3,5'-[1,2,4]triazinane]-tetraones with potent antiproliferative activ Journal of medicinal chemistry, 2008, Dec-25, Volume: 51, Issue:24 Topics: Antineoplastic Agents; Catalysis; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; DNA; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Neoplasms; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors	2008
Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents. Journal of medicinal chemistry, 2008, Dec-25, Volume: 51, Issue:24 Topics: Anisoles; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Humans; Indoles; Inhibitory Concentration 50; Models, Chemical; Naphthalenes; Neoplasms; Structure-Activity Relationship; Tubulin; Tubulin Modulators	2008
2-Thienyl-4-furyl-6-aryl pyridine derivatives: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study. Bioorganic & medicinal chemistry, 2010, Jan-01, Volume: 18, Issue:1 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Neoplasms; Pyrimidines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors	2010
New benzoxanthone derivatives as topoisomerase inhibitors and DNA cross-linkers. Bioorganic & medicinal chemistry, 2010, Volume: 18, Issue:3 Topics: Antineoplastic Agents; Benzene Derivatives; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Xanthones	2010
Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. Bioorganic & medicinal chemistry, 2010, May-01, Volume: 18, Issue:9 Topics: alpha-Mannosidase; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Hematologic Neoplasms; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Teprotide	2010
Novel effects of glycyrrhetinic acid on the central nervous system tumorigenic progenitor cells: induction of actin disruption and tumor cell-selective toxicity. European journal of medicinal chemistry, 2010, Volume: 45, Issue:7 Topics: Actins; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Central Nervous System; Genes, myc; Genes, ras; Glycyrrhetinic Acid; Humans; Mice; Neoplasms; Stem Cells; Transfection	2010
Synthesis and evaluation of aroylthiourea derivatives of 4-β-amino-4'-O-demethyl-4-desoxypodophyllotoxin as novel topoisomerase II inhibitors. European journal of medicinal chemistry, 2011, Volume: 46, Issue:3 Topics: Antineoplastic Agents; Cell Cycle; Cell Proliferation; DNA Topoisomerases, Type II; HCT116 Cells; Hep G2 Cells; Humans; Neoplasms; Podophyllotoxin; Podophyllum; Thiourea; Topoisomerase II Inhibitors	2011
Synthesis of 4β-carbamoyl epipodophyllotoxins as potential antitumour agents. Bioorganic & medicinal chemistry, 2011, May-01, Volume: 19, Issue:9 Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Etoposide; Humans; Neoplasms; Podophyllotoxin; Topoisomerase II Inhibitors	2011
Synthesis of 2,4-diaryl chromenopyridines and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship. European journal of medicinal chemistry, 2011, Volume: 46, Issue:8 Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzopyrans; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Female; Humans; Male; Neoplasms; Pyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors	2011
Synthesis and biological evaluation of 4β-acrylamidopodophyllotoxin congeners as DNA damaging agents. Bioorganic & medicinal chemistry, 2011, Aug-01, Volume: 19, Issue:15 Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Comet Assay; DNA; DNA Damage; Drug Screening Assays, Antitumor; Etoposide; Humans; Neoplasms; Podophyllotoxin	2011
A modular approach to trim cellular targets in anticancer drug discovery. Bioorganic & medicinal chemistry letters, 2011, Nov-15, Volume: 21, Issue:22 Topics: Anaphase; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Drug Discovery; Humans; Metaphase; Neoplasms; Oxidation-Reduction; Pyrimidines; Structure-Activity Relationship	2011
Synthesis and biological evaluation of conjugates of deoxypodophyllotoxin and 5-FU as inducer of caspase-3 and -7. European journal of medicinal chemistry, 2012, Volume: 49 Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Drugs, Chinese Herbal; Enzyme Activation; Fluorouracil; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; Neoplasms; Podophyllotoxin	2012
Dihydroxylated 2,4,6-triphenyl pyridines: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study. European journal of medicinal chemistry, 2012, Volume: 49 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Neoplasms; Pyridines; Topoisomerase Inhibitors	2012
Hybrids of privileged structures benzothiazoles and pyrrolo[2,1-c] [1,4]benzodiazepin-5-one, and diversity-oriented synthesis of benzothiazoles. European journal of medicinal chemistry, 2012, Volume: 50 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzodiazepines; Benzothiazoles; Etoposide; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured	2012
Triterpenes possessing an unprecedented skeleton isolated from hydrolyzate of total saponins from Gynostemma pentaphyllum. European journal of medicinal chemistry, 2012, Volume: 50 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cells, Cultured; Gynostemma; Humans; Magnetic Resonance Spectroscopy; Models, Chemical; Molecular Structure; Neoplasms; Plant Extracts; Quantitative Structure-Activity Relationship; Saponins; Triterpenes	2012
Synthesis and biological evaluation of 4β-sulphonamido and 4β-[(4'-sulphonamido)benzamide]podophyllotoxins as DNA topoisomerase-IIα and apoptosis inducing agents. Bioorganic & medicinal chemistry, 2012, Mar-15, Volume: 20, Issue:6 Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Comet Assay; DNA Breaks; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Etoposide; Humans; Neoplasms; Podophyllotoxin; Podophyllum	2012
The first total synthesis and biological evaluation of marine natural products ma'edamines A and B. Bioorganic & medicinal chemistry letters, 2013, Feb-15, Volume: 23, Issue:4 Topics: Animals; Biological Products; Cell Line, Tumor; Comet Assay; Humans; MCF-7 Cells; Neoplasms; Porifera; Pyrazines	2013
Indenoindolone derivatives as topoisomerase II-inhibiting anticancer agents. Bioorganic & medicinal chemistry letters, 2013, Feb-15, Volume: 23, Issue:4 Topics: Antineoplastic Agents; DNA Topoisomerases, Type II; Humans; Indoles; Models, Molecular; Neoplasms; Topoisomerase II Inhibitors	2013
Furanylazaindoles: potent anticancer agents in vitro and in vivo. Journal of medicinal chemistry, 2013, Oct-24, Volume: 56, Issue:20 Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Female; Heterocyclic Compounds, 2-Ring; HT29 Cells; Humans; Indoles; Inhibitory Concentration 50; Mice, Nude; Molecular Structure; Neoplasms; Polymerization; Sulfonamides; Tubulin; Xenograft Model Antitumor Assays	2013
Anilides and quinolones with nitrogen-bearing substituents from benzothiophene and thienothiophene series: synthesis, photochemical synthesis, cytostatic evaluation, 3D-derived QSAR analysis and DNA-binding properties. European journal of medicinal chemistry, 2014, Volume: 71 Topics: Anilides; Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; DNA; Drug Screening Assays, Antitumor; Humans; Neoplasms; Nitrogen; Quantitative Structure-Activity Relationship; Quinolones; Thiophenes; Topoisomerase II Inhibitors	2014
Toward synthesis of third-generation spin-labeled podophyllotoxin derivatives using isocyanide multicomponent reactions. European journal of medicinal chemistry, 2014, Mar-21, Volume: 75 Topics: Antineoplastic Agents; Cell Line, Tumor; Cyanides; Drug Screening Assays, Antitumor; Etoposide; Humans; Neoplasms; Podophyllotoxin; Spin Labels; Structure-Activity Relationship	2014
Synthesis, antitumor activity, and structure-activity relationship study of trihydroxylated 2,4,6-triphenyl pyridines as potent and selective topoisomerase II inhibitors. European journal of medicinal chemistry, 2014, Sep-12, Volume: 84 Topics: Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Molecular Docking Simulation; Molecular Structure; Neoplasms; Phenols; Pyridines; Structure-Activity Relationship; Topoisomerase II Inhibitors	2014
In vitro radical scavenging and cytotoxic activities of novel hybrid selenocarbamates. Bioorganic & medicinal chemistry, 2015, Apr-15, Volume: 23, Issue:8 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyanates; Free Radical Scavengers; Humans; Neoplasms; Organoselenium Compounds; Selenium Compounds	2015
Structure-Activity Relationships of Neplanocin A Analogues as S-Adenosylhomocysteine Hydrolase Inhibitors and Their Antiviral and Antitumor Activities. Journal of medicinal chemistry, 2015, Jun-25, Volume: 58, Issue:12 Topics: Adenine; Adenosine; Adenosylhomocysteinase; Animals; Antineoplastic Agents; Antiviral Agents; Cell Line, Tumor; Chlorocebus aethiops; Enzyme Inhibitors; Humans; Molecular Docking Simulation; Neoplasms; Structure-Activity Relationship; Vero Cells; Virus Diseases; Viruses	2015
Isolation of bioactive biphenyl compounds from the twigs of Chaenomeles sinensis. Bioorganic & medicinal chemistry letters, 2016, Jan-15, Volume: 26, Issue:2 Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Biphenyl Compounds; Cell Line; Cell Line, Tumor; Humans; Mice; Microglia; Neoplasms; Nerve Growth Factor; Nitric Oxide; Rosaceae	2016
Synthesis and biological evaluation of new securinine analogues as potential anticancer agents. European journal of medicinal chemistry, 2016, Feb-15, Volume: 109 Topics: Antineoplastic Agents; Apoptosis; Azepines; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Euphorbiaceae; Heterocyclic Compounds, Bridged-Ring; Humans; Lactones; Neoplasms; Piperidines	2016
Novel cis-selective and non-epimerisable C3 hydroxy azapodophyllotoxins targeting microtubules in cancer cells. European journal of medicinal chemistry, 2016, Mar-03, Volume: 110 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Humans; MCF-7 Cells; Microtubules; Molecular Docking Simulation; Neoplasms; Podophyllotoxin; Stereoisomerism; Tubulin; Tubulin Modulators	2016
Discovery of antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of synthesis and evaluation of antitumor properties. European journal of medicinal chemistry, 2016, Apr-13, Volume: 112 Topics: Animals; Anthracenes; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Furans; Humans; Leukemia; Mice; Neoplasms; Protein Kinase Inhibitors; Structure-Activity Relationship; Topoisomerase Inhibitors	2016
Anticancer activity studies of cubebin isolated from Piper cubeba and its synthetic derivatives. Bioorganic & medicinal chemistry letters, 2016, Apr-01, Volume: 26, Issue:7 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Humans; Lignans; Models, Molecular; Neoplasms; Piper; Seeds	2016
New cytotoxic neo-clerodane diterpenoids from Scutellaria strigillosa. Bioorganic & medicinal chemistry letters, 2016, Apr-01, Volume: 26, Issue:7 Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Diterpenes, Clerodane; Drug Screening Assays, Antitumor; Humans; Neoplasms; Scutellaria	2016
Synthesis of novel flavone derivatives possessing substituted benzamides and their biological evaluation against human cancer cells. Bioorganic & medicinal chemistry letters, 2016, 09-01, Volume: 26, Issue:17 Topics: Antineoplastic Agents; Benzamides; Cell Survival; Flavanones; Flavones; Flavonoids; Hep G2 Cells; Humans; MCF-7 Cells; Neoplasms; Structure-Activity Relationship	2016
Synthesis and biological evaluation of crown ether acyl derivatives. Bioorganic & medicinal chemistry letters, 2016, 11-15, Volume: 26, Issue:22 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antineoplastic Agents; Candida albicans; Candidiasis; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Drug Screening Assays, Antitumor; Humans; Neoplasms; Staphylococcal Infections; Staphylococcus aureus; Structure-Activity Relationship	2016
Synthesis and biological evaluation of novel quinazoline-sulfonamides as anti-cancer agents. Bioorganic & medicinal chemistry letters, 2017, 05-01, Volume: 27, Issue:9 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Neoplasms; Quinazolines; Structure-Activity Relationship; Sulfonamides	2017
Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and IIα dual inhibitors with DNA non-intercalative catalytic activity. European journal of medicinal chemistry, 2017, Jun-16, Volume: 133 Topics: Antineoplastic Agents; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Halogenation; Humans; Neoplasms; Pyridines; Topoisomerase II Inhibitors	2017
Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-β-benzyl ester derivatives as potent topoisomerase IIα inhibitors. Bioorganic & medicinal chemistry, 2017, 06-15, Volume: 25, Issue:12 Topics: Antigens, Neoplasm; Antineoplastic Agents; Aspartic Acid; Cell Line, Tumor; DNA Topoisomerases, Type II; DNA-Binding Proteins; HeLa Cells; Humans; Molecular Docking Simulation; Neoplasms; Phenylalanine; Structure-Activity Relationship; Topoisomerase II Inhibitors	2017
2-Chlorophenyl-substituted benzofuro[3,2-b]pyridines with enhanced topoisomerase inhibitory activity: The role of the chlorine substituent. Bioorganic & medicinal chemistry letters, 2017, 08-01, Volume: 27, Issue:15 Topics: Antineoplastic Agents; Benzofurans; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Halogenation; Humans; Neoplasms; Pyridines; Topoisomerase Inhibitors	2017
Four new antitumor metabolites isolated from a mutant 3-f-31 strain derived from Penicillium purpurogenum G59. European journal of medicinal chemistry, 2018, Oct-05, Volume: 158 Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Products; Cell Line, Tumor; HCT116 Cells; Humans; Mice; Models, Molecular; Mutation; Neoplasms; Penicillium	2018
Discover the leading compound of 4β-S-(5-fluorobenzoxazole)-4-deoxy-4'-demethylepipodophyllotoxin with millimolar-potency toxicity by modifying the molecule structure of 4'-demethylepipodophyllotoxin. European journal of medicinal chemistry, 2018, Oct-05, Volume: 158 Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Drug Design; Halogenation; Hep G2 Cells; Humans; Models, Molecular; Neoplasms; Oxazoles; Podophyllotoxin	2018
Structure-activity relationship of leucyladenylate sulfamate analogues as leucyl-tRNA synthetase (LRS)-targeting inhibitors of Mammalian target of rapamycin complex 1 (mTORC1). Bioorganic & medicinal chemistry, 2019, 03-15, Volume: 27, Issue:6 Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; HEK293 Cells; Humans; Leucine; Leucine-tRNA Ligase; Mechanistic Target of Rapamycin Complex 1; Neoplasms; Signal Transduction; Structure-Activity Relationship	2019
Design and synthesis of 4β-Acetamidobenzofuranone-podophyllotoxin hybrids and their anti-cancer evaluation. Bioorganic & medicinal chemistry letters, 2019, 08-15, Volume: 29, Issue:16 Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Podophyllotoxin; Structure-Activity Relationship	2019
Structural simplification of evodiamine: Discovery of novel tetrahydro-β-carboline derivatives as potent antitumor agents. Bioorganic & medicinal chemistry letters, 2021, 05-15, Volume: 40 Topics: Animals; Antineoplastic Agents; Apoptosis; Carbolines; Cell Proliferation; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; Humans; Male; Mice, Nude; Molecular Structure; Neoplasms; Proof of Concept Study; Quinazolines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays	2021
Discovery of novel ataxia telangiectasia mutated (ATM) kinase modulators: Computational simulation, biological evaluation and cancer combinational chemotherapy study. European journal of medicinal chemistry, 2022, Apr-05, Volume: 233 Topics: Ataxia Telangiectasia; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; DNA-Binding Proteins; Humans; Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases	2022
A Risk-Prediction Nomogram for Neutropenia or Febrile Neutropenia after Etoposide-Based Chemotherapy in Cancer Patients: A Retrospective Cohort Study. Pharmacology, 2022, Volume: 107, Issue:1-2 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Etoposide; Female; Humans; Logistic Models; Male; Middle Aged; Neoplasms; Nomograms; Predictive Value of Tests; Retrospective Studies; Risk Assessment; ROC Curve	2022
Common cancer treatments targeting DNA double strand breaks affect long-term memory and relate to immediate early gene expression in a sex-dependent manner. Oncotarget, 2022, Volume: 13 Topics: Amifostine; Animals; DNA; DNA Breaks, Double-Stranded; Etoposide; Female; Genes, Immediate-Early; Male; Memory, Long-Term; Mice; Neoplasms; Pharmaceutical Preparations	2022
The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress. eLife, 2022, 05-03, Volume: 11 Topics: Cell Line, Tumor; DNA Damage; Etoposide; Humans; Neoplasms; Oncogene Proteins; Proto-Oncogene Proteins c-bcl-6	2022
A novel NRF2/ARE inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy responses in chemo-refractory cancer cells. Journal of food and drug analysis, 2021, 12-15, Volume: 29, Issue:4 Topics: Antioxidant Response Elements; Cisplatin; Etoposide; Gossypol; Humans; Neoplasms; NF-E2-Related Factor 2	2021
Practice patterns and outcomes of hemophagocytic lymphohistiocytosis in adults: a 2-decade provincial retrospective review. Annals of hematology, 2022, Volume: 101, Issue:10 Topics: Adult; Etoposide; Female; Humans; Hyperbilirubinemia; Lymphohistiocytosis, Hemophagocytic; Male; Neoplasms; Retrospective Studies	2022
Synthesis, Anticancer Activities and Molecular Docking Studies of a Novel Class of 2-Phenyl-5,6,7,8-tetrahydroimidazo [1,2- Molecules (Basel, Switzerland), 2022, Aug-17, Volume: 27, Issue:16 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Etoposide; Fluorouracil; Humans; Molecular Docking Simulation; Molecular Structure; Neoplasms; Pyridazines; Structure-Activity Relationship; Sulfanilamide; Sulfonamides	2022
A single-beam of light priming the immune responses and boosting cancer photoimmunotherapy. Journal of controlled release : official journal of the Controlled Release Society, 2022, Volume: 350 Topics: Adjuvants, Immunologic; Antigens, Neoplasm; B7-H1 Antigen; Etoposide; Humans; Immune Checkpoint Inhibitors; Immunity; Immunotherapy; Lipids; Neoplasms; Phototherapy; Tumor Microenvironment	2022
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial. Leukemia, 2022, Volume: 36, Issue:11 Topics: Busulfan; Child; Cyclophosphamide; Etoposide; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Neoplasms; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation	2022
Multi-omics characterization of autophagy-related molecular features for therapeutic targeting of autophagy. Nature communications, 2022, 10-26, Volume: 13, Issue:1 Topics: Antineoplastic Agents; Autophagy; Etoposide; Humans; Neoplasms	2022
Etoposide hypersensitivity reactions associated with in-line filter use: A retrospective cohort study at CHU de Québec-Université Laval. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2023, Volume: 29, Issue:7 Topics: Adult; Child; Drug Hypersensitivity; Etoposide; Humans; Neoplasms; Quebec; Retrospective Studies	2023
A novel electron source for a compact x-ray tube for microbeam radiotherapy with very high dose rates. Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB), 2023, Volume: 106 Topics: Electrons; Etoposide; Humans; Monte Carlo Method; Neoplasms; Radiation Oncology; Radiotherapy Planning, Computer-Assisted; X-Rays	2023
Gastrointestinal bleeding/ulcer among paediatric cancer patients after proton beam therapy. Japanese journal of clinical oncology, 2023, Jun-01, Volume: 53, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Etoposide; Gastrointestinal Hemorrhage; Humans; Ifosfamide; Neoplasms; Proton Therapy; Ulcer; Vincristine	2023
Impact of Synthesized Indoloquinoline Analog to Isolates from Cells, 2023, 03-27, Volume: 12, Issue:7 Topics: Animals; Carcinoma, Ehrlich Tumor; Chemical and Drug Induced Liver Injury; Cryptolepis; DNA Topoisomerases, Type II; Etoposide; Female; Mice; Molecular Docking Simulation; Neoplasms; Tumor Necrosis Factor-alpha	2023
Tolerability of ifosfamide-containing regimen in patients with high-risk renal and INI-1-deficient tumors. Pediatric blood & cancer, 2023, Volume: 70, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Etoposide; Humans; Ifosfamide; Infant; Kidney; Neoplasms; Vincristine	2023
Naturally mutagenic sequence diversity in a human type II topoisomerase. Proceedings of the National Academy of Sciences of the United States of America, 2023, 07-11, Volume: 120, Issue:28 Topics: DNA; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Humans; Mutagens; Neoplasms; Topoisomerase II Inhibitors	2023
DNA-PK inhibition extends the therapeutic effects of Top2 poisoning to non-proliferating cells, increasing activity at a cost. Scientific reports, 2023, 08-01, Volume: 13, Issue:1 Topics: Animals; DNA; DNA Breaks, Double-Stranded; DNA Repair; DNA Topoisomerases, Type II; DNA-Activated Protein Kinase; DNA-Binding Proteins; Etoposide; Humans; Isomerases; Mice; Neoplasms; Topoisomerase II Inhibitors	2023
Effect of Moderate Malnutrition on the Pharmacokinetics of Etoposide and Vincristine in Freshly Weaned Rats. European journal of drug metabolism and pharmacokinetics, 2023, Volume: 48, Issue:6 Topics: Animals; Child; Child, Preschool; Disease Models, Animal; Etoposide; Humans; Malnutrition; Mice; Neoplasms; Rats; Rats, Sprague-Dawley; Vincristine	2023
Real-time monitoring of etoposide prodrug activated by hydrogen peroxide with improved safety. Journal of materials chemistry. B, 2019, 12-21, Volume: 7, Issue:47 Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Coumarins; Drug Liberation; Etoposide; Humans; Hydrogen Peroxide; Mice; Mice, Nude; Microscopy, Confocal; Neoplasms; Prodrugs; Reactive Oxygen Species; Survival Rate; Transplantation, Heterologous; Zebrafish	2019
Effects of cryotherapy on high-dose melphalan-induced oral mucositis in pediatric patients undergoing autologous stem cell transplantation. Pediatric blood & cancer, 2020, Volume: 67, Issue:9 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Cryotherapy; Dose-Response Relationship, Drug; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Melphalan; Neoplasms; Prognosis; Retrospective Studies; Stomatitis; Transplantation, Autologous; Young Adult	2020
5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study. BMC pharmacology & toxicology, 2020, 10-06, Volume: 21, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Capecitabine; Carboplatin; Dexamethasone; Etoposide; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Oxaliplatin; Paclitaxel; Pre-Exposure Prophylaxis; Serotonin 5-HT3 Receptor Antagonists; Vomiting	2020
Preparation of parenteral nanocrystal suspensions of etoposide from the excipient free dry state of the drug to enhance in vivo antitumoral properties. Scientific reports, 2020, 10-22, Volume: 10, Issue:1 Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Disease Models, Animal; Dosage Forms; Drug Compounding; Etoposide; Mice; Nanoparticles; Nanotechnology; Neoplasms; Suspensions	2020
The lncRNA MEG3/miR-16-5p/VGLL4 regulatory axis is involved in etoposide-induced senescence of tumor cells. The journal of gene medicine, 2021, Volume: 23, Issue:2 Topics: A549 Cells; Aging; Apoptosis; beta-Galactosidase; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Etoposide; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HEK293 Cells; Humans; MCF-7 Cells; MicroRNAs; Models, Biological; Neoplasms; RNA, Long Noncoding; Senescence-Associated Secretory Phenotype; Transcription Factors	2021
Six-step etoposide desensitization protocol: A pediatric, adolescent, and young adult case series. Pediatric blood & cancer, 2021, Volume: 68, Issue:1 Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Desensitization, Immunologic; Drug Hypersensitivity; Etoposide; Female; Follow-Up Studies; Humans; Infant; Male; Neoplasms; Prognosis; Retrospective Studies; Young Adult	2021
Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-κB. Oncogene, 2021, Volume: 40, Issue:6 Topics: Ataxia Telangiectasia Mutated Proteins; Cisplatin; CRISPR-Cas Systems; Cytidine Deaminase; DNA Repair; Etoposide; Fluorouracil; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; HCT116 Cells; Humans; MCF-7 Cells; Minor Histocompatibility Antigens; Mutation; Neoplasms; NF-kappa B; Transcription Factor RelA; Tumor Suppressor Protein p53	2021
Mutant p53 promotes RCP-dependent chemoresistance coinciding with increased delivery of P-glycoprotein to the plasma membrane. Cell death & disease, 2021, 02-24, Volume: 12, Issue:2 Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Membrane; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; HCT116 Cells; Humans; Male; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasms; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2021
The Circadian Protein PER1 Modulates the Cellular Response to Anticancer Treatments. International journal of molecular sciences, 2021, Mar-15, Volume: 22, Issue:6 Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Cycle; Cell Line, Tumor; Circadian Rhythm; Cisplatin; Docetaxel; Drug Chronotherapy; Etoposide; Humans; Mice; Neoplasms; Period Circadian Proteins; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2021
Risks and mitigation strategies to prevent etoposide infusion-related reactions in children. Pharmacotherapy, 2021, Volume: 41, Issue:8 Topics: Antineoplastic Agents; Child; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Infusions, Intravenous; Neoplasms; Risk Factors	2021
Downregulation of GSK3B by miR-132-3p Enhances Etoposide-Induced Breast Cancer Cell Apoptosis. Annals of clinical and laboratory science, 2021, Volume: 51, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Etoposide; Female; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Humans; MicroRNAs; Neoplasms; Prognosis; Survival Rate; Tumor Cells, Cultured	2021
BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy. Scientific reports, 2021, 07-07, Volume: 11, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Neoplasms; Outcome Assessment, Health Care; Podophyllotoxin; Transplantation Conditioning	2021
The Cancer SENESCopedia: A delineation of cancer cell senescence. Cell reports, 2021, 07-27, Volume: 36, Issue:4 Topics: Aniline Compounds; Azepines; Cell Line, Tumor; Cellular Senescence; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Pyrimidines; Reproducibility of Results; Senescence-Associated Secretory Phenotype; Senotherapeutics; Sulfonamides	2021
Quantitative identification of senescent cells in aging and disease. Aging cell, 2017, Volume: 16, Issue:4 Topics: Aging; Animals; beta-Galactosidase; Biomarkers; Cellular Senescence; Epithelial Cells; Etoposide; Fibrosis; Flow Cytometry; Gene Expression; Histones; HMGB1 Protein; Humans; Image Processing, Computer-Assisted; Lymphocytes; Mice; Molecular Imaging; Neoplasms; Primary Cell Culture; Single-Cell Analysis; Staining and Labeling; Stromal Cells	2017
Folic Acid-Targeted Etoposide Cubosomes for Theranostic Application of Cancer Cell Imaging and Therapy. Medical science monitor : international medical journal of experimental and clinical research, 2017, May-22, Volume: 23 Topics: Animals; Calorimetry, Differential Scanning; Cell Death; Cell Survival; Diagnostic Imaging; Drug Delivery Systems; Drug Liberation; Etoposide; Folic Acid; Humans; Inhibitory Concentration 50; Liquid Crystals; MCF-7 Cells; Mice; Neoplasms; Particle Size; Proton Magnetic Resonance Spectroscopy; Static Electricity; Theranostic Nanomedicine	2017
Engineered polymeric amphiphiles self-assembling into nanostructures and acting as efficient gene and drug carriers. Journal of biomaterials applications, 2017, Volume: 32, Issue:1 Topics: Alkylation; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; DNA; Drug Carriers; Etoposide; Humans; Hydrophobic and Hydrophilic Interactions; Neoplasms; Plasmids; Polyethyleneimine; Surface-Active Agents; Transfection	2017
Slow release of etoposide from dextran conjugation shifts etoposide activity from cytotoxicity to differentiation: A promising tool for dosage control in anticancer metronomic therapy. Nanomedicine : nanotechnology, biology, and medicine, 2017, Volume: 13, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Differentiation; Cells, Cultured; Dextrans; Etoposide; Humans; Monocytes; Neoplasms	2017
Smurf2-Mediated Stabilization of DNA Topoisomerase IIα Controls Genomic Integrity. Cancer research, 2017, 08-15, Volume: 77, Issue:16 Topics: Animals; Antigens, Neoplasm; Cell Line, Tumor; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Genomic Instability; Humans; Interphase; Mice; Mice, Knockout; Neoplasms; Ubiquitin-Protein Ligases	2017
Making moves: Transitioning R-EPOCH to the ambulatory setting. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2018, Volume: 24, Issue:8 Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hospitalization; Humans; Male; Middle Aged; Neoplasms; Prednisone; Retrospective Studies; Rituximab; Vincristine	2018
Towards a high throughput impedimetric screening of chemosensitivity of cancer cells suspended in hydrogel and cultured in a paper substrate. Biosensors & bioelectronics, 2018, Feb-15, Volume: 100 Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Screening Assays, Antitumor; Electric Impedance; Equipment Design; Etoposide; Hep G2 Cells; High-Throughput Screening Assays; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Neoplasms; Paper	2018
A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC cancer, 2017, Oct-16, Volume: 17, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Dose-Response Relationship, Drug; Etoposide; Humans; Maximum Tolerated Dose; Mice; Neoplasms	2017
Model-based optimization of G-CSF treatment during cytotoxic chemotherapy. Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:2 Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocytes; Hematopoiesis; Humans; Leukopenia; Models, Biological; Neoplasms; Polyethylene Glycols; Prednisone; Procarbazine; Randomized Controlled Trials as Topic; Reproducibility of Results; Vincristine	2018
A20/TNFAIP3 Regulates the DNA Damage Response and Mediates Tumor Cell Resistance to DNA-Damaging Therapy. Cancer research, 2018, 02-15, Volume: 78, Issue:4 Topics: Cell Line, Tumor; DNA Damage; Drug Resistance, Neoplasm; Etoposide; HEK293 Cells; HeLa Cells; Humans; MCF-7 Cells; Neoplasms; NF-kappa B; Promoter Regions, Genetic; Signal Transduction; Transfection; Tumor Necrosis Factor alpha-Induced Protein 3; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligases; Ubiquitination; Up-Regulation	2018
Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence. European journal of cancer (Oxford, England : 1990), 2018, Volume: 91 Topics: Adolescent; Age Factors; Antineoplastic Agents; Area Under Curve; Busulfan; Carboplatin; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Drug Dosage Calculations; Drug Monitoring; Etoposide; Humans; Infant; Models, Biological; Neoplasms; Patient Safety; Risk Factors	2018
Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies. Journal of pharmaceutical and biomedical analysis, 2018, Sep-05, Volume: 158 Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Daunorubicin; Doxorubicin; Drug Monitoring; Etoposide; Fluorescence; Humans; Limit of Detection; Male; Neoplasms; Occupational Exposure; Personnel, Hospital; Prednisone; Reproducibility of Results; Solid Phase Extraction; Vincristine	2018
Etoposide-Induced Apoptosis in Cancer Cells Can Be Reinforced by an Uncoupled Link between Hsp70 and Caspase-3. International journal of molecular sciences, 2018, Aug-25, Volume: 19, Issue:9 Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Drug Resistance, Neoplasm; Etoposide; HSP70 Heat-Shock Proteins; Humans; Neoplasms; Protein Binding	2018
Co-delivery of siRNA and etoposide to cancer cells using an MDEA esterquat based drug delivery system. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2019, Jan-15, Volume: 127 Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Combined Modality Therapy; Drug Delivery Systems; Etoposide; Gene Silencing; Green Fluorescent Proteins; Humans; Neoplasms; Quaternary Ammonium Compounds; RNA, Small Interfering	2019
Structure-Activity Relationships of Cytotoxic Lactones as Inhibitors and Mechanisms of Action. Current drug discovery technologies, 2020, Volume: 17, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Drug Design; Etoposide; Humans; Lactones; Ligands; Molecular Docking Simulation; Neoplasms; Paclitaxel; Sesquiterpenes; Structural Homology, Protein; Structure-Activity Relationship; Topotecan; Tubulin; Tubulin Modulators	2020
Oxygenated theranostic nanoplatforms with intracellular agglomeration behavior for improving the treatment efficacy of hypoxic tumors. Biomaterials, 2019, Volume: 197 Topics: Animals; Antineoplastic Agents, Phytogenic; Blood Substitutes; Drug Carriers; Drug Delivery Systems; Etoposide; Fluorocarbons; Hep G2 Cells; Humans; Hypoxia; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice, Nude; Neoplasms; Theranostic Nanomedicine; Treatment Outcome; Tumor Hypoxia	2019
Learning Cancer-Related Drug Efficacy Exploiting Consensus in Coordinated Motility Within Cell Clusters. IEEE transactions on bio-medical engineering, 2019, Volume: 66, Issue:10 Topics: Antineoplastic Agents, Phytogenic; Biomechanical Phenomena; Biosensing Techniques; Cell Movement; Dose-Response Relationship, Drug; Etoposide; Humans; Image Processing, Computer-Assisted; Machine Learning; Microscopy, Video; Neoplasms; PC-3 Cells; Software; Time-Lapse Imaging	2019
Enhanced surface plasmon resonance (SPR) signals based on immobilization of core-shell nanoparticles incorporated boron nitride nanosheets: Development of molecularly imprinted SPR nanosensor for anticancer drug, etoposide. Biosensors & bioelectronics, 2019, Apr-01, Volume: 130 Topics: Antineoplastic Agents; Biosensing Techniques; Boron Compounds; Dielectric Spectroscopy; Etoposide; Gold; Humans; Metal Nanoparticles; Molecular Imprinting; Neoplasms; Polymers; Spectroscopy, Fourier Transform Infrared; Surface Plasmon Resonance	2019
Structure Based Drug Design and Molecular Docking Studies of Anticancer Molecules Paclitaxel, Etoposide and Topotecan using Novel Ligands. Current drug discovery technologies, 2020, Volume: 17, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Drug Design; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lactones; Ligands; Molecular Docking Simulation; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-myb; Sesquiterpenes; Structure-Activity Relationship; Topotecan	2020
Octreotide-Conjugated Core-Cross-Linked Micelles with pH/Redox Responsivity Loaded with Etoposide for Neuroendocrine Neoplasms Therapy and Bioimaging with Photoquenching Resistance. ACS applied materials & interfaces, 2019, May-22, Volume: 11, Issue:20 Topics: A549 Cells; Animals; Antineoplastic Agents; Delayed-Action Preparations; Etoposide; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Micelles; Neoplasms; Octreotide; Xenograft Model Antitumor Assays	2019
Release of paused RNA polymerase II at specific loci favors DNA double-strand-break formation and promotes cancer translocations. Nature genetics, 2019, Volume: 51, Issue:6 Topics: Animals; Cell Line, Tumor; Cells, Cultured; DNA Breaks, Double-Stranded; DNA Repair; Enhancer Elements, Genetic; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Genetic Loci; Genomics; Introns; Neoplasms; Promoter Regions, Genetic; RNA Polymerase II; RNA Splice Sites; Topoisomerase Inhibitors; Transcription Initiation Site	2019
Role of nitric oxide in the chemistry and anticancer activity of etoposide (VP-16,213). Chemical research in toxicology, 2013, Mar-18, Volume: 26, Issue:3 Topics: Animals; Antineoplastic Agents; Cell Line; Drug Resistance, Neoplasm; Electron Spin Resonance Spectroscopy; Etoposide; HL-60 Cells; Humans; Mice; Neoplasms; Nitric Oxide; Spectrophotometry, Ultraviolet	2013
One-pot laccase-catalysed synthesis of 5,6-dihydroxylated benzo[b]furans and catechol derivatives, and their anticancer activity. Archiv der Pharmazie, 2013, Volume: 346, Issue:4 Topics: Antineoplastic Agents; Benzofurans; Catechols; Cell Line, Tumor; Etoposide; HeLa Cells; Humans; Laccase; Lethal Dose 50; MCF-7 Cells; Neoplasms	2013
Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer. Molecular cancer therapeutics, 2013, Volume: 12, Issue:6 Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Camptothecin; Clinical Trials as Topic; DNA-Binding Proteins; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; HCT116 Cells; Heterocyclic Compounds, 3-Ring; Humans; Mice; Neoplasms; Pyrones; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2013
Hypersensitivity reactions to etoposide phosphate. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014, Volume: 20, Issue:2 Topics: Adult; Antineoplastic Agents; Drug Hypersensitivity; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Organophosphorus Compounds; Young Adult	2014
A new p53 target gene, RKIP, is essential for DNA damage-induced cellular senescence and suppression of ERK activation. Neoplasia (New York, N.Y.), 2013, Volume: 15, Issue:7 Topics: Antineoplastic Agents; Cell Line, Tumor; Cellular Senescence; DNA Damage; Doxorubicin; Enzyme Activation; Etoposide; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Phosphatidylethanolamine Binding Protein; Phosphorylation; Signal Transduction; Topoisomerase II Inhibitors; Tumor Suppressor Protein p53	2013
ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. Nature communications, 2013, Volume: 4 Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Aurora Kinase B; Autophagy; Autophagy-Related Protein 5; Cell Line, Tumor; Cell Nucleus; Cisplatin; DNA Damage; Etoposide; HeLa Cells; HSP90 Heat-Shock Proteins; Humans; Inhibitor of Apoptosis Proteins; Jurkat Cells; M Phase Cell Cycle Checkpoints; Microtubule-Associated Proteins; Mitosis; Neoplasms; RNA Interference; RNA, Small Interfering; Signal Transduction; Survivin	2013
Encapsulation of podophyllotoxin and etoposide in biodegradable poly-D,L-lactide nanoparticles improved their anticancer activity. Journal of microencapsulation, 2014, Volume: 31, Issue:3 Topics: Animals; Antineoplastic Agents, Phytogenic; CHO Cells; Cricetinae; Cricetulus; Delayed-Action Preparations; Drug Screening Assays, Antitumor; Etoposide; Humans; Nanoparticles; Neoplasms; Podophyllotoxin; Polyesters	2014
Clozapine, cancer chemotherapy and neutropenia - dilemmas in management. Psychiatria Danubina, 2013, Volume: 25, Issue:4 Topics: Adult; Antineoplastic Agents; Antipsychotic Agents; Bleomycin; Breast Neoplasms; Carcinoma; Cisplatin; Clozapine; Etoposide; Female; Humans; Intestinal Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Schizophrenia; Seminoma; Testicular Neoplasms	2013
CARS based label-free assay for assessment of drugs by monitoring lipid droplets in tumour cells. Journal of biophotonics, 2014, Volume: 7, Issue:11-12 Topics: Algorithms; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Drug Screening Assays, Antitumor; Etoposide; Fluorescent Dyes; HCT116 Cells; Humans; Lipid Droplets; Lipids; Microscopy, Fluorescence; Neoplasms; Spectrum Analysis, Raman; Staurosporine	2014
Radium beam therapy. The Journal of the Faculty of Radiologists. Faculty of Radiologists (Great Britain), 1951, Volume: 3, Issue:2 Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms; Radium	1951
Radium beam therapy at the Western Infirmary of Glasgow, 1938-48. The Journal of the Faculty of Radiologists. Faculty of Radiologists (Great Britain), 1951, Volume: 3, Issue:2 Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms; Radium	1951
A whole-body dual-modality radionuclide optical strategy for preclinical imaging of metastasis and heterogeneous treatment response in different microenvironments. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:4 Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; DNA Damage; Environment; Etoposide; Female; Fluorescence; Humans; Lymph Nodes; Microscopy, Confocal; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sodium Pertechnetate Tc 99m; Symporters; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Whole Body Imaging	2014
Stability of etoposide solutions in disposable infusion devices for day hospital cancer practices. Drugs in R&D, 2014, Volume: 14, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Chemical Precipitation; Chromatography, High Pressure Liquid; Disposable Equipment; Drug Stability; Etoposide; Infusions, Intravenous; Neoplasms	2014
Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies. Cancer biology & therapy, 2014, Volume: 15, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cell Proliferation; Clathrin; Endocytosis; Etoposide; Gangliosides; Humans; Immunoglobulin G; Liposomes; Neoplasms; Topoisomerase Inhibitors; Tumor Cells, Cultured	2014
Spectroscopic detection of etoposide binding to chromatin components: the role of histone proteins. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, 2014, Dec-10, Volume: 133 Topics: Antineoplastic Agents, Phytogenic; Chromatin; DNA; Etoposide; Histones; Humans; Intercalating Agents; Neoplasms; Protein Structure, Secondary; Spectrum Analysis	2014
Hypoxia-induced miR-424 decreases tumor sensitivity to chemotherapy by inhibiting apoptosis. Cell death & disease, 2014, Jun-26, Volume: 5 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Hypoxia; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Mice; Mice, Nude; MicroRNAs; Neoplasms; RNA, Neoplasm	2014
Atypical cell populations associated with acquired resistance to cytostatics and cancer stem cell features: the role of mitochondria in nuclear encapsulation. DNA and cell biology, 2014, Volume: 33, Issue:11 Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport; Cell Nucleus; Cytostatic Agents; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Mice; MicroRNAs; Mitochondria; Neoplasms; Neoplastic Stem Cells; Tumor Cells, Cultured	2014
HPLC-UV method for quantifying etoposide in plasma and tumor interstitial fluid by microdialysis: application to pharmacokinetic studies. Biomedical chromatography : BMC, 2015, Volume: 29, Issue:4 Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Etoposide; Extracellular Fluid; Male; Microdialysis; Neoplasms; Rats	2015
Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin-N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA. Bioorganic & medicinal chemistry, 2014, Nov-01, Volume: 22, Issue:21 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; Etoposide; Humans; Leukemia; Molecular Docking Simulation; Mustard Compounds; Neoplasms; Podophyllotoxin; Topoisomerase II Inhibitors	2014
Bulletin of the World Health Organization, 2014, Nov-01, Volume: 92, Issue:11 Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Arachidonic Acids; Asbestos; Asbestosis; Attitude of Health Personnel; Carboplatin; Child; Child, Preschool; Curriculum; Databases, Factual; Education, Medical; Enzyme Inhibitors; Etoposide; Europe; Female; General Surgery; Germany; Hospitals, University; Humans; Ifosfamide; Lung Neoplasms; Male; Medical History Taking; Mesothelioma; Mice; Mice, Inbred C57BL; Mice, Knockout; Motor Neurons; Muscular Atrophy; Neoplasms; Neuroprotective Agents; Phospholipase A2 Inhibitors; Phospholipases A2, Cytosolic; Physical Examination; Quality Improvement; Spinal Cord Injuries; Topotecan; Universities; World Health Organization; Young Adult	2014
Comprehensive silencing of target-sharing microRNAs is a mechanism for SIRT1 overexpression in cancer. RNA biology, 2014, Volume: 11, Issue:11 Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Line, Tumor; CpG Islands; DNA Methylation; Etoposide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Mice; MicroRNAs; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sirtuin 1; Tumor Suppressor Protein p53	2014
γH2AX is a biomarker of modulated cytostatic drug resistance. Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2015, Volume: 87, Issue:8 Topics: Apoptosis; Biomarkers; Cytostatic Agents; DNA Damage; Drug Resistance; Etoposide; Histones; Humans; Neoplasms	2015
Chemical profiling of the genome with anti-cancer drugs defines target specificities. Nature chemical biology, 2015, Volume: 11, Issue:7 Topics: Aclarubicin; Antineoplastic Agents; Cell Line, Tumor; Chromatin; Daunorubicin; DNA Damage; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Genome, Human; Histones; Humans; Molecular Targeted Therapy; Neoplasms; Organ Specificity; Protein Transport; Structure-Activity Relationship; Topoisomerase Inhibitors; Topotecan	2015
YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors. Molecular cancer research : MCR, 2015, Volume: 13, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Cell Line, Tumor; Circular Dichroism; Colorectal Neoplasms; DNA Breaks, Double-Stranded; DNA Repair; Drug Synergism; Etoposide; Glioma; High-Throughput Screening Assays; Humans; Intercalating Agents; Mice; Mice, Nude; Molecular Structure; Neoplasms; Osteosarcoma; Poly(ADP-ribose) Polymerase Inhibitors; Radiation-Sensitizing Agents; Small Molecule Libraries; Sulfonamides; Xenograft Model Antitumor Assays	2015
Optimization of drug regimen in chemotherapy based on semi-mechanistic model for myelosuppression. Journal of biomedical informatics, 2015, Volume: 57 Topics: Antineoplastic Agents; Etoposide; Humans; Models, Theoretical; Neoplasms; Neutropenia	2015
M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC cancer, 2015, Aug-08, Volume: 15 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Communication; Cell Differentiation; Cell Line, Tumor; Cytokines; Drug Resistance, Neoplasm; Etoposide; Humans; Inflammation Mediators; Macrophage Activation; Macrophages; Neoplasms	2015
Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content. The Journal of biological chemistry, 2015, Oct-02, Volume: 290, Issue:40 Topics: Animals; Antineoplastic Agents; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Cetuximab; Culture Media, Conditioned; DNA; ErbB Receptors; Etoposide; Exosomes; Extracellular Vesicles; Glioma; Humans; Mice; Mice, SCID; Morpholines; Neoplasm Transplantation; Neoplasms; Phosphoproteins; Phosphorylation; Proteomics; Quinazolinones; Transfection	2015
Tetra-O-Methyl Nordihydroguaiaretic Acid Broadly Suppresses Cancer Metabolism and Synergistically Induces Strong Anticancer Activity in Combination with Etoposide, Rapamycin and UCN-01. PloS one, 2016, Volume: 11, Issue:2 Topics: Antineoplastic Agents; Autophagy; Carbohydrate Metabolism; Caspase 7; Cell Line, Tumor; Down-Regulation; Drug Synergism; Energy Metabolism; Etoposide; Glutathione; Humans; Lipid Metabolism; Male; Masoprocol; Metabolic Networks and Pathways; Metabolome; Neoplasms; Oxidative Stress; Reactive Oxygen Species; Sirolimus; Staurosporine	2016
Fluorescence Characterization of Gold Modified Liposomes with Antisense N-myc DNA Bound to the Magnetisable Particles with Encapsulated Anticancer Drugs (Doxorubicin, Ellipticine and Etoposide). Sensors (Basel, Switzerland), 2016, Feb-25, Volume: 16, Issue:3 Topics: DNA, Antisense; Doxorubicin; Drug Delivery Systems; Ellipticines; Etoposide; Fluorescence; Gold; Humans; Liposomes; Magnetite Nanoparticles; N-Myc Proto-Oncogene Protein; Neoplasms	2016
Population Pharmacokinetic Modeling of Etoposide Free Concentrations in Solid Tumor. Pharmaceutical research, 2016, Volume: 33, Issue:7 Topics: Animals; Etoposide; Male; Microdialysis; Neoplasms; Rats; Rats, Wistar; Tissue Distribution	2016
Effect of MPS1 Inhibition on Genotoxic Stress Responses in Murine Tumour Cells. Anticancer research, 2016, Volume: 36, Issue:6 Topics: Animals; Cell Cycle; Cell Line, Tumor; Centrosome; DNA Damage; Etoposide; Mice; Mitosis; Neoplasms; Protein Serine-Threonine Kinases	2016
G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status. Cancer letters, 2016, 10-01, Volume: 380, Issue:2 Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; DNA Breaks, Double-Stranded; DNA End-Joining Repair; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; HCT116 Cells; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Neoplasms; Phleomycins; Quinazolines; RNA Interference; Signal Transduction; Time Factors; Topoisomerase II Inhibitors; Transfection; Tumor Suppressor Protein p53	2016
RNF168 and USP10 regulate topoisomerase IIα function via opposing effects on its ubiquitylation. Nature communications, 2016, 08-25, Volume: 7 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chromosome Segregation; Craniofacial Abnormalities; DNA Topoisomerases, Type II; DNA, Catenated; Drug Resistance, Neoplasm; Etoposide; Fibroblasts; Gene Knockdown Techniques; HEK293 Cells; Humans; Immunologic Deficiency Syndromes; Learning Disabilities; Mice; Mutagenesis, Site-Directed; Neoplasms; Poly-ADP-Ribose Binding Proteins; Primary Immunodeficiency Diseases; Proteomics; RNA, Small Interfering; Topoisomerase II Inhibitors; Ubiquitin Thiolesterase; Ubiquitin-Protein Ligases; Ubiquitination	2016
Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells. Cellular signalling, 2017, Volume: 29 Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cellular Senescence; DNA Damage; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxyurea; Models, Biological; Mutation; Neoplasms; NF-kappa B; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine	2017
HIC1 (hypermethylated in cancer 1) SUMOylation is dispensable for DNA repair but is essential for the apoptotic DNA damage response (DDR) to irreparable DNA double-strand breaks (DSBs). Oncotarget, 2017, Jan-10, Volume: 8, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Checkpoint Kinase 2; DNA Breaks, Double-Stranded; DNA Repair; Etoposide; Histone Deacetylases; Humans; Kruppel-Like Transcription Factors; Models, Molecular; Neoplasms; Promoter Regions, Genetic; Protein Binding; Repressor Proteins; Sirtuin 1; Sumoylation; Trans-Activators; Tumor Suppressor Protein p53	2017
Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy. Molecular pharmacology, 2017, Volume: 91, Issue:1 Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cytoprotection; DNA; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; Glutathione; Histones; Humans; Mitoxantrone; Myeloid Cells; Neoplasms; Peroxidase; Phosphorylation; Poly-ADP-Ribose Binding Proteins; Small Molecule Libraries	2017
PTK2-mediated degradation of ATG3 impedes cancer cells susceptible to DNA damage treatment. Autophagy, 2017, Mar-04, Volume: 13, Issue:3 Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis Regulatory Proteins; Autophagy-Related Proteins; Cell Line, Tumor; Cell Proliferation; DNA Damage; Etoposide; Focal Adhesion Kinase 1; Mice; Mice, Knockout; Mitosis; Neoplasms; Phosphorylation; Proteolysis; Ubiquitin-Conjugating Enzymes	2017
Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy. Clinical lymphoma, myeloma & leukemia, 2017, Volume: 17, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Posterior Leukoencephalopathy Syndrome; Prednisone; Retrospective Studies; Risk Factors; Rituximab; Vincristine	2017
Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes. Ethnicity & disease, 2008,Spring, Volume: 18, Issue:2 Suppl 2 Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cloning, Molecular; DNA Damage; Etoposide; Flow Cytometry; Genotype; Humans; Imidazoles; Neoplasms; Phenotype; Piperazines; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-mdm2; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53	2008
Metronomic etoposide/cyclophosphamide/celecoxib regimen given to children and adolescents with refractory cancer: a preliminary monocentric study. Clinical therapeutics, 2008, Volume: 30, Issue:7 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Child, Preschool; Cyclophosphamide; Drug Administration Schedule; Drug Resistance; Etoposide; Humans; Neoplasms; Pyrazoles; Retrospective Studies; Sulfonamides	2008
Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Molecular and cellular biology, 2008, Volume: 28, Issue:20 Topics: Animals; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; Cisplatin; Cyclin D1; Diploidy; DNA Damage; DNA Repair; DNA-Binding Proteins; Epigenesis, Genetic; Etoposide; G2 Phase; Genomic Instability; Histones; Humans; Mice; Neoplasms; Phenotype; Polymorphism, Single Nucleotide; Protein Transport; Rhabdoid Tumor; SMARCB1 Protein; Transcription Factors	2008
Oral bioavailability of etoposide after administration of a single dose to tumor-bearing dogs. American journal of veterinary research, 2008, Volume: 69, Issue:10 Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Cross-Over Studies; Dog Diseases; Dogs; Etoposide; Infusions, Intravenous; Kinetics; Neoplasms	2008
High-dose etoposide: from phase I to a component of curative therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-20, Volume: 26, Issue:33 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Neoplasms	2008
F14512, a potent antitumor agent targeting topoisomerase II vectored into cancer cells via the polyamine transport system. Cancer research, 2008, Dec-01, Volume: 68, Issue:23 Topics: Animals; Binding, Competitive; Biogenic Polyamines; Breast Neoplasms; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Delivery Systems; Etoposide; Female; Humans; Leukemia L1210; Lung Neoplasms; Mice; Mice, Nude; Neoplasms; Podophyllotoxin; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays	2008
Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer biology & therapy, 2009, Volume: 8, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspases, Initiator; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; eIF-2 Kinase; Endoplasmic Reticulum; Etoposide; Female; Gene Deletion; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; JNK Mitogen-Activated Protein Kinases; Male; Neoplasms; Signal Transduction; Stress, Physiological	2009
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2009, Volume: 17, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Mucositis; Multiple Myeloma; Neoplasms; Severity of Illness Index; Whole-Body Irradiation; Young Adult	2009
On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents. Bioorganic & medicinal chemistry letters, 2009, Aug-01, Volume: 19, Issue:15 Topics: Acridines; Aminacrine; Antineoplastic Agents; Cell Line; Chemistry, Pharmaceutical; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Doxorubicin; Drug Design; Drug Screening Assays, Antitumor; Etoposide; Humans; Models, Chemical; Neoplasms; RNA, Small Interfering	2009
Cytotoxic activity and cell cycle analysis of quinoline alkaloids isolated from Haplophyllum canaliculatum Boiss. Planta medica, 2009, Volume: 75, Issue:14 Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Etoposide; Flow Cytometry; G1 Phase; HL-60 Cells; Humans; Jurkat Cells; Neoplasms; Phytotherapy; Plant Extracts; Quinolines; Rutaceae	2009
Downregulation of uridine-cytidine kinase like-1 decreases proliferation and enhances tumor susceptibility to lysis by apoptotic agents and natural killer cells. Apoptosis : an international journal on programmed cell death, 2009, Volume: 14, Issue:10 Topics: Apoptosis; Caspase 3; Caspase 7; Cell Cycle; Cell Proliferation; Cytotoxicity, Immunologic; Down-Regulation; Etoposide; Gene Expression Regulation, Neoplastic; Gene Silencing; Green Fluorescent Proteins; Humans; K562 Cells; Killer Cells, Natural; Neoplasms; RNA, Messenger; RNA, Small Interfering; Staurosporine; Time Factors; Uridine Kinase	2009
Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Count; Cell Enlargement; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Fluorouracil; Humans; Models, Biological; Myelopoiesis; Neoplasms; Neutrophils; Observation; Paclitaxel; Precision Medicine; Taxoids; Topotecan	2010
Chemotherapy induces ATP release from tumor cells. Cell cycle (Georgetown, Tex.), 2009, Nov-15, Volume: 8, Issue:22 Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Cadmium; Cell Line, Tumor; Cisplatin; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Mice; Mitomycin; Mitoxantrone; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Sphingosine; Thapsigargin	2009
Production of hyperpolarized [1,4-13C2]malate from [1,4-13C2]fumarate is a marker of cell necrosis and treatment response in tumors. Proceedings of the National Academy of Sciences of the United States of America, 2009, Nov-24, Volume: 106, Issue:47 Topics: Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carbon Isotopes; Etoposide; Female; Fumarate Hydratase; Fumarates; Lymphoma; Malates; Mice; Mice, Inbred C57BL; Necrosis; Neoplasm Transplantation; Neoplasms; Nuclear Magnetic Resonance, Biomolecular; Tissue Extracts; Treatment Outcome	2009
Hypoxic enlarged mitochondria protect cancer cells from apoptotic stimuli. Journal of cellular physiology, 2010, Volume: 222, Issue:3 Topics: Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Hypoxia; Cell Proliferation; Drug Resistance, Neoplasm; Etoposide; GTP Phosphohydrolases; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Membrane Potential, Mitochondrial; Membrane Proteins; Membrane Transport Proteins; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Proteins; Mitochondrial Swelling; Neoplasms; Phenotype; Proto-Oncogene Proteins; RNA Interference; Staurosporine; Time Factors; Transfection; Tumor Suppressor Proteins	2010
Synergistic enhancement of cancer therapy using a combination of carbon nanotubes and anti-tumor drug. Nanomedicine (London, England), 2009, Volume: 4, Issue:8 Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Synergism; Etoposide; Flow Cytometry; HeLa Cells; Humans; Microscopy, Electron, Transmission; Nanotubes, Carbon; Neoplasms	2009
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature, 2010, Jan-07, Volume: 463, Issue:7277 Topics: Animals; Apoptosis; Biphenyl Compounds; Cell Line; Cell Line, Tumor; Cell Survival; DNA Damage; Docetaxel; Etoposide; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Half-Life; Humans; Lysine; Mice; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Nitrophenols; Phosphorylation; Piperazines; Polyubiquitin; Prognosis; Protein Binding; Protein Stability; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Sulfonamides; Taxoids; Ubiquitin Thiolesterase; Ubiquitination; Ultraviolet Rays; Xenograft Model Antitumor Assays	2010
Novel 4 beta-anilino-podophyllotoxin derivatives: design synthesis and biological evaluation as potent DNA-topoisomerase II poisons and anti-MDR agents. Molecular bioSystems, 2010, Volume: 6, Issue:2 Topics: Aniline Compounds; Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Humans; Mice; Neoplasms; Podophyllotoxin; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays	2010
Opposing effects of hMOF and SIRT1 on H4K16 acetylation and the sensitivity to the topoisomerase II inhibitor etoposide. Oncogene, 2010, Apr-15, Volume: 29, Issue:15 Topics: Acetylation; Animals; Cell Death; Cell Line, Tumor; DNA Damage; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Histone Acetyltransferases; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Lysine; Male; Neoplasms; Sirtuin 1; Topoisomerase II Inhibitors; Valproic Acid	2010
In vitro interaction of high-LET heavy-ion irradiation and chemotherapeutic agents in two cell lines with different radiosensitivities and different p53 status. Anticancer research, 2010, Volume: 30, Issue:6 Topics: Animals; Antineoplastic Agents; Carbon; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Radiation; Etoposide; Genes, p53; Heavy Ion Radiotherapy; Linear Energy Transfer; Neoplasms; Radiation Tolerance; Rats	2010
Differential regulation of MRN (Mre11-Rad50-Nbs1) complex subunits and telomerase activity in cancer cells. Biochemical and biophysical research communications, 2010, Sep-03, Volume: 399, Issue:4 Topics: Acid Anhydride Hydrolases; Antineoplastic Agents, Phytogenic; Cell Cycle Proteins; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair Enzymes; DNA-Binding Proteins; Etoposide; Humans; MRE11 Homologue Protein; Neoplasms; Nuclear Proteins; RNA, Small Interfering; Telomerase	2010
Peroxiredoxin II restrains DNA damage-induced death in cancer cells by positively regulating JNK-dependent DNA repair. The Journal of biological chemistry, 2011, Mar-11, Volume: 286, Issue:10 Topics: Antineoplastic Agents, Phytogenic; Antioxidants; Cell Death; Cell Nucleus; Cell Survival; DNA Damage; DNA Repair; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HeLa Cells; Humans; MAP Kinase Kinase 4; Neoplasms; Peroxiredoxins; Proto-Oncogene Proteins c-jun	2011
Praf2 is a novel Bcl-xL/Bcl-2 interacting protein with the ability to modulate survival of cancer cells. PloS one, 2010, Dec-20, Volume: 5, Issue:12 Topics: Apoptosis; bcl-X Protein; Carrier Proteins; Cell Line; Cell Line, Tumor; Cell Survival; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Membrane Potentials; Membrane Proteins; Mitochondria; Models, Biological; Mutation; Neoplasms; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2	2010
DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging, 2010, Volume: 2, Issue:12 Topics: Cell Cycle; Cell Line; Cell Proliferation; Cell Shape; Cellular Senescence; DNA Damage; Doxorubicin; Enzyme Activation; Etoposide; Humans; Imidazoles; Neoplasms; Piperazines; Protein Kinase Inhibitors; Retinal Pigment Epithelium; Serum; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Up-Regulation	2010
Polyploid tumour cells elicit paradiploid progeny through depolyploidizing divisions and regulated autophagic degradation. Cell biology international, 2011, Volume: 35, Issue:7 Topics: Autophagy; Cell Line, Tumor; Chromatin; Chromatin Assembly and Disassembly; DNA Fragmentation; DNA Replication; Etoposide; Gamma Rays; Genome, Human; Homeodomain Proteins; Humans; Mitosis; Nanog Homeobox Protein; Neoplasms; Octamer Transcription Factor-3; Paclitaxel; Ploidies; Tumor Suppressor Protein p53	2011
Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases. The American Journal of dermatopathology, 2011, Volume: 33, Issue:4 Topics: Alopecia; Antineoplastic Agents; Busulfan; Cisplatin; Dermis; Diagnosis, Differential; Docetaxel; Etoposide; Female; Hair; Humans; Male; Neoplasms; Taxoids	2011
Copy number polymorphisms and anticancer pharmacogenomics. Genome biology, 2011, Volume: 12, Issue:5 Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carboplatin; Cell Line, Tumor; Cisplatin; Daunorubicin; Etoposide; Gene Dosage; Gene Expression; Genetic Predisposition to Disease; Genetic Variation; Genome-Wide Association Study; Genome, Human; Humans; Inhibitory Concentration 50; Neoplasms; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Quantitative Trait Loci; Topoisomerase II Inhibitors	2011
Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Child; Child, Preschool; Computer Simulation; Cyclophosphamide; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Etoposide; Female; Humans; Infant; Male; Melphalan; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Protein Binding	2012
The role of heat shock protein 90 in the regulation of tumor cell apoptosis. Bulletin of experimental biology and medicine, 2011, Volume: 150, Issue:4 Topics: Apoptosis; Benzoquinones; Caspase 3; Etoposide; HSP90 Heat-Shock Proteins; Humans; Jurkat Cells; Lactams, Macrocyclic; Neoplasms	2011
Nrf2 protein up-regulates antiapoptotic protein Bcl-2 and prevents cellular apoptosis. The Journal of biological chemistry, 2012, Mar-23, Volume: 287, Issue:13 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gamma Rays; Gene Expression Regulation, Neoplastic; HEK293 Cells; Hep G2 Cells; Humans; Mice; Mutagenesis; Neoplasms; NF-E2-Related Factor 2; Proto-Oncogene Proteins c-bcl-2; Response Elements; Ultraviolet Rays; Up-Regulation	2012
Cdt1 is differentially targeted for degradation by anticancer chemotherapeutic drugs. PloS one, 2012, Volume: 7, Issue:3 Topics: Antineoplastic Agents; Cell Cycle Proteins; Cisplatin; Doxorubicin; Etoposide; Fluorouracil; HeLa Cells; Hep G2 Cells; Humans; Methyl Methanesulfonate; Neoplasms; Proteolysis; Tamoxifen; Ultraviolet Rays	2012
Comparison of caspase-3 activation in tumor cells upon treatment of chemotherapeutic drugs using capillary electrophoresis. Protein & cell, 2012, Volume: 3, Issue:5 Topics: Antineoplastic Agents; Camptothecin; Caspase 3; Cisplatin; Drug Screening Assays, Antitumor; Electrophoresis, Capillary; Enzyme Activation; Etoposide; HeLa Cells; Hep G2 Cells; Humans; Neoplasms; Time Factors; Tumor Necrosis Factor-alpha	2012
Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience. Oncology, 2012, Volume: 82, Issue:5 Topics: Administration, Metronomic; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Child, Preschool; Dacarbazine; Etoposide; Europe; Feasibility Studies; Female; Fenofibrate; Humans; Infant; Isotretinoin; Male; Neoplasms; Pyrazoles; Registries; Sulfonamides; Temozolomide; Vitamin D; Young Adult	2012
Nature and dynamics of nucleosome release from neoplastic and non-neoplastic cells. Anticancer research, 2012, Volume: 32, Issue:5 Topics: Apoptosis; Blast Crisis; Cytarabine; Etoposide; Hep G2 Cells; Humans; L-Lactate Dehydrogenase; Leukemia; Neoplasms; Neutrophils; Nucleosomes; Tetradecanoylphorbol Acetate; TNF-Related Apoptosis-Inducing Ligand	2012
Interaction between serotonin reuptake inhibitors, 5-HT3 antagonists, and NK1 antagonists in cancer patients receiving highly emetogenic chemotherapy: a case-control study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:9 Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Phytogenic; Aprepitant; Case-Control Studies; Drug Interactions; Drug Therapy, Combination; Etoposide; Female; Humans; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Platinum; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Vomiting	2012
iASPPsv antagonizes apoptosis induced by chemotherapeutic agents in MCF-7 cells and mouse thymocytes. Biochemical and biophysical research communications, 2012, Aug-03, Volume: 424, Issue:3 Topics: Animals; Apoptosis; Cell Line, Tumor; Dexamethasone; DNA Breaks, Double-Stranded; Etoposide; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Transgenic; Neoplasms; Repressor Proteins; T-Lymphocytes	2012
The polyoma virus large T binding protein p150 is a transcriptional repressor of c-MYC. PloS one, 2012, Volume: 7, Issue:9 Topics: Antineoplastic Agents, Phytogenic; Base Sequence; Cell Line, Tumor; DNA-Binding Proteins; Etoposide; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Molecular Sequence Data; Neoplasms; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-myc; Transcription Factors; Transcription, Genetic	2012
A novel carbazole derivative, MHY407, sensitizes cancer cells to doxorubicin-, etoposide-, and radiation treatment via DNA damage. European journal of pharmacology, 2012, Dec-15, Volume: 697, Issue:1-3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carbazoles; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Epoxy Compounds; Etoposide; Female; G1 Phase Cell Cycle Checkpoints; Humans; MCF-7 Cells; Neoplasms; Radiation-Sensitizing Agents; S Phase Cell Cycle Checkpoints; Time Factors	2012
Hypoxia-induced modulation of apoptosis and BCL-2 family proteins in different cancer cell types. PloS one, 2012, Volume: 7, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Cell Hypoxia; Cell Line, Tumor; DNA Damage; Etoposide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Models, Biological; Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; Tumor Suppressor Protein p53	2012
STK295900, a dual inhibitor of topoisomerase 1 and 2, induces G(2) arrest in the absence of DNA damage. PloS one, 2013, Volume: 8, Issue:1 Topics: Aniline Compounds; Antineoplastic Agents, Phytogenic; Benzimidazoles; Camptothecin; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Dose-Response Relationship, Drug; Etoposide; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; HeLa Cells; Hep G2 Cells; HT29 Cells; Humans; Immunoblotting; MCF-7 Cells; Molecular Structure; Neoplasms; Phosphorylation; Topoisomerase Inhibitors	2013
Advancement towards tin-based anticancer chemotherapeutics: structural modification and computer modeling approach to drug-enzyme interactions. Current topics in medicinal chemistry, 2012, Volume: 12, Issue:24 Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Survival; Cisplatin; Computer Simulation; Computer-Aided Design; Crystallography, X-Ray; Drug Design; Drug Screening Assays, Antitumor; Etoposide; Fluorouracil; Humans; Molecular Docking Simulation; Neoplasms; Organotin Compounds; Protein Binding	2012
Synthesis and characterization of a catalytic antibody-HPMA copolymer-Conjugate as a tool for tumor selective prodrug activation. Bioorganic & medicinal chemistry, 2002, Volume: 10, Issue:9 Topics: Antibodies, Catalytic; Cell Division; Etoposide; Humans; Immunoconjugates; Inhibitory Concentration 50; Methacrylates; Neoplasms; Prodrugs; Tumor Cells, Cultured	2002
Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization. Transfusion, 2002, Volume: 42, Issue:11 Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cellular Senescence; Combined Modality Therapy; Cytarabine; Dexamethasone; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Ifosfamide; Leukapheresis; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Predictive Value of Tests; ROC Curve; Transplantation, Autologous	2002
[Salvage thermochemotherapy in advanced refractory malignant tumors in children]. Voprosy onkologii, 2002, Volume: 48, Issue:3 Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Female; Humans; Hyperthermia, Induced; Interleukin-2; Male; Melphalan; Monitoring, Immunologic; Neoplasms; Neuroleptanalgesia; Salvage Therapy; Time Factors; Vincristine	2002
EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation. European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:18 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Kidney Diseases; Male; Neoplasms; Vincristine	2002
Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Société Française d'Oncologie Pédiatrique. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-15, Volume: 21, Issue:6 Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Bone Marrow; Case-Control Studies; Chemotherapy, Adjuvant; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; France; Humans; Leukemia; Male; Multivariate Analysis; Neoplasms; Neoplasms, Second Primary; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors	2003
RADIO-COBALT beam therapy. British medical journal, 1953, Mar-21, Volume: 1, Issue:4811 Topics: Carmustine; Cobalt; Cobalt Radioisotopes; Etoposide; Humans; Neoplasms; Radioactivity	1953
[Utilization of contiguous orthogonal beams in the treatment of semi-deep-seated tumors]. Journal de radiologie, d'electrologie & archives d'electricite medicale, 1953, Volume: 34, Issue:5-6 Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms	1953
[The use of moving beam irradiation in gynecology]. Medizinische Monatsschrift, 1954, Volume: 8, Issue:10 Topics: Etoposide; Genitalia; Genitalia, Female; Gynecology; Neoplasms; Radiotherapy	1954
[Contribution to the study of convergence beam radiotherapy]. Journal belge de radiologie, 1956, Volume: 39, Issue:5 Topics: Carmustine; Etoposide; Humans; Melphalan; Neoplasms; Radiotherapy	1956
Cobalt 60 beam therapy: some impressions after five years. Canadian Medical Association journal, 1957, Aug-15, Volume: 77, Issue:4 Topics: Carmustine; Cobalt; Cobalt Radioisotopes; Etoposide; Humans; Melphalan; Neoplasms; Radioactivity	1957
Arc therapy with wedge-filtered beams of cobalt 60 radiation. The British journal of radiology, 1962, Volume: 35 Topics: Cobalt; Cobalt Radioisotopes; Etoposide; Humans; Neoplasms; Radioactivity	1962
Our experience with cobalt beam unit GUT-CO-400-2. Radiologia clinica, 1963, Volume: 32 Topics: Cobalt; Cobalt Isotopes; Etoposide; Melphalan; Neoplasms	1963
Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. International journal of cancer, 2004, Volume: 109, Issue:1 Topics: Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Body Weight; Camptothecin; Cell Line, Tumor; Cisplatin; Coloring Agents; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; Heme Oxygenase (Decyclizing); Humans; Hydrogen Peroxide; Male; Metalloporphyrins; Mice; Mitomycin; Neoplasms; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxygen; Polyethylene Glycols; Proline; Reactive Oxygen Species; Tetrazolium Salts; Thiazoles	2004
Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Molecular cancer therapeutics, 2004, Volume: 3, Issue:2 Topics: Animals; Antibodies; Cadherins; Cell Cycle; Cell Line, Tumor; Drug Resistance; Etoposide; Fluorouracil; Humans; Mice; Neoplasms; Paclitaxel; Protein Kinase C; Protein Kinase C beta; Spheroids, Cellular; Vinblastine	2004
Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Molecular and cellular biology, 2004, Volume: 24, Issue:7 Topics: Animals; Apoptosis; bcl-2-Associated X Protein; BH3 Interacting Domain Death Agonist Protein; Carrier Proteins; Cell Line, Tumor; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Neoplasms; Nuclear Proteins; Nucleic Acid Synthesis Inhibitors; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Transcription Factors; Transplantation, Heterologous	2004
A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors. Cancer, 2004, Jun-15, Volume: 100, Issue:12 Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type I; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphocytes; Male; Middle Aged; Neoplasms; Paclitaxel; Topotecan	2004
The DNA double-stranded break repair protein endo-exonuclease as a therapeutic target for cancer. Molecular cancer therapeutics, 2004, Volume: 3, Issue:8 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Coloring Agents; DNA; DNA Damage; DNA Repair; Down-Regulation; Drug Evaluation, Preclinical; Endonucleases; Etoposide; Exonucleases; Fluorouracil; HeLa Cells; Humans; Kinetics; Mice; Mitomycin; Neoplasms; Pentamidine; Plasmids; Recombination, Genetic; RNA, Small Interfering; Tetrazolium Salts; Thiazoles; Time Factors	2004
Downregulation of peroxiredoxin V stimulates formation of etoposide-induced double-strand DNA breaks. FEBS letters, 2004, Aug-13, Volume: 572, Issue:1-3 Topics: Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Nucleus; Clone Cells; Cloning, Molecular; DNA Damage; DNA Polymerase II; DNA Primers; Etoposide; Flow Cytometry; Gene Expression Regulation; HeLa Cells; Histones; Humans; Lung Neoplasms; Neoplasms; Peroxidases; Peroxiredoxins; Phospholipases A; Phosphorylation	2004
The role of telomeres in Etoposide induced tumor cell death. Cell cycle (Georgetown, Tex.), 2004, Volume: 3, Issue:9 Topics: Adaptation, Physiological; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; DNA; DNA Damage; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Genes, cdc; Humans; Neoplasms; Telomerase; Telomere; Topoisomerase II Inhibitors	2004
The technique and results of treatment of cancer of the tongue with a 10 gram radium beam unit. The American journal of roentgenology and radium therapy, 1950, Volume: 63, Issue:5 Topics: Etoposide; Humans; Melphalan; Neoplasms; Radium; Tongue; Tongue Neoplasms	1950
Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, Volume: 18, Issue:15 Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Cell Cycle Proteins; Cell Hypoxia; Cell Line, Tumor; Cell Respiration; Cyclin-Dependent Kinase Inhibitor p21; Etoposide; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Membrane Glycoproteins; Mitochondria; Neoplasms; Periodicity; Proto-Oncogene Proteins c-bcl-2; Radiation, Ionizing; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Tumor Necrosis Factor-alpha; Tumor Suppressor Protein p53	2004
Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible? Cancer chemotherapy and pharmacology, 2005, Volume: 55, Issue:3 Topics: Adolescent; Anal Canal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Etoposide; Fingers; Humans; Infant; Infant, Newborn; Neoplasms; Organophosphorus Compounds; Retrospective Studies; Skin Diseases; Toes	2005
Immune thrombocytopenia following successful treatment of cancer in children. Pediatric blood & cancer, 2006, Volume: 46, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Cells; Carmustine; Child, Preschool; Cyclophosphamide; Daunorubicin; Etoposide; Female; Humans; Infant; Male; Neoplasms; Platelet Count; Prednisone; Purpura, Thrombocytopenic, Idiopathic; Vincristine	2006
Optimizing drug regimens in cancer chemotherapy. Basic & clinical pharmacology & toxicology, 2005, Volume: 96, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Humans; Neoplasms	2005
Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells. Molecular cancer therapeutics, 2005, Volume: 4, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Bleomycin; Breast; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Genome; Humans; Neoplasms; Nuclear Proteins; Phosphoproteins; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Time Factors; Transfection	2005
High cumulative rate of secondary leukemia after continuous etoposide treatment for solid tumors in children and young adults. Pediatric blood & cancer, 2005, Volume: 45, Issue:1 Topics: Adolescent; Antineoplastic Agents, Phytogenic; Case-Control Studies; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; France; Humans; Incidence; Infant; Leukemia; Male; Neoplasms; Neoplasms, Second Primary; Palliative Care; Survival Rate	2005
Sensitization for anticancer drug-induced apoptosis by betulinic Acid. Neoplasia (New York, N.Y.), 2005, Volume: 7, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Betulinic Acid; Caspases; Cells, Cultured; Cisplatin; Complement Membrane Attack Complex; Complement System Proteins; Cytochromes c; Dactinomycin; Doxorubicin; Drug Synergism; Enzyme Activation; Etoposide; Fibroblasts; Glycoproteins; Humans; Membrane Potentials; Mitochondria; Mutation; Neoplasms; Paclitaxel; Pentacyclic Triterpenes; Proto-Oncogene Proteins c-bcl-2; Triterpenes; Tumor Stem Cell Assay; Tumor Suppressor Protein p53	2005
Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and gamma radiation. Molecular cancer therapeutics, 2005, Volume: 4, Issue:4 Topics: Animals; Antigens, Nuclear; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Line, Tumor; Cricetinae; Dimerization; DNA Damage; DNA Repair; DNA-Binding Proteins; Dose-Response Relationship, Radiation; Etoposide; Gamma Rays; HeLa Cells; Humans; Ku Autoantigen; Microscopy, Fluorescence; Neoplasms; Phenotype; RNA, Messenger; RNA, Small Interfering; Telomere; Time Factors; Topoisomerase II Inhibitors; Transfection; VDJ Recombinases	2005
NHS76/PEP2, a fully human vasopermeability-enhancing agent to increase the uptake and efficacy of cancer chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Apr-15, Volume: 11, Issue:8 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Paclitaxel; Peptide Fragments; Taxoids; Time Factors; Tissue Distribution; Treatment Outcome; Vinblastine; Xenograft Model Antitumor Assays	2005
Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation. Molecular cancer research : MCR, 2005, Volume: 3, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Blotting, Western; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Etoposide; HeLa Cells; Humans; Imatinib Mesylate; K562 Cells; Neoplasms; Paclitaxel; Phosphorus Radioisotopes; Phosphorylation; Piperazines; Precipitin Tests; Pyrimidines; RNA Helicases; RNA Interference; Stilbenes; Tumor Necrosis Factor-alpha	2005
Induction of apoptotic cell death specifically in rat and human cancer cells by pancratistatin. Artificial cells, blood substitutes, and immobilization biotechnology, 2005, Volume: 33, Issue:3 Topics: Amaryllidaceae Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Etoposide; Fibroblasts; Humans; Isoquinolines; Neoplasms; Paclitaxel; Rats	2005
A novel isoform of TUCAN is overexpressed in human cancer tissues and suppresses both caspase-8- and caspase-9-mediated apoptosis. Cancer research, 2005, Oct-01, Volume: 65, Issue:19 Topics: Adaptor Proteins, Signal Transducing; Adult; Amino Acid Sequence; Apoptosis; CARD Signaling Adaptor Proteins; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Etoposide; fas Receptor; Fas-Associated Death Domain Protein; Humans; Jurkat Cells; Molecular Sequence Data; Neoplasm Proteins; Neoplasms; Protein Isoforms; Protein Structure, Tertiary; RNA, Messenger; RNA, Small Interfering; Staurosporine; Transfection	2005
Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Molecular pharmacology, 2006, Volume: 69, Issue:2 Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Etoposide; Genetic Vectors; Green Fluorescent Proteins; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Isoquinolines; Neoplasms; Oxygen; Sequence Deletion; Topotecan; Transcriptional Activation	2006
Long-term survival following a phase I/II trial with VETOPEC for solid tumors in childhood. Journal of pediatric hematology/oncology, 2006, Volume: 28, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Etoposide; Follow-Up Studies; Humans; Infant; Medical Records; Neoplasms; Prognosis; Survival Rate; Time Factors; Vincristine	2006
Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Molecular cancer therapeutics, 2006, Volume: 5, Issue:2 Topics: Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Nucleus; Cisplatin; Cytosol; DNA; DNA-Activated Protein Kinase; ErbB Receptors; Etoposide; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; RNA, Small Interfering; Wortmannin	2006
Synthesis of variously substituted 3-phenoxymethyl quinoxalin-2-ones and quinoxalines capable to potentiate in vitro the antiproliferative activity of anticancer drugs in multi-drug resistant cell lines. Medicinal chemistry (Shariqah (United Arab Emirates)), 2006, Volume: 2, Issue:2 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Cell Proliferation; Doxorubicin; Drug Resistance, Multiple; Drug Synergism; Etoposide; Humans; KB Cells; Neoplasms; Quinoxalines; Tumor Cells, Cultured; Vincristine	2006
Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression. Molecular cancer therapeutics, 2006, Volume: 5, Issue:6 Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; cdc25 Phosphatases; Cell Cycle Proteins; Cell Division; Cell Survival; DNA Damage; Etoposide; Flow Cytometry; Fluorescent Antibody Technique, Indirect; G2 Phase; Humans; Neoplasms; Tetracycline; Tumor Cells, Cultured; Tumor Stem Cell Assay	2006
Information sources used by New South Wales cancer clinicians: a qualitative study. Internal medicine journal, 2006, Volume: 36, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Drug Information Services; Etoposide; Female; Health Personnel; Hodgkin Disease; Hospitals, Public; Humans; Internet; Interviews as Topic; Male; Medical Oncology; Middle Aged; Neoplasms; New South Wales; Online Systems; Prednisone; Procarbazine; Vincristine	2006
Chemotherapy-related secondary leukemias: A role for DNA repair by error-prone non-homologous end joining in topoisomerase II - Induced chromosomal rearrangements. Gene, 2007, Apr-15, Volume: 391, Issue:1-2 Topics: Antineoplastic Agents, Phytogenic; Chromatin Immunoprecipitation; Chromosome Aberrations; Chromosome Breakage; Core Binding Factor Alpha 2 Subunit; DNA Breaks, Double-Stranded; DNA Repair; DNA Topoisomerases, Type II; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Jurkat Cells; Leukemia; Neoplasms; Protein Binding; Rad52 DNA Repair and Recombination Protein; Recombination, Genetic; Topoisomerase II Inhibitors	2007
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity. Cancer immunology, immunotherapy : CII, 2007, Volume: 56, Issue:8 Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid	2007
Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene, 2007, Jul-19, Volume: 26, Issue:33 Topics: Activating Transcription Factor 4; Antineoplastic Agents; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Cell Survival; Chromatin Immunoprecipitation; Cisplatin; CLOCK Proteins; Drug Resistance, Neoplasm; Etoposide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Neoplasms; Oxidation-Reduction; RNA Interference; Trans-Activators; Transcription, Genetic	2007
The role of cordycepin in cancer treatment via induction or inhibition of apoptosis: implication of polyadenylation in a cell type specific manner. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Caspase 6; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxyadenosines; DNA Fragmentation; Etoposide; Flow Cytometry; Fluorescent Dyes; Humans; Image Processing, Computer-Assisted; Indoles; Leukemia; Membrane Potentials; Mitochondrial Membranes; Neoplasms; Poly A	2008
Restoration of p53 expression in human cancer cell lines upregulates the expression of Notch1: implications for cancer cell fate determination after genotoxic stress. Neoplasia (New York, N.Y.), 2007, Volume: 9, Issue:5 Topics: Apoptosis; Cell Line, Tumor; DNA Damage; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasms; Receptor, Notch1; RNA, Messenger; Tumor Suppressor Protein p53; Up-Regulation	2007
Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain. Molecular cancer therapeutics, 2007, Volume: 6, Issue:9 Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Genes, MDR; HeLa Cells; Humans; Hydrolysis; JNK Mitogen-Activated Protein Kinases; Neoplasms; Phosphorylation; RNA Interference; Surface Plasmon Resonance; Topoisomerase II Inhibitors; Tumor Stem Cell Assay; Xanthones	2007
Differential effects of hypoxia on etoposide-induced apoptosis according to the cancer cell lines. Molecular cancer, 2007, Sep-26, Volume: 6 Topics: Apoptosis; Cell Hypoxia; Cell Line, Tumor; DNA; DNA Damage; Etoposide; Gene Expression Profiling; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1; Neoplasms; Oligonucleotide Array Sequence Analysis; Tumor Suppressor Protein p53	2007
Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy, 2008, Volume: 4, Issue:2 Topics: Apoptosis; Autophagy; Caspases; Cell Hypoxia; Cells, Cultured; Etoposide; Humans; Membrane Proteins; Neoplasms; Proto-Oncogene Proteins; RNA Interference; Time Factors	2008
Hemophagocytic lymphohistiocytosis as severe adverse event of antineoplastic treatment in children. Haematologica, 2008, Volume: 93, Issue:2 Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Daclizumab; Dexamethasone; Etoposide; Female; Humans; Immunoglobulin G; Infant; Infliximab; Lymphohistiocytosis, Hemophagocytic; Male; Neoplasms; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous	2008
Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. Journal of the American Academy of Dermatology, 2008, Volume: 58, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Erythema; Etoposide; Humans; Infant; Neoplasms; Pigmentation Disorders; Retrospective Studies; Skin; Skin Diseases; Stem Cell Transplantation; Thiotepa	2008
Wilms' tumor gene WT1-shRNA as a potent apoptosis-inducing agent for solid tumors. International journal of oncology, 2008, Volume: 32, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Doxorubicin; Drug Synergism; Etoposide; Exons; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Genes, Wilms Tumor; Genetic Therapy; HeLa Cells; Humans; Neoplasms; Protein Isoforms; RNA, Small Interfering; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Cells, Cultured; WT1 Proteins	2008
Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2008, Volume: 14, Issue:1 Topics: Adolescent; Adult; Aged; Anti-Allergic Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Chlorpheniramine; Drug Hypersensitivity; Etoposide; Female; Humans; Hydrocortisone; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Organophosphorus Compounds	2008
Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis, 2008, Volume: 11, Issue:3 Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Humans; Hydroxamic Acids; Mice; Mice, Nude; Neoplasms; Thyroid Hormones; Thyroxine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2008
Cathepsin D overexpressed by cancer cells can enhance apoptosis-dependent chemo-sensitivity independently of its catalytic activity. Advances in experimental medicine and biology, 2008, Volume: 617 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 9; Catalysis; Cathepsin D; Cytochromes c; Cytosol; Drug Resistance, Neoplasm; Etoposide; Humans; Neoplasms; Pepstatins; Protease Inhibitors; Tumor Cells, Cultured	2008
Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study. European journal of cancer & clinical oncology, 1984, Volume: 20, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Transplantation, Autologous	1984
Etoposide: a new anti-cancer agent. Lancet (London, England), 1981, Oct-24, Volume: 2, Issue:8252 Topics: Animals; Drug Evaluation; Etoposide; Female; Humans; Kinetics; Lung Neoplasms; Male; Mitosis; Neoplasms; Podophyllotoxin; Testicular Neoplasms	1981
A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer research, 1983, Volume: 43, Issue:2 Topics: Antineoplastic Agents; Cell Line; Cell Survival; Doxorubicin; Drug Evaluation, Preclinical; Eosine Yellowish-(YS); Etoposide; Fluorouracil; Hematoxylin; Humans; Leukemia, Myeloid, Acute; Mechlorethamine; Melphalan; Neoplasms; Staining and Labeling	1983
Drug testing using a soft agar stem cell assay on patient and xenograft tumor material. International journal of radiation oncology, biology, physics, 1984, Volume: 10, Issue:9 Topics: Animals; Antineoplastic Agents; Bleomycin; Cisplatin; Colony-Forming Units Assay; Drug Synergism; Etoposide; Female; Granulosa Cell Tumor; Humans; Melphalan; Methotrexate; Mice; Misonidazole; Neoplasm Transplantation; Neoplasms; Ovarian Neoplasms; Transplantation, Heterologous; Tumor Stem Cell Assay; Vinblastine	1984
Etoposide single-agent chemotherapy for solid tumors. Cancer treatment reviews, 1982, Volume: 9 Suppl Topics: Carcinoma, Hepatocellular; Etoposide; Female; Head and Neck Neoplasms; Humans; Liver Neoplasms; Neoplasms; Ovarian Neoplasms; Podophyllotoxin; Sarcoma; Soft Tissue Neoplasms	1982
High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1983, Volume: 1, Issue:11 Topics: Adolescent; Adult; Aged; Blood Cell Count; Bone Marrow; Bone Marrow Transplantation; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Evaluation; Drug Resistance; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Podophyllotoxin	1983
Perspectives for the use of high-dose chemotherapy in the treatment of solid malignant tumors. European journal of cancer & clinical oncology, 1984, Volume: 20, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Drug Evaluation; Etoposide; Humans; Melphalan; Neoplasms; Whole-Body Irradiation	1984
[Current clinical status of new anticancer drugs]. Gan no rinsho. Japan journal of cancer clinics, 1983, Volume: 29, Issue:10 Topics: Altretamine; Anthraquinones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Etoposide; Humans; Mitoxantrone; Neoplasms	1983
Data recycling and misreading: two potential errors in pooled data from small studies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:9 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Communication; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Neoplasms; Ovarian Neoplasms; Research Design; Statistics as Topic; Uterine Neoplasms	1984
Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. Journal of neuro-oncology, 1984, Volume: 2, Issue:2 Topics: Brain Neoplasms; Etoposide; Glioma; Half-Life; Humans; Kinetics; Necrosis; Neoplasms; Podophyllotoxin	1984
High-dose etoposide for refractory malignancies: a phase I study. Cancer treatment reports, 1984, Volume: 68, Issue:12 Topics: Adult; Aged; Bone Marrow; Diarrhea; Drug Evaluation; Erythema; Etoposide; Female; Humans; Male; Middle Aged; Mouth Diseases; Neoplasm Metastasis; Neoplasms; Paresthesia; Podophyllotoxin; Reflex	1984
Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. Cancer research, 1984, Volume: 44, Issue:7 Topics: Adolescent; Adult; Child; Child, Preschool; Cisplatin; Etoposide; Female; Humans; Kinetics; Leukemia; Male; Metabolic Clearance Rate; Neoplasms; Podophyllotoxin	1984
Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer research, 1984, Volume: 44, Issue:1 Topics: Etoposide; Half-Life; Humans; Kinetics; Neoplasms; Podophyllotoxin	1984
New anticancer drug class. JAMA, 1983, Mar-25, Volume: 249, Issue:12 Topics: Child; Etoposide; Humans; Legislation, Drug; Neoplasms; Podophyllotoxin; Teniposide; United States	1983
Pilot studies of various combinations of dibromodulcitol, VP-16, and AMSA. Oncology, 1982, Volume: 39, Issue:5 Topics: Aged; Aminoacridines; Amsacrine; Drug Evaluation; Drug Therapy, Combination; Etoposide; Female; Humans; Male; Middle Aged; Mitolactol; Neoplasms; Pilot Projects; Podophyllotoxin	1982
[Prospects of new chemotherapies]. Revue medicale de Bruxelles, 1982, Volume: 3, Issue:8 Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Cisplatin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Female; Humans; Male; Neoplasms; Podophyllotoxin; Vinblastine; Vindesine	1982
High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors. Cancer, 1980, Jun-15, Volume: 45, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Leukocyte Count; Male; Middle Aged; Neoplasms; Pilot Projects; Platelet Count; Time Factors; Transplantation, Autologous; Vincristine	1980
Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors. Cancer chemotherapy and pharmacology, 1982, Volume: 7, Issue:2-3 Topics: Antineoplastic Agents; Cells, Cultured; Etoposide; Humans; Neoplasms; Neoplasms, Experimental; Podophyllotoxin; Teniposide	1982
Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer. Cancer chemotherapy and pharmacology, 1982, Volume: 7, Issue:2-3 Topics: Biotransformation; Child; Chromatography, High Pressure Liquid; Etoposide; Humans; Kinetics; Leukemia; Models, Biological; Neoplasms; Podophyllotoxin; Teniposide	1982
A phase I trial of continuous infusion VP16-213 (etoposide). Cancer chemotherapy and pharmacology, 1982, Volume: 7, Issue:2-3 Topics: Adult; Aged; Drug Evaluation; Etoposide; Female; Heart Diseases; Hematologic Diseases; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplasms; Podophyllotoxin	1982
Proceedings of the German Cancer Society (Clinical Oncology Section) and Bristol-Myers GmbH Symposium on Etoposide (VP-16). Current status and new developments. Frankfurt, 21-22 May 1981. Cancer treatment reviews, 1982, Volume: 9 Suppl Topics: Etoposide; Humans; Neoplasms; Podophyllotoxin	1982
[Etoposide: VP-16]. Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg, 1982, Volume: 119, Issue:2 Topics: Etoposide; Humans; Lung Neoplasms; Lymphoma; Neoplasms; Podophyllotoxin	1982
Preliminary study of the combination, dianhydrogalactitol, cis-diaminedichloroplatinum (II), and VP-16-213 in patients with advanced cancer. Oncology, 1981, Volume: 38, Issue:5 Topics: Brain Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Dianhydrogalactitol; Drug Evaluation; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Pilot Projects; Podophyllotoxin; Sugar Alcohols	1981
VP-16-213. A phase II trial using a weekly schedule. Cancer clinical trials, 1981,Winter, Volume: 4, Issue:4 Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Etoposide; Humans; Neoplasms; Podophyllotoxin	1981
[Relations between hematological toxicity and total and free plasma levels of etoposide in daily oral administration]. Bulletin du cancer, 1995, Volume: 82, Issue:8 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biological Availability; Drug Administration Schedule; Etoposide; Female; Humans; Leukocyte Count; Male; Middle Aged; Neoplasms; Neutropenia; Neutrophils	1995
Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group. Cancer, 1994, Apr-01, Volume: 73, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Leukocyte Count; Male; Middle Aged; Neoplasms; Pilot Projects; Remission Induction; Survival Rate	1994
Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin- subpopulation from mobilized peripheral blood. Blood, 1995, Jan-15, Volume: 85, Issue:2 Topics: Animals; Antigens, CD; Antigens, CD34; Blood Cell Count; Bone Marrow; Chimera; Cyclophosphamide; Etoposide; Flow Cytometry; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Mice; Mice, SCID; Neoplasms; Thy-1 Antigens; Time Factors; Transplantation, Heterologous	1995
New method for stem cell quantification: applications to the management of peripheral blood stem cell transplantation. Bone marrow transplantation, 1995, Volume: 15, Issue:1 Topics: Adult; Blood Cell Count; Cell Division; Cyclophosphamide; DNA; Etoposide; Female; Filgrastim; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasms; Recombinant Proteins; Retrospective Studies; Stem Cells	1995
Analysis of human hematopoietic stem cell populations. Blood cells, 1994, Volume: 20, Issue:2-3 Topics: Animals; Antigens, CD; Antigens, CD34; Biomarkers; Bone Marrow; Bone Marrow Cells; Bone Transplantation; Chimera; Cyclophosphamide; Etoposide; Fetal Tissue Transplantation; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Immunophenotyping; Mice; Mice, SCID; Neoplasms; Thy-1 Antigens; Thymus Gland; Transplantation, Heterologous	1994
Harvesting, characterization, and culture of CD34+ cells from human bone marrow, peripheral blood, and cord blood. Blood cells, 1994, Volume: 20, Issue:2-3 Topics: Adult; Antibodies, Monoclonal; Antigens, CD; Antigens, CD34; Blood Cells; Bone Marrow Cells; Cell Differentiation; Cell Separation; Cells, Cultured; Colony-Forming Units Assay; Culture Techniques; Cyclophosphamide; Etoposide; Fetal Blood; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cells; Humans; Immunomagnetic Separation; Infant, Newborn; Neoplasms	1994
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation. Blood, 1995, Jun-01, Volume: 85, Issue:11 Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Marrow; Bone Marrow Cells; Carboplatin; Carmustine; Cell Adhesion Molecules; Cell Movement; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Fluorouracil; Gene Expression; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; L-Selectin; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Neutrophils; Platelet Count; Podophyllotoxin; Receptors, Very Late Antigen; Thiotepa	1995
Etoposide protein binding in cancer patients. Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:6 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Protein Binding; Regression Analysis	1995
Adenovirus E1a-mediated tumor suppression by a c-erbB-2/neu-independent mechanism. Cancer research, 1995, Dec-01, Volume: 55, Issue:23 Topics: Adenovirus E1A Proteins; Animals; Apoptosis; Cisplatin; Etoposide; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Genes, Tumor Suppressor; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Receptor, ErbB-2; Tumor Cells, Cultured	1995
Bone marrow transplantation through standard central venous catheters. Transplantation proceedings, 1995, Volume: 27, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Catheterization, Central Venous; Catheters, Indwelling; Cyclophosphamide; Etoposide; Humans; Neoplasms; Transplantation, Autologous; Transplantation, Homologous; Transplantation, Isogeneic; Whole-Body Irradiation	1995
[Influence of cytotoxic chemotherapy on superoxide production by neutrophils in cancer patients]. Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1993, Volume: 67, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Luminescent Measurements; Male; Neoplasms; Neutrophils; Superoxides	1993
[Chemotherapy for older cancer patients]. Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:7 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Etoposide; Female; Floxuridine; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasms; Neoplasms, Multiple Primary; Palliative Care; Quality of Life	1993
Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin. British journal of haematology, 1993, Volume: 84, Issue:3 Topics: Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Blood Transfusion, Autologous; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Ifosfamide; Leukapheresis; Leukocyte Count; Male; Middle Aged; Neoplasms; Neutrophils; Platelet Count	1993
Inhibition of CFU-C growth by VP-16 containing plasma samples obtained from patients after conditioning therapy for bone marrow transplantation. Bone marrow transplantation, 1995, Volume: 15, Issue:1 Topics: Adolescent; Adult; Bone Marrow Transplantation; Child; Etoposide; Hematopoietic Stem Cells; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Tumor Cells, Cultured; Tumor Stem Cell Assay	1995
ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood, 1995, Jun-01, Volume: 85, Issue:11 Topics: Acute Disease; Adolescent; Bone Marrow Transplantation; Child; Child, Preschool; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 11; Combined Modality Therapy; Dactinomycin; DNA-Binding Proteins; Etoposide; Female; Genes; Histone-Lysine N-Methyltransferase; Humans; Infant; Leukemia; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Myelodysplastic Syndromes; Myeloid-Lymphoid Leukemia Protein; Neoplasm Proteins; Neoplasms; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogenes; Radiotherapy; Teniposide; Topoisomerase II Inhibitors; Transcription Factors; Translocation, Genetic; Whole-Body Irradiation	1995
Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation. Blood, 1995, Jun-01, Volume: 85, Issue:11 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Busulfan; Carmustine; Cell Count; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasms; Prognosis; Radiation Injuries; Treatment Outcome; Vincristine; Whole-Body Irradiation	1995
Collection and transplantation of peripheral blood stem cells in very small children weighting 20 kg or less. Blood, 1995, Jul-01, Volume: 86, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Blood Preservation; Body Weight; Bone Marrow Diseases; Carboplatin; Catheterization, Central Venous; Catheters, Indwelling; Child, Preschool; Cisplatin; Colony-Forming Units Assay; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Male; Neoplasms; Platelet Transfusion; Retrospective Studies; Safety	1995
Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair. British journal of cancer, 1995, Volume: 71, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Specimen Collection; Carboplatin; Cisplatin; DNA Adducts; DNA Repair; DNA, Neoplasm; Etoposide; Humans; Kinetics; Leukocytes; Neoplasms; Platinum	1995
Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:9 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Male; Mouth Mucosa; Neoplasms; Stomatitis; Thiotepa; Whole-Body Irradiation	1994
Busulfan-containing pre-transplant regimens for the treatment of solid tumors. Bone marrow transplantation, 1994, Volume: 14, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Busulfan; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasms; Ovarian Neoplasms; Pilot Projects; Retrospective Studies; Sarcoma	1994
Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:7 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Chromatography, High Pressure Liquid; Drug Interactions; Etoposide; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Phenytoin; Therapeutic Equivalency	1994
Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. British journal of cancer, 1993, Volume: 68, Issue:5 Topics: Alkaloids; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Carrier Proteins; Daunorubicin; Doxorubicin; Drug Resistance; Etoposide; Genistein; Humans; Hydrogen-Ion Concentration; Isoflavones; Lung Neoplasms; Membrane Glycoproteins; Neoplasms; Protein-Tyrosine Kinases; Staurosporine; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured	1993
Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series. Leukemia, 1993, Volume: 7, Issue:12 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Cisplatin; Cohort Studies; Denmark; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Female; Germinoma; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms; Neoplasms, Second Primary; Regression Analysis; Risk	1993
Enhanced expression of the DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells. Cancer research, 1993, Mar-01, Volume: 53, Issue:5 Topics: Camptothecin; DNA Topoisomerases, Type II; Etoposide; Gene Expression; Hot Temperature; Humans; Irinotecan; KB Cells; Neoplasms; RNA, Messenger; Teniposide	1993
High-dose chemotherapy with etoposide, cyclophosphamide and escalating dose of carboplatin followed by autologous bone marrow transplantation in cancer patients. A pilot study. European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:10 Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Prognosis; Prospective Studies; Salvage Therapy; Thrombocytopenia	1993
Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation. Cancer research, 1993, Oct-15, Volume: 53, Issue:20 Topics: Adolescent; Brain Neoplasms; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Male; Metabolic Clearance Rate; Neoplasms; Neuroblastoma; Pineal Gland; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sarcoma; Soft Tissue Neoplasms; Teratoma	1993
Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision. Journal of the National Cancer Institute, 1993, Feb-03, Volume: 85, Issue:3 Topics: Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Etoposide; Humans; Models, Statistical; Neoplasms	1993
Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. Cancer chemotherapy and pharmacology, 1993, Volume: 31, Issue:5 Topics: Adult; Aged; Etoposide; Female; Half-Life; Humans; Male; Middle Aged; Neoplasms	1993
Limited sampling models for reliable estimation of etoposide area under the curve. European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:11 Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Chemical; Neoplasms	1995
Investigation of the comparative effects of 2-chlorodeoxyadenosine on tumor colony forming units in vitro. Investigational new drugs, 1995, Volume: 13, Issue:2 Topics: Antineoplastic Agents; Cell Division; Cisplatin; Cladribine; Dose-Response Relationship, Drug; Doxorubicin; Drugs, Investigational; Etoposide; Fluorouracil; Humans; Mitomycin; Neoplasms; Neoplastic Stem Cells; Tumor Stem Cell Assay; Vinblastine	1995
Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Cancer, 1995, Nov-01, Volume: 76, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Etoposide; Humans; Ifosfamide; Neoplasms; Remission Induction	1995
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6 Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Etoposide; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Pilot Projects; Remission Induction; Sarcoma; Thrombocytopenia	1996
Overexpression of multidrug resistance protein gene in human cancer cell lines selected for drug resistance to epipodophyllotoxins. Japanese journal of cancer research : Gann, 1996, Volume: 87, Issue:7 Topics: Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Drug Resistance, Multiple; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Multidrug Resistance-Associated Proteins; Neoplasms; Teniposide; Tumor Cells, Cultured	1996
Chemotherapy enhancer passes first test. Oncology (Williston Park, N.Y.), 1995, Volume: 9, Issue:11 Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clinical Trials, Phase I as Topic; Cyclosporins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Male; Neoplasms; Paclitaxel	1995
Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival. Cancer research, 1996, Sep-01, Volume: 56, Issue:17 Topics: Apoptosis; Cell Death; Cell Survival; Epithelium; Etoposide; HeLa Cells; Humans; Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Transfection	1996
Absence of correlation between chemo- and radioresistance in a range of human tumour cell lines. Cytotechnology, 1996, Volume: 19, Issue:3 Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma; Carcinoma, Squamous Cell; Cell Division; Cisplatin; Clone Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; HeLa Cells; Humans; Laryngeal Neoplasms; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Radiation Tolerance; Selection, Genetic; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Vincristine	1996
Improved priming for mobilization of and optimal timing for harvest of peripheral blood stem cells. Journal of hematotherapy, 1996, Volume: 5, Issue:4 Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Blood Transfusion, Autologous; Bone Marrow; Carmustine; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Synergism; Epirubicin; Etoposide; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Injections, Subcutaneous; Leukapheresis; Leukocyte Count; Male; Melphalan; Middle Aged; Neoplasms; Recombinant Proteins	1996
Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC). Bone marrow transplantation, 1996, Volume: 18, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; Carboplatin; Cyclophosphamide; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasms; Patient Acceptance of Health Care; Remission Induction; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome	1996
Plasma concentrations of polysorbate 80 measured in patients following administration of docetaxel or etoposide. Cancer chemotherapy and pharmacology, 1997, Volume: 39, Issue:6 Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polysorbates; Surface-Active Agents; Taxoids	1997
Circulating immature cell counts on the harvest day predict the yields of CD34+ cells collected after granulocyte colony-stimulating factor plus chemotherapy-induced mobilization of peripheral blood stem cell. Blood, 1997, Jun-15, Volume: 89, Issue:12 Topics: Adolescent; Adult; Aged; Antigens, CD34; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Cytarabine; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukocyte Count; Male; Middle Aged; Neoplasms	1997
Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation. The American journal of the medical sciences, 1997, Volume: 314, Issue:5 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bicarbonates; Carboplatin; Creatinine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Kidney; Magnesium; Male; Middle Aged; Neoplasms; Potassium; Retrospective Studies	1997
Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone marrow transplantation, 1997, Volume: 20, Issue:10 Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Infant; Life Tables; Male; Multiple Organ Failure; Neoplasms; Severity of Illness Index; Survival Analysis; Thrombophilia; Transplantation Conditioning; Treatment Outcome	1997
[Expression of DNA topoisomerases (I, II alpha, II beta) mRNA in etoposide- and mAMSA-resistant cell lines]. Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:15 Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Northern; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Humans; Isoenzymes; Neoplasms; RNA, Messenger; Tumor Cells, Cultured	1997
Population pharmacokinetics of total and unbound etoposide. Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biological Availability; Blood Proteins; Chemistry, Pharmaceutical; Etoposide; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Protein Binding; Retrospective Studies	1998
A risk-benefit assessment of irinotecan in solid tumours. Drug safety, 1998, Volume: 18, Issue:6 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Colorectal Neoplasms; Diarrhea; Drug Therapy, Combination; Etoposide; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Risk Assessment	1998
[Incidence of mutation and deletion in topoisomerase II mRNA of etoposide and m-AMSA resistant cell lines]. Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:8 Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Gene Deletion; Humans; Mutation; Neoplasms; RNA, Messenger; Tumor Cells, Cultured	1998
Paclitaxel, cisplatin and etoposide combination chemotherapy: a comparison of dose intensity in two multifractionated dose schemas. European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Paclitaxel	1998
IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer research, 1998, Dec-01, Volume: 58, Issue:23 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Base Sequence; bcl-2-Associated X Protein; Caspase Inhibitors; Caspases; Cytochrome c Group; Drug Screening Assays, Antitumor; Etoposide; fas Receptor; Humans; Inhibitor of Apoptosis Proteins; Isoenzymes; Microtubule-Associated Proteins; Molecular Sequence Data; Neoplasm Proteins; Neoplasms; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Survivin; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein	1998
Anti-apoptotic oncogenes prevent caspase-dependent and independent commitment for cell death. Cell death and differentiation, 1998, Volume: 5, Issue:4 Topics: Amino Acid Chloromethyl Ketones; Antibodies, Monoclonal; Apoptosis; Caspase Inhibitors; Caspases; Cysteine Proteinase Inhibitors; Dactinomycin; Enzyme Activation; Etoposide; fas Receptor; HL-60 Cells; Humans; Jurkat Cells; Neoplasms; Oncogenes; Staurosporine	1998
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units. Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:4 Topics: Alkyl and Aryl Transferases; Cell Survival; Cisplatin; Clone Cells; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Humans; Neoplasms; Neoplastic Stem Cells; Paclitaxel; Piperidines; Pyridines; Sensitivity and Specificity; Tumor Cells, Cultured; Tumor Stem Cell Assay	1999
A novel podophyllotoxin-derived compound GL331 is more potent than its congener VP-16 in killing refractory cancer cells. Pharmaceutical research, 1999, Volume: 16, Issue:7 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Death; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Etoposide; Humans; Neoplasms; Podophyllotoxin; Tumor Cells, Cultured	1999
Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens. Haematologica, 1999, Volume: 84, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cyclophosphamide; Drug Synergism; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Ifosfamide; Immunophenotyping; Leukapheresis; Leukocyte Count; Male; Neoplasms	1999
Oral cancer chemotherapy: the promise and the pitfalls. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:10 Topics: Administration, Oral; Antineoplastic Agents; Etoposide; Humans; Neoplasms; Patient Compliance	1999
Testicular cancer seen as "stalking horse" for other cancers. Journal of the National Cancer Institute, 1999, Nov-03, Volume: 91, Issue:21 Topics: alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Chorionic Gonadotropin; Chromosomes, Human, Pair 12; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Drug Resistance, Neoplasm; Etoposide; Evidence-Based Medicine; Humans; L-Lactate Dehydrogenase; Male; Neoplasms; Testicular Neoplasms	1999
Highly sensitive liquid chromatography-electrospray mass spectrometry (LC-MS) method for the determination of etoposide levels in human serum and plasma. Journal of chromatography. B, Biomedical sciences and applications, 2000, Jul-07, Volume: 744, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Calibration; Chromatography, Liquid; Etoposide; Humans; Mass Spectrometry; Neoplasms; Quality Control; Sensitivity and Specificity	2000
Cyclophosphamide and etoposide for pediatric solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Nov-01, Volume: 18, Issue:21 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials, Phase II as Topic; Cyclophosphamide; Etoposide; Humans; Neoplasms; Research Design	2000
Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. Methods in cell biology, 2001, Volume: 64 Topics: Antineoplastic Agents; Benzimidazoles; Cell Communication; Cell Separation; Cell Size; Chromatin; DNA, Neoplasm; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Fluorescent Dyes; Gene Expression Regulation, Neoplastic; Neoplasms; Spheroids, Cellular; Tumor Cells, Cultured	2001
Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proceedings of the National Academy of Sciences of the United States of America, 2001, Mar-13, Volume: 98, Issue:6 Topics: Animals; Antineoplastic Agents; Cell Line, Transformed; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Doxorubicin; Etoposide; Fluorouracil; Mice; Neoplasms; Proto-Oncogene Proteins c-myc; ras Proteins; RNA; Telomerase; Telomere; Tumor Suppressor Protein p53	2001
Simulation tool for schedule-dependent etoposide exposure based on pharmacokinetic findings published in the literature. Anti-cancer drugs, 2001, Volume: 12, Issue:2 Topics: Adolescent; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Child; Child, Preschool; Computer Simulation; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Infant; Infusions, Intravenous; Neoplasms; Predictive Value of Tests; Regression Analysis; Time Factors	2001
Quality of life in cancer patients treated by chemotherapy. Neoplasma, 2000, Volume: 47, Issue:6 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Colorectal Neoplasms; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Neoplasms; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires	2000
Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation. Oncogene, 2001, Mar-08, Volume: 20, Issue:10 Topics: Antineoplastic Agents; Apoptosis; Caspases; Enzyme Activation; Etoposide; fas Receptor; HeLa Cells; Humans; Immunoblotting; Jurkat Cells; Mitochondria; Mitomycin; Neoplasms; Signal Transduction; Staurosporine; Transfection; Tumor Cells, Cultured	2001
PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. The Journal of biological chemistry, 2002, Feb-15, Volume: 277, Issue:7 Topics: Blotting, Western; Cell Cycle; Cell Line; Cell Nucleus; Cloning, Molecular; Coloring Agents; Cytoplasm; DNA Damage; Dose-Response Relationship, Drug; Down-Regulation; Etoposide; Genes, Reporter; Glioblastoma; Humans; Microscopy, Confocal; Mutation; Neoplasms; Nuclear Proteins; Phosphoric Monoester Hydrolases; Precipitin Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; PTEN Phosphohydrolase; Retroviridae; Signal Transduction; Tetrazolium Salts; Thiazoles; Transcription, Genetic; Transduction, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2002
The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nature cell biology, 2001, Volume: 3, Issue:12 Topics: Animals; Apoptosis; Cells, Cultured; Dermis; DNA-Binding Proteins; Early Growth Response Protein 1; Etoposide; Fibroblasts; Gamma Rays; Gene Expression Regulation, Neoplastic; Humans; Immediate-Early Proteins; Mammary Glands, Animal; Mice; Mice, Knockout; Neoplasms; Nucleic Acid Synthesis Inhibitors; Phosphoric Monoester Hydrolases; Promoter Regions, Genetic; PTEN Phosphohydrolase; RNA, Messenger; Signal Transduction; Transcription Factors; Tumor Suppressor Proteins; Ultraviolet Rays	2001
[Globalization of anti-cancer therapies]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms	2002
The effect of heat shock, cisplatin, etoposide and quercetin on Hsp27 expression in human normal and tumour cells. Folia histochemica et cytobiologica, 2002, Volume: 40, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Culture Techniques; Cell Transformation, Neoplastic; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Eukaryotic Cells; Fibroblasts; Heat-Shock Proteins; HeLa Cells; Hot Temperature; HSP27 Heat-Shock Proteins; Humans; Models, Biological; Molecular Chaperones; Neoplasm Proteins; Neoplasms; Quercetin; Stress, Physiological	2002
Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens. Anti-cancer drugs, 2002, Volume: 13, Issue:1 Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Bone Marrow Transplantation; Child; Child, Preschool; Etoposide; Female; Half-Life; Humans; Infant; Male; Neoplasms; Protein Binding; Transplantation Conditioning	2002
Autologous peripheral blood progenitor cell transplantation with <2 x 10(6) CD34(+)/kg: an analysis of variables concerning mobilisation and engraftment. The hematology journal : the official journal of the European Haematology Association, 2000, Volume: 1, Issue:6 Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Caspase 14; Caspases; Cerebral Hemorrhage; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Erythropoietin; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Infections; Leukapheresis; Life Tables; Male; Middle Aged; Neoplasms; Proportional Hazards Models; Transplantation Conditioning; Transplantation, Autologous	2000
Overview of early and investigational chemotherapeutic agents in solid tumors. Medical and pediatric oncology, 1976, Volume: 2, Issue:4 Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Aziridines; Azo Compounds; Camptothecin; Cycloleucine; Etoposide; Floxuridine; Humans; Neoplasms; Nitrogen Mustard Compounds; Picolinic Acids; Platinum; Porfiromycin; Streptonigrin; Teniposide; Thiotepa; Tubercidin	1976
[Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors]. Schweizerische medizinische Wochenschrift, 1975, Oct-18, Volume: 105, Issue:42 Topics: Adenocarcinoma; Bronchial Neoplasms; Carcinoma; Carcinoma, Small Cell; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Podophyllotoxin; Prostatic Neoplasms; Remission, Spontaneous	1975
Total-body hyperthermia with and without chemotherapy for advanced human neoplasms. Cancer research, 1979, Volume: 39, Issue:5 Topics: Adult; Antineoplastic Agents; Bone Marrow; Burns; Creatine Kinase; Electroencephalography; Etoposide; Female; Humans; Hyperthermia, Induced; L-Lactate Dehydrogenase; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Neoplasms; Peripheral Nervous System Diseases; Remission, Spontaneous; Tachycardia	1979
Lack of severe hypotension with VP-16-213 administered directly lv. Cancer treatment reports, 1977, Volume: 61, Issue:7 Topics: Adult; Aged; Blood Pressure; Etoposide; Humans; Infusions, Parenteral; Middle Aged; Neoplasms; Podophyllotoxin	1977
Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives. European journal of cancer, 1975, Volume: 11, Issue:10 Topics: Body Water; Etoposide; Humans; Metabolic Clearance Rate; Models, Biological; Neoplasms; Podophyllotoxin; Teniposide	1975
Use of GM-CSF in children after high-dose chemotherapy. Medical and pediatric oncology. Supplement, 1992, Volume: 2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Child; Child, Preschool; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infant; Leukocyte Count; Male; Neoplasms; Neutropenia; Platelet Transfusion; Recombinant Proteins; Remission Induction	1992
Clinical experiences with platinum and etoposide therapy in lung cancer. Oncology, 1992, Volume: 49 Suppl 1 Topics: Etoposide; Humans; Neoplasms; Platinum	1992
Novel Approaches to the Use of Etoposide. Proceedings of a workshop. December 5-7, 1991. Seminars in oncology, 1992, Volume: 19, Issue:6 Suppl 14 Topics: Etoposide; Humans; Neoplasms	1992
Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood, 1992, Mar-01, Volume: 79, Issue:5 Topics: Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Cisplatin; Erythrocytes; Erythroid Precursor Cells; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cells; Humans; Ifosfamide; Immunophenotyping; Interleukin-3; Male; Megakaryocytes; Middle Aged; Monocytes; Neoplasms	1992
Bone marrow purging in patients with refractory cancer. Progress in clinical and biological research, 1992, Volume: 377 Topics: Adolescent; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Breast Neoplasms; Child; Child, Preschool; Colony-Forming Units Assay; Etoposide; Female; Hematopoietic Stem Cells; Humans; In Vitro Techniques; Leukemia; Lymphoma; Male; Methylprednisolone; Middle Aged; Neoplasms; Transplantation, Autologous	1992
What is the optimal dose and duration of treatment with etoposide? I. Maximum tolerated duration of daily treatment with 50, 75, and 100 mg of oral etoposide. Seminars in oncology, 1992, Volume: 19, Issue:6 Suppl 14 Topics: Administration, Oral; Adolescent; Adult; Aged; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms	1992
What is the optimal dose and duration of treatment with etoposide? II. Comparative pharmacokinetic study of three schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of oral etoposide daily for 21 days. Seminars in oncology, 1992, Volume: 19, Issue:6 Suppl 14 Topics: Administration, Oral; Adolescent; Adult; Aged; Biological Availability; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Regression Analysis	1992
Dose escalation of cisplatin (P), etoposide (E), and ifosfamide (I) with GM-CSF for advanced germ cell tumors. Pathologie-biologie, 1992, Volume: 39, Issue:9 Topics: Cisplatin; Drug Therapy, Combination; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ifosfamide; Neoplasms	1992
Influence of mobilized peripheral blood cells on the hematopoietic recovery by autologous marrow and recombinant human granulocyte-macrophage colony-stimulating factor after high-dose cyclophosphamide, etoposide, and cisplatin. Blood, 1992, Jun-15, Volume: 79, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Component Transfusion; Blood Transfusion; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoiesis; Humans; Leukocyte Count; Neoplasms; Platelet Count; Recombinant Proteins; Transplantation, Autologous	1992
The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer. Clinical pharmacology and therapeutics, 1992, Volume: 51, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Neoplasms	1992
In vitro and in vivo modulation of multi-drug resistance with amiodarone. International journal of cancer, 1991, Jun-19, Volume: 48, Issue:4 Topics: Adult; Amiodarone; Biological Transport; Carcinoma, Small Cell; Cell Line; Cell Survival; Colonic Neoplasms; DNA Damage; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Kinetics; Lung Neoplasms; Male; Neoplasms; Tumor Stem Cell Assay; Vincristine	1991
Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer research, 1991, Aug-01, Volume: 51, Issue:15 Topics: Carcinoma, Squamous Cell; DNA; DNA Topoisomerases, Type II; Etoposide; Humans; KB Cells; Mutation; Neoplasms; Phosphorylation; Tumor Cells, Cultured	1991
Recent advances in etoposide therapy. Combined proceedings of two symposia: University of Maryland School of Medicine program, Alexandria, Virginia and a satellite symposium of the 9th International Symposium on Future Trends in Chemotherapy, Geneva, Swit Cancer, 1991, Jan-01, Volume: 67, Issue:1 Suppl Topics: Etoposide; Humans; Neoplasms	1991
Placental site trophoblastic tumor in a postmenopausal woman. American journal of clinical pathology, 1991, Volume: 95, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dactinomycin; Etoposide; Female; Humans; Menopause; Methotrexate; Middle Aged; Neoplasms; Placenta Diseases; Pregnancy; Trophoblastic Neoplasms	1991
Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study. Journal of cancer research and clinical oncology, 1991, Volume: 117 Suppl 4 Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Stability; Epirubicin; Etoposide; Feasibility Studies; Female; Humans; Ifosfamide; Infusion Pumps, Implantable; Infusions, Intravenous; Male; Mesna; Middle Aged; Mitoxantrone; Neoplasms	1991
High-dose chemotherapy with autologous bone marrow rescue: haematopoietic reconstitution by non-cryopreserved marrow. Bone marrow transplantation, 1991, Volume: 7 Suppl 2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Carmustine; Cyclophosphamide; Etoposide; Humans; Middle Aged; Neoplasms; Remission Induction; Tissue Preservation; Transplantation, Autologous	1991
Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clinical pharmacology and therapeutics, 1991, Volume: 50, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Leukocyte Count; Linear Models; Male; Middle Aged; Neoplasms; Platelet Count; Protein Binding	1991
Is treatment intensification by adding etoposide and carboplatin to fractionated total body irradiation and melphalan acceptable in children with solid tumors with respect to toxicity? Bone marrow transplantation, 1991, Volume: 8, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Humans; Infant; Melphalan; Neoplasms	1991
In vitro data supporting interferon plus cytotoxic agent combinations. Seminars in oncology, 1991, Volume: 18, Issue:5 Suppl 7 Topics: Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Fluorouracil; Humans; Interferon-alpha; Neoplasms	1991
Drug monitoring in cancer therapy. Journal of the National Cancer Institute, 1991, Nov-06, Volume: 83, Issue:21 Topics: Antineoplastic Agents; Bone Marrow; Drug Monitoring; Etoposide; Humans; Neoplasms	1991
Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments. Journal of hepatology, 1991, Volume: 12, Issue:1 Topics: Acute Disease; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Liver; Male; Middle Aged; Necrosis; Neoplasms	1991
Potentiation of etoposide and vincristine by two synthetic 1,4-dihydropyridine derivatives in multidrug-resistant and atypical multidrug-resistant human cancer cells. Anti-cancer drug design, 1991, Volume: 6, Issue:1 Topics: Antineoplastic Agents; Cell Survival; Dihydropyridines; Dioxins; Drug Resistance; Drug Synergism; Etoposide; Humans; Intracellular Fluid; Neoplasms; Tritium; Tumor Cells, Cultured; Vincristine	1991
Chronic daily administration of oral etoposide. Seminars in oncology, 1990, Volume: 17, Issue:1 Suppl 2 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Small Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasms; Neoplasms, Germ Cell and Embryonal	1990
Clinical pharmacodynamics of continuous-infusion etoposide. Cancer chemotherapy and pharmacology, 1990, Volume: 25, Issue:5 Topics: Adult; Aged; Blood Cell Count; Carcinoma, Small Cell; Chromatography, High Pressure Liquid; Drug Resistance; Etoposide; Humans; Infusions, Intravenous; Kidney Function Tests; Leukocyte Count; Liver Function Tests; Lung Neoplasms; Middle Aged; Neoplasms	1990
Infusion of high doses of undiluted etoposide through central venous catheters during preparation for bone marrow transplantation. Cancer investigation, 1990, Volume: 8, Issue:1 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Bone Marrow Transplantation; Carcinoma, Non-Small-Cell Lung; Catheterization, Central Venous; Colonic Neoplasms; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Middle Aged; Neoplasms	1990
A pilot study of high-dose carboplatin and pulsed etoposide in the treatment of childhood solid tumors. Pediatric hematology and oncology, 1990, Volume: 7, Issue:2 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Child; Child, Preschool; Drug Evaluation; Etoposide; Female; Gastrointestinal Diseases; Hearing Loss, Sensorineural; Humans; Infant; Male; Neoplasms; Pilot Projects	1990
Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients. Cancer research, 1990, Nov-01, Volume: 50, Issue:21 Topics: Adult; Aged; Aged, 80 and over; Bilirubin; Blood Proteins; Etoposide; Evaluation Studies as Topic; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Prospective Studies; Protein Binding; Serum Albumin	1990
Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:10 Topics: Adolescent; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Remission Induction; Survival Rate; Thrombocytopenia	1990
Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Chromatography, High Pressure Liquid; Cisplatin; Creatinine; Etoposide; Female; Humans; Liver; Liver Function Tests; Male; Neoplasms; Protein Binding; Regression Analysis	1990
Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours. British journal of cancer, 1990, Volume: 62, Issue:5 Topics: Etoposide; Humans; Infusions, Parenteral; Neoplasms; Time Factors	1990
Changes of stapedius reflex and hearing threshold in patients receiving high-dose cisplatin treatment. Audiology : official organ of the International Society of Audiology, 1990, Volume: 29, Issue:5 Topics: Adult; Aged; Audiometry, Pure-Tone; Auditory Threshold; Cisplatin; Cochlear Diseases; Etoposide; Female; Hearing Disorders; Humans; Male; Middle Aged; Neoplasms; Stapedius	1990
Combination high-dose etoposide and vincristine infusion. Investigational new drugs, 1990, Volume: 8 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Etoposide; Humans; Infusions, Intravenous; Neoplasms; Vincristine	1990
Is ectopic production of human chorionic gonadotrophin (hCG) or alpha fetoprotein (AFP) by tumours a marker of chemosensitivity? European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:12 Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chorionic Gonadotropin; Cisplatin; Dactinomycin; Doxorubicin; Etoposide; Hormones, Ectopic; Humans; Leucovorin; Methotrexate; Neoplasms; Vincristine	1986
Progenitor cell numbers (CFU-GM, CFU-D, and CFU-Mix) and hemopoietic recovery following autologous marrow transplantation. Experimental hematology, 1989, Volume: 17, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Colony-Forming Units Assay; Cyclophosphamide; Etoposide; Hematopoiesis; Hematopoietic Stem Cells; Humans; Neoplasms; Time Factors; Transplantation, Autologous; Whole-Body Irradiation	1989
Clinical, analytical and pharmacokinetic aspects in cancer chemotherapy with platinum coordination compounds. Annali dell'Istituto superiore di sanita, 1989, Volume: 25, Issue:3 Topics: Adolescent; Antineoplastic Agents; Carboplatin; Child; Child, Preschool; Cisplatin; Etoposide; Humans; Infant; Neoplasms; Organoplatinum Compounds; Spectrum Analysis	1989
Phase I study of vincristine and escalating doses of etoposide. Investigational new drugs, 1989, Volume: 7, Issue:2-3 Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow Diseases; Drug Evaluation; Etoposide; Humans; Neoplasms; Vincristine	1989
Treatment strategies in relation to drug action. NCI monographs : a publication of the National Cancer Institute, 1987, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; DNA Topoisomerases, Type II; Etoposide; Hodgkin Disease; Humans; Leukemia; Lung Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Podophyllotoxin; Teniposide	1987
Altered protein binding of etoposide in patients with cancer. Clinical pharmacology and therapeutics, 1989, Volume: 45, Issue:1 Topics: Adult; Aged; Bilirubin; Blood Proteins; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Protein Binding; Serum Albumin	1989
Chronic daily administration of oral etoposide--a phase I trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:3 Topics: Administration, Oral; Blood Cell Count; Bone Marrow; Capsules; Dose-Response Relationship, Drug; Drug Evaluation; Etoposide; Female; Hematocrit; Humans; Male; Neoplasms; Time Factors	1989
Etoposide: a pharmacokinetic profile including an assessment of bioavailability. Medical oncology and tumor pharmacotherapy, 1986, Volume: 3, Issue:2 Topics: Administration, Oral; Biological Availability; Carcinoma; Carcinoma, Small Cell; Etoposide; Female; Hodgkin Disease; Humans; Injections, Intravenous; Kinetics; Lung Neoplasms; Lymphoma; Male; Neoplasms; Podophyllotoxin	1986
Evidence for capillary leakage during chemotherapy in man. European journal of clinical investigation, 1986, Volume: 16, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capillary Permeability; Cyclophosphamide; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Serum Albumin	1986
High-dose cisplatin and etoposide in advanced malignancies of childhood. Pediatric hematology and oncology, 1987, Volume: 4, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Child; Cisplatin; Drug Evaluation; Etoposide; Hearing Loss, Sensorineural; Humans; Neoplasms; Vomiting	1987
Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group. Investigational new drugs, 1988, Volume: 6, Issue:1 Topics: Adolescent; Adult; Blood Cell Count; Child; Child, Preschool; Drug Evaluation; Etoposide; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Neoplasms	1988
VP-16. Journal of the Association of Pediatric Oncology Nurses, 1988, Volume: 5, Issue:3 Topics: Child; Etoposide; Humans; Neoplasms	1988
Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide. Cancer chemotherapy and pharmacology, 1987, Volume: 20, Issue:1 Topics: Adult; Aged; Chromatography, High Pressure Liquid; Etoposide; Female; Half-Life; Humans; Infusions, Intravenous; Kinetics; Male; Middle Aged; Neoplasms; Tissue Distribution	1987
Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients. Cancer chemotherapy and pharmacology, 1986, Volume: 17, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Interactions; Etoposide; Female; Humans; Kinetics; Male; Middle Aged; Neoplasms; Pharmaceutical Vehicles; Podophyllotoxin; Polysorbates	1986
Etoposide pharmacokinetics in patients with normal and abnormal organ function. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:11 Topics: Adult; Aged; Bile; Bilirubin; Chromatography, High Pressure Liquid; Creatinine; Etoposide; Female; Humans; Kinetics; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Urine	1986
[High dose cytotoxic agents followed by autologous bone marrow transplantation; treatment results in 25 patients with various malignancies]. Nederlands tijdschrift voor geneeskunde, 1985, Jun-22, Volume: 129, Issue:25 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms; Transplantation, Autologous	1985
[Research project of cancer chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:3 Pt 2 Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Cisplatin; Dacarbazine; Etoposide; Humans; International Cooperation; Japan; Neoplasms; Research; Thioguanine; United States	1985
[A phase I study of VP-16-213 (VP, etoposide) by single and 5-day intravenous administration]. Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:2 Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Kinetics; Leukopenia; Male; Middle Aged; Neoplasms; Podophyllotoxin; Thrombocytopenia	1986